Liver cancer detection kit or device, and detection method

Abstract

To provide a kit or device for the detection of liver cancer and a method for detecting liver cancer.SOLUTION: The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to a kit or device for detecting liver cancer, which contains a nucleic acid capable of specifically binding to a specific miRNA and is used for detecting the presence or absence of liver cancer in a subject, and a method for detecting liver cancer, which includes measuring the expression level of the miRNA using the nucleic acid.

Background Art

[0002] The liver is the largest organ in the body located in the upper right of the abdomen, and its main roles are metabolism of nutrients and detoxification and excretion of harmful substances. According to the cancer statistics by site in Japan in 2011 disclosed by the Cancer Countermeasure Information Center of the National Cancer Center, National Institute of Biomedical Innovation, Health and Nutrition, the number of liver cancer patients was 4 7,271, that is, one in 35 Japanese people is considered to suffer from liver cancer, and it is the sixth most common cancer site. Also, men are nearly twice as likely to suffer from it as women. The number of deaths due to liver cancer is 30,690 for both men and women, and it is the fourth most common cancer site in terms of the number of deaths. In the United States, the estimated number of liver cancer patients in 2014 was also over 33,190, and about 23,000 of them are considered to die (Non-Patent Document 1).

[0003] Generally, primary liver cancer often refers to hepatocellular carcinoma, which accounts for about 80% of it, but in addition, there are also rarer cancer types such as intrahepatic cholangiocarcinoma and biliary cystadenocarcinoma, which account for 1 to 2% of all primary liver cancers.

[0004] The progression of liver cancer is defined separately for hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Non-Patent Document 2. Here, in particular, for hepatocellular carcinoma, the spread of the tumor (T0 - 4), lymph node metastasis (N0, N1 ​) According to the degree of distant metastasis (M0, M1), it is classified into stage I (T1 / N0 / M0), stage II (T2 / N0 / M0), stage IIIA (T3a / N0 / M0), stage I IIB (T3b / N0 / M0), stage IIIC (T4 / N0 / M0), stage IV A (N1 / M0), and stage IVB (M1).

[0005] The 5-year relative survival rate of liver cancer varies depending on the degree of progression. According to Non-Patent Document 1, for cancers confined within the liver (stage 1, stage 2, and some stage 3), it is 28%, for cases with metastasis found adjacent to the liver (stage IIIC, stage IVA), it is 7%, and for cases with distant metastasis found (stage IVB), it is reported to be 2%. Therefore, detecting and treating liver cancer at an early stage before metastasis is found can greatly contribute to improving the survival rate.

[0006] The treatment of liver cancer mainly includes surgical treatment such as resection and liver transplantation, local treatment that kills cancer by injecting drugs or cauterizing through puncture, and transcatheter arterial embolization, and drug therapy and radiotherapy are combined with these. Especially for very early liver cancer where no cancer is found in blood vessels or surrounding tissues, partial resection of the liver often leads to a complete cure (Non-Patent Document 1). On the other hand, even if the cancer is locally present, if resection is impossible due to reasons such as a large tumor diameter or proximity to blood vessels, liver transplantation is desirable, and

[0007] As described in Non-Patent Document 1, primary examinations for liver cancer include, in addition to visual inspection and palpation, imaging examinations such as ultrasound examination, CT examination, MRI examination, AFP (alpha-fetoprotein) and PIVKA-II (protein induced by vitamin K absence or antagonist-II) are known as tumor markers for the detection of hepatocellular carcinoma, and are often used in combination with ultrasonography. When findings suggesting hepatocellular carcinoma are detected by these primary tests, a pathological examination is performed as a secondary test by inserting a needle into the lesion to collect cells or tissues and examining them under a microscope.

[0008] On the other hand, it is known that the most important risk factors for hepatocellular carcinoma are chronic infections with hepatitis B and C viruses. Therefore, when hepatocellular carcinoma is suspected, hepatitis virus tests may be performed in addition to the above primary tests.

[0009] Although still in the research stage, as shown in Patent Documents 1 to 5, methods for detecting hepatocellular carcinoma using the expression levels of microRNAs (miRNAs) in biological samples including blood and liver tissues have been reported.

[0010] Patent Document 1 shows a method for detecting leukemia, breast cancer, and hepatocellular carcinoma using hsa-miR-92a-3p, hsa-miR-92b-3p, hsa-miR-92a-2-5p, and hsa-miR-92b-5p, which are miRNAs in tissues, as markers.

[0011] Patent Document 2 reports a method for diagnosing various cancers using miRNAs such as hsa-miR-23a-3p, hsa-miR-23b-3p, hsa-miR-24-3p, hsa-miR-557, hsa-miR-564, hsa-miR-614, hsa-miR-150-3p, and hsa-miR-486-3p, which are contained in vesicles circulating in body fluids, as markers.

[0012] Patent Document 3 discloses a method for detecting various diseases including liver cancer using miRNAs such as hsa-miR-23b-3p, hsa-miR-30 c-1-3p, hsa-miR-125a-3p, hsa-miR-486-3p in tissues and body fluids as markers. There is.

[0013] Patent Document 4 discloses a method for detecting various pathological conditions including liver cancer using miRNAs such as hsa-miR-16-5p, hs a-miR-92a-3p, hsa-miR-663a, hsa-miR-1913, h sa-miR-625-3p and proteins in vesicles circulating in body fluids as markers. There is.

[0014] Patent Document 5 shows that hsa-miR-187-5p, hsa-miR-92a-3 p, hsa-miR-16-5p, hsa-miR-30c-1-3p in plasma are markers for colorectal cancer, liver cancer, and lung cancer.

Prior Art Documents

Patent Documents

[0015]

Patent Document 1

Patent Document 2

Patent Document 3

Patent Document 4

Patent Document 5

Non-Patent Documents

[0016] ​

Non-Patent Document 1

Non-Patent Document 2

Non-Patent Document 3

Non-Patent Document 4

Non-Patent Document 5

Summary of the Invention

Problems to be Solved by the Invention

[0017] The problem of the present invention is to find a novel liver cancer tumor marker and provide a method capable of effectively detecting liver cancer using a nucleic acid that can specifically bind to the marker. Liver cancer is difficult to detect early because the cancer progresses without such symptoms.

[0018] Moreover, since most of the liver is stored within the right rib cage, detection by palpation is difficult. Currently, for the general population without risks of liver cancer such as hepatitis virus infection and liver cirrhosis, an effective screening method for liver cancer has not been established (Non-Patent Document 1). Ultrasonic examination is a widely used liver cancer examination method because it places less burden on patients and is simple. depending on the site of cancer occurrence, it may be difficult to detect, and since the test results greatly depend on the skill of the technician, it is considered desirable to use it in combination with a tumor marker (Non Patent Document 3). AFP is known as a tumor marker for detecting liver cancer, but when an increase in AFP is recognized, liver cancer has already progressed, and in many cases, it is inoperable or has metastasized outside the liver (Non-Patent Document 1). In addition, while it has been reported that some liver cancers do not produce AFP, AFP also increases in cancers other than liver cancer, such as testicular cancer and ovarian cancer, and further increases in non-cancerous liver diseases, such as persistent hepatitis virus infection, etc., so it is regarded as a marker with low specificity (Non-Patent Document 1). For example, if another cancer is misdiagnosed as liver cancer, the opportunity for appropriate treatment may be missed, or the patient may be burdened with unnecessary economic and physical burdens by applying the wrong medical treatment. In addition, according to the results of a large-scale screening study (Non-Patent Document 4) targeting hepatitis B virus-infected individuals and patients with persistent hepatitis, the detection sensitivity of liver cancer by AFP test is only 69%, and the test performance is insufficient for use as a screening test for liver cancer. In addition, although CT examination and MRI examination can detect liver cancer with high performance, special equipment is required and the examination cost is high, so it is not suitable for wide spread as a primary examination.

[0019] Also, although still in the research stage, there are reports of discriminating liver cancer using the expression levels of microRNA (miR NA) in biological samples such as blood, but none of them have reached practical application.

[0020] Patent Document 1 discloses a method for detecting leukemia, breast cancer, and liver cancer using hsa-miR-92a-3p, hsa-miR-92b-3p, hsa-miR-92a-2-5p, and hsa-miR -92b-5p as markers in blood cells and tissues. However, this detection method requires tissue resection by surgery to obtain specimens, which places a heavy physical burden on patients and is not preferable as a detection method. In addition, Patent Document 1 does not describe the specific accuracy, sensitivity, specificity, and other detection performances of this detection method for discriminating liver cancer,

[0021] resulting in poor industrial practicality.

[0021] Patent Document 2 reports a method for diagnosing various cancers using miRNAs such as hsa-miR-23a-3p, h sa-miR-23b-3p, hsa-miR-24-3p, hsa-miR-557, hsa-miR-564, hsa-miR-614, hsa-miR-150-3p, h sa-miR-486-3p contained in vesicles circulating in body fluids as markers. However, Patent Document 2 does not describe a specific method for diagnosing liver cancer using this detection method, nor does it describe the detection performances such as accuracy, sensitivity, and specificity for discriminating liver cancer, resulting in poor industrial practicality.

[0022] Patent Document 3 discloses a method for detecting various diseases including liver cancer using miRNAs such as hsa-miR-23b-3p, hsa-miR-30 c-1-3p, hsa-miR-125a-3p, hsa-miR-486-3p, etc. as markers in tissues and body fluids. However, this detection method is based on experimental results of a mouse model and has not been verified in humans. Regarding the detection of liver cancer, it is unclear. In addition, Patent Document 3 does not describe the detection performance such as the accuracy, sensitivity, and specificity for discriminating liver cancer, so it has poor industrial applicability. Since there is no description about the detection performance such as the accuracy, sensitivity, and specificity for discriminating liver cancer, it has poor industrial applicability.

[0023] Patent Document 4 shows a method for detecting various pathological conditions including liver cancer using miRNAs such as hsa-miR-16-5p, hsa-miR-92a-3p, hsa-miR-663a, hsa-miR-1913, hsa-miR-625-3p and proteins contained in vesicles circulating in body fluids as markers. However, Patent Document 4 does not describe a specific diagnostic method for liver cancer using this detection method, and the above miRNA markers have not been verified in an independent sample group, so they lack reliability. a-miR-92a-3p, hsa-miR-663a, hsa-miR-1913, h sa-miR-625-3p and other miRNAs and proteins as markers to detect various pathological conditions including liver cancer. However, Patent Document 4 does not describe a specific diagnostic method for liver cancer using this detection method, and the above miRNA markers have not been verified in an independent sample group, so they lack reliability. Regarding the detection of liver cancer, Patent Document 4 does not describe a specific diagnostic method using this detection method, and the above miRNA markers have not been verified in an independent sample group, so they lack reliability. Since the above miRNA markers have not been verified in an independent sample group, they lack reliability.

[0024] Patent Document 5 shows that hsa-miR-187-5p, hsa-miR-92a-3 p, hsa-miR-16-5p, hsa-miR-30c-1-3p in plasma are markers for colorectal cancer, liver cancer, and lung cancer. However, these markers are markers for discriminating the colorectal cancer group from the group consisting of liver cancer, lung cancer, and healthy subjects, and are not markers for detecting liver cancer.

[0025] Thus, in the detection of liver cancer, the performance of existing tumor markers is low, or for markers at the research stage, the performance and detection methods are not specifically shown. Therefore, when using these, there may be a waste of additional examinations due to misdetecting healthy subjects as liver cancer patients, or a loss of treatment opportunities due to overlooking liver cancer patients. In addition, measuring dozens to hundreds of miRNAs increases the test cost, so for health checkups when using these, there may be a waste of additional examinations due to misdetecting healthy subjects as liver cancer patients, or a loss of treatment opportunities due to overlooking liver cancer patients. Measuring dozens to hundreds of miRNAs increases the test cost, so for health checkups when using these, there may be a waste of additional examinations due to misdetecting healthy subjects as liver cancer patients, or a loss of treatment opportunities due to overlooking liver cancer patients. In addition, measuring dozens to hundreds of miRNAs increases the test cost, so for health checkups It is difficult to use for large-scale screening such as diagnosis. In addition, collecting liver tissue to measure tumor markers is highly invasive to patients and not preferable, so detection from blood that can be collected with low invasiveness is possible, and a highly accurate liver cancer marker that can correctly distinguish liver cancer patients from liver cancer patients and healthy subjects from healthy subjects is required. In particular, liver cancer can improve the survival rate by being detected and treated early, and since it is often cured by partial resection of the liver, a highly sensitive liver cancer marker that can detect even low-stage liver cancer is eagerly desired. Since collecting liver tissue to measure tumor markers is highly invasive to patients and not preferable, detection from blood that can be collected with low invasiveness is possible, and a highly accurate liver cancer marker that can correctly distinguish liver cancer patients from liver cancer patients and healthy subjects from healthy subjects is required. In particular, liver cancer can improve the survival rate by being detected and treated early, and since it is often cured by partial resection of the liver, a highly sensitive liver cancer marker that can detect even low-stage liver cancer is eagerly desired.

Means for Solving the Problems

Means for Solving the Problems

[0026] As a result of intensive studies to solve the above problems, the present inventors have found several genes that can be used as detection markers for liver cancer from blood that can be collected with low invasiveness, and have found that liver cancer can be significantly detected by using a nucleic acid that can specifically bind thereto, and have completed the present invention. That is, the present invention has the following features. (1) miR-1343-3p, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641, miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p, miR-6717-5p, miR-6870-5p, miR, which are liver cancer markers

Means for Solving the Problems

[0027] <Summary of the Invention> That is, the present invention has the following features.

[0028] (1) miR-1343-3p, miR-6726-5p, m iR-6515-3p, miR-4651, miR-4257, miR-3188, mi R-6131, miR-6766-3p, miR-7641, miR-1249, miR -3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977 、miR-7110-5p, miR-6717-5p, miR-6870-5p, miR -663b, miR-6875-5p, miR-8072, miR-6816-5p, m iR-4281, miR-6729-5p, miR-8069, miR-4706, mi R-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6 857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p, miR-615-5p, miR-128 -1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR- 6840-3p, miR-6765-5p, miR-296-5p, miR-3675- 3p, miR-6781-5p, miR-423-5p, miR-3663-3p, mi R-6784-5p, miR-6749-5p, miR-1231, miR-4746- 3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-679 1-5p, miR-3185, miR-1260a, miR-3197, miR-684 5-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p , miR-4497, miR-1229-5p, miR-6820-5p, miR-67 77-5p, miR-3917, miR-5787, miR-4286, miR-687 7-5p, miR-1225-3p, miR-6088, miR-6800-5p, mi R-1246, miR-4467, miR-4419b, miR-1914-3p, mi R-4632-5p, miR-1915-5p, miR-3940-5p, miR-11 85-2-3p, miR-6746-5p, miR-5001-5p, miR-1228 -5p, miR-5572, miR-4327, miR-4638-5p, miR-67 99-5p, miR-6861-5p, miR-6727-5p, miR-4513, m iR-6805-3p, miR-6808-5p, miR-4449, miR-1199 -5p, miR-1275, miR-4792, miR-4443, miR-6891- 5p, miR-6826-5p, miR-6807-5p, miR-7150, miR- 4534, miR-4476, miR-4649-5p, miR-4525, miR-1 915-3p, miR-4516, miR-4417, miR-642b-3p, miR -3141, miR-5100, miR-6848-5p, miR-4739, miR- 4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-134 3-5p, miR-1247-3p, miR-6805-5p, miR-4492, mi R-1469, miR-1268b, miR-6858-5p, miR-3937, mi R-939-5p, miR-3656, miR-744-5p, miR-4687-3p 、miR-4763-3p, miR-3620-5p, miR-3195, miR-68 42-5p, miR-4707-5p, miR-642a-3p, miR-7113-3 p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3 p, miR-4463, miR-128-2-5p, miR-4508, miR-680 6-5p, miR-7111-5p, miR-6782-5p, miR-4734, mi R-3162-5p, miR-887-3p, miR-6752-5p, miR-672 4-5p, miR-6757-5p, miR-4448, miR-671-5p, miR -3178, miR-4725-3p, miR-940, miR-6789-5p, mi R-4484, miR-4634, miR-4745-5p, miR-4730, miR -6803-5p, miR-6798-5p, miR-3648, miR-4783-3 At least one or more polynucleotides selected from the group consisting of p and miR-6836-3p A kit for detecting liver cancer, comprising a nucleic acid capable of specifically binding to a nucleotide

[0029] (2) miR-1343-3p is hsa-miR-1343-3p, and miR-67 26-5p is hsa-miR-6726-5p, and miR-6515-3p is hsa -miR-6515-3p, miR-4651 is hsa-miR-4651 , miR-4257 is hsa-miR-4257, miR-3188 is hsa-m iR-3188, miR-6131 is hsa-miR-6131, miR- 6766-3p is hsa-miR-6766-3p, miR-7641 is hsa- miR-7641, miR-1249 is hsa-miR-1249, miR -3679-3p is hsa-miR-3679-3p, miR-6787-5p is hsa-miR-6787-5p, miR-4454 is hsa-miR-4454 where miR-3135b is hsa-miR-3135b, miR-6765- 3p is hsa-miR-6765-3p, miR-7975 is hsa-miR-7 975, miR-204-3p is hsa-miR-204-3p, miR- 7977 is hsa-miR-7977, miR-7110-5p is hsa-miR -7110-5p, miR-6717-5p is hsa-miR-6717-5p and miR-6870-5p is hsa-miR-6870-5p, miR-66 3b is hsa-miR-663b, miR-6875-5p is hsa-miR-6 875-5p, miR-8072 is hsa-miR-8072, miR-6 816-5p is hsa-miR-6816-5p, miR-4281 is hsa-m iR-4281, miR-6729-5p is hsa-miR-6729-5p and miR-8069 is hsa-miR-8069, miR-4706 is hsa- miR-4706, miR-7108-5p is hsa-miR-7108-5p and miR-4433b-3p is hsa-miR-4433b-3p, miR- 6893-5p is hsa-miR-6893-5p, miR-6857-5p is h sa-miR-6857-5p, miR-1227-5p is hsa-miR-12 27-5p, miR-6741-5p is hsa-miR-6741-5p, miR-451a is hsa-miR-451a, miR-8063 is hsa-mi R-8063, miR-3622a-5p is hsa-miR-3622a-5p and miR-615-5p is hsa-miR-615-5p, miR-128- 1-5p is hsa-miR-128-1-5p, and miR-6825-5p is hsa -miR-6825-5p, and miR-1260b is hsa-miR-1260b and miR-4433-3p is hsa-miR-4433-3p, miR-46 65-5p is hsa-miR-4665-5p, and miR-7845-5p is hsa -miR-7845-5p, and miR-1908-5p is hsa-miR-1908 -5p, and miR-6840-3p is hsa-miR-6840-3p, mi R-6765-5p is hsa-miR-6765-5p, and miR-296-5p is hsa-miR-296-5p, and miR-3675-3p is hsa-miR-36 75-3p, and miR-6781-5p is hsa-miR-6781-5p, and miR-423-5p is hsa-miR-423-5p, miR-3663-3p is hsa-miR-3663-3p, and miR-6784-5p is hsa-miR- 6784-5p, and miR-6749-5p is hsa-miR-6749-5p and miR-1231 is hsa-miR-1231, miR-4746-3p is h sa-miR-4746-3p, and miR-6780b-5p is hsa-miR-6 780b-5p, and miR-4758-5p is hsa-miR-4758-5p and miR-3679-5p is hsa-miR-3679-5p, miR-318 4-5p is hsa-miR-3184-5p, and miR-6125 is hsa-miR -6125, and miR-6721-5p is hsa-miR-6721-5p, miR-6791-5p is hsa-miR-6791-5p, and miR-3185 is hsa-miR-3185, miR-1260a is hsa-miR-1260a and miR-3197 is hsa-miR-3197, miR-6845-5p is hsa-miR-6845-5p, miR-6887-5p is hsa-miR-6 887-5p, miR-6738-5p is hsa-miR-6738-5p and miR-6872-3p is hsa-miR-6872-3p, miR-4497 is hsa-miR-4497, miR-1229-5p is hsa-miR-122 9-5p, miR-6820-5p is hsa-miR-6820-5p, m iR-6777-5p is hsa-miR-6777-5p, miR-3917 is h sa-miR-3917, miR-5787 is hsa-miR-5787, miR-4286 is hsa-miR-4286, miR-6877-5p is hsa -miR-6877-5p, miR-1225-3p is hsa-miR-1225 -3p, miR-6088 is hsa-miR-6088, miR-6800 -5p is hsa-miR-6800-5p, miR-1246 is hsa-miR- 1246, miR-4467 is hsa-miR-4467, miR-441 9b is hsa-miR-4419b, miR-1914-3p is hsa-miR- 1914-3p, miR-4632-5p is hsa-miR-4632-5p and miR-1915-5p is hsa-miR-1915-5p, miR-394 0-5p is hsa-miR-3940-5p, miR-1185-2-3p is hs a-miR-1185-2-3p, where miR-6746-5p is hsa-miR-6 746-5p, miR-5001-5p is hsa-miR-5001-5p , miR-1228-5p is hsa-miR-1228-5p, miR-5572 is hsa-miR-5572, miR-4327 is hsa-miR-4327 and miR-4638-5p is hsa-miR-4638-5p, miR-679 9-5p is hsa-miR-6799-5p, miR-6861-5p is hsa- miR-6861-5p, miR-6727-5p is hsa-miR-6727- 5p, miR-4513 is hsa-miR-4513, miR-6805- 3p is hsa-miR-6805-3p, miR-6808-5p is hsa-mi R-6808-5p, miR-4449 is hsa-miR-4449, mi R-1199-5p is hsa-miR-1199-5p, miR-1275 is hs a-miR-1275, miR-4792 is hsa-miR-4792, m iR-4443 is hsa-miR-4443, miR-6891-5p is hsa- miR-6891-5p, miR-6826-5p is hsa-miR-6826- 5p, miR-6807-5p is hsa-miR-6807-5p, miR -7150 is hsa-miR-7150, miR-4534 is hsa-miR-4 534, miR-4476 is hsa-miR-4476, miR-4649 -5p is hsa-miR-4649-5p, miR-4525 is hsa-miR- It is 4525, miR-1915-3p is hsa-miR-1915-3p, m iR-4516 is hsa-miR-4516, miR-4417 is hsa-mi -4417, miR-642b-3p is hsa-miR-642b-3p, miR-3141 is hsa-miR-3141, miR-5100 is hsa-mi R-5100, miR-6848-5p is hsa-miR-6848-5p and miR-4739 is hsa-miR-4739, miR-4459 is hsa-m iR-4459, miR-1237-5p is hsa-miR-1237-5p and miR-296-3p is hsa-miR-296-3p, miR-4665- 3p is hsa-miR-4665-3p, miR-6786-5p is hsa-mi R-6786-5p, miR-4258 is hsa-miR-4258, mi R-6510-5p is hsa-miR-6510-5p, miR-1343-5p is hsa-miR-1343-5p, miR-1247-3p is hsa-miR- 1247-3p, miR-6805-5p is hsa-miR-6805-5p and miR-4492 is hsa-miR-4492, miR-1469 is hsa- miR-1469, miR-1268b is hsa-miR-1268b, m iR-6858-5p is hsa-miR-6858-5p, miR-3937 is h sa-miR-3937, miR-939-5p is hsa-miR-939-5p and miR-3656 is hsa-miR-3656, miR-744-5p is hsa-miR-744-5p, miR-4687-3p is hsa-miR-46 It is 87-3p, miR-4763-3p is hsa-miR-4763-3p, miR-3620-5p is hsa-miR-3620-5p, miR-3195 is hsa-miR-3195, miR-6842-5p is hsa-miR-6842 -5p, miR-4707-5p is hsa-miR-4707-5p, mi R-642a-3p is hsa-miR-642a-3p, miR-7113-3p is hsa-miR-7113-3p, miR-4728-5p is hsa-miR- 4728-5p, miR-5195-3p is hsa-miR-5195-3p and miR-1185-1-3p is hsa-miR-1185-1-3p, miR -6774-5p is hsa-miR-6774-5p, miR-8059 is hsa -miR-8059, miR-3131 is hsa-miR-3131, mi R-7847-3p is hsa-miR-7847-3p, miR-4463 is hs a-miR-4463, miR-128-2-5p is hsa-miR-128-2 -5p, miR-4508 is hsa-miR-4508, miR-6806 -5p is hsa-miR-6806-5p, miR-7111-5p is hsa-m iR-7111-5p, miR-6782-5p is hsa-miR-6782-5 p, miR-4734 is hsa-miR-4734, miR-3162-5 p is hsa-miR-3162-5p, miR-887-3p is hsa-miR- 887-3p, miR-6752-5p is hsa-miR-6752-5p and , miR-6724-5p is hsa-miR-6724-5p, and miR-6757 -5p is hsa-miR-6757-5p, and miR-4448 is hsa-miR- 4448, miR-671-5p is hsa-miR-671-5p, and miR -3178 is hsa-miR-3178 and miR-4725-3p is hsa-mi R-4725-3p, miR-940 is hsa-miR-940, and miR- 6789-5p is hsa-miR-6789-5p, and miR-4484 is hsa- miR-4484, miR-4634 is hsa-miR-4634, and miR -4745-5p is hsa-miR-4745-5p, and miR-4730 is hsa -miR-4730 and miR-6803-5p is hsa-miR-6803-5p and miR-6798-5p is hsa-miR-6798-5p and miR-3 648 is hsa-miR-3648, and miR-4783-3p is hsa-miR- 4783-3p, and miR-6836-3p is hsa-miR-6836-3 The kit according to (1), wherein p.

[0030] (3) The nucleic acid is a polynucleotide represented by any one of (a) to (e) below: (a) a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729, or the corresponding A polynucleotide having a base sequence in which u is replaced by t, a mutant thereof, Derivatives or fragments thereof containing 15 or more consecutive bases; (b) a polypeptide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729; nucleotide, (c) a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 167 and 714 to 729 or the corresponding A polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence , its variant, its derivative, or a fragment thereof containing 15 or more consecutive bases (d) A polynucleotide represented by any of SEQ ID NOs: 1 to 167 and 714 to 729 or a polynucleotide containing a nucleotide sequence complementary to the nucleotide sequence in which u is t in the nucleotide sequence , and and (e) A polynucleotide that hybridizes with any of the polynucleotides of (a) to (d) under stringent conditions , wherein the kit according to (1) or (2) is a polynucleotide selected from the group consisting of .

[0031] (4) The kit further comprises a nucleic acid that can specifically bind to at least one or more polynucleotides selected from the group consisting of miR-23b-3p, miR-2 3a-3p, miR-625-3p, miR-1228-3p, miR-614, miR -1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3 p, miR-92b-5p, miR-92a-3p, and miR-663a, which are other liver cancer markers , wherein the kit according to any of (1) to (3) further comprises .

[0032] (5) miR-23b-3p is hsa-miR-23b-3p, miR-23a- 3p is hsa-miR-23a-3p, miR-625-3p is hsa-miR- 625-3p, miR-1228-3p is hsa-miR-1228-3p , miR-614 is hsa-miR-614, miR-1913 is hsa-miR -1913, where miR-92a-2-5p is hsa-miR-92a-2-5p and miR-187-5p is hsa-miR-187-5p, miR-16-5p is hsa-miR-16-5p, miR-92b-3p is hsa-miR-92b-3p, miR-150-3p is hsa-miR-150-3p, miR- 564 is hsa-miR-564, miR-125a-3p is hsa-miR-1 25a-3p, miR-92b-5p is hsa-miR-92b-5p, m iR-92a-3p is hsa-miR-92a-3p, and miR-663a is hsa-miR-663a, the kit according to (4).

[0033] (6) The nucleic acid is a polynucleotide represented by any of the following (f) to (j): (f) A polynucleotide consisting of a base sequence represented by any of SEQ ID NOs: 168 to 183 or a base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 1 5 or more consecutive bases, (g) A polynucleotide containing a base sequence represented by any of SEQ ID NOs: 168 to 183, (h) A polynucleotide consisting of a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 168 to 183 or a base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases, (i) A polynucleotide containing a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 168 to 183 or a base sequence in which u is t in the base sequence, and (j) A polynucleotide that hybridizes with any of the polynucleotides of (f) to (i) under stringent conditions, ​​​​The kit according to (4) or (5), which is a polynucleotide selected from the group consisting of

[0034] (7) The kit further comprises miR-4688, miR-464 8, miR-6085, miR-6126, miR-6880-5p, miR-328- 5p, miR-6768-5p, miR-3180, miR-6087, miR-127 3g-3p, miR-1225-5p, miR-3196, miR-4695-5p, m iR-6732-5p, miR-638, miR-6813-5p, miR-665, m iR-486-3p, miR-4466, miR-30c-1-3p, miR-3621 , miR-6743-5p, miR-4298, miR-4741, miR-3619- 3p, miR-6824-5p, miR-5698, miR-371a-5p, miR- 4488, miR-1233-5p, miR-4723-5p, miR-24-3p, m iR-1238-5p, miR-4442, miR-3928-3p, miR-6716 -5p, miR-6089, miR-6124, miR-6778-5p, miR-55 7 and at least one or more polynucleotides selected from the group consisting of miR-6090 The kit according to any one of (1) to (6), further comprising a nucleic acid that can specifically bind to

[0035] (8) miR-4688 is hsa-miR-4688, miR-4648 is hsa -miR-4648, miR-6085 is hsa-miR-6085, mi R-6126 is hsa-miR-6126, miR-6880-5p is hsa-m iR-6880-5p, miR-328-5p is hsa-miR-328-5p Yes, miR-6768-5p is hsa-miR-6768-5p, and miR-31 80 is hsa-miR-3180, and miR-6087 is hsa-miR-6087 Yes, miR-1273g-3p is hsa-miR-1273g-3p, and miR -1225-5p is hsa-miR-1225-5p, and miR-3196 is hsa -miR-3196, and miR-4695-5p is hsa-miR-4695-5p Yes, miR-6732-5p is hsa-miR-6732-5p, and miR-6 38 is hsa-miR-638, and miR-6813-5p is hsa-miR-68 13-5p, and miR-665 is hsa-miR-665, and miR-486- 3p is hsa-miR-486-3p, and miR-4466 is hsa-miR-44 66, and miR-30c-1-3p is hsa-miR-30c-1-3p, and m iR-3621 is hsa-miR-3621, and miR-6743-5p is hsa- miR-6743-5p, and miR-4298 is hsa-miR-4298, and miR-4741 is hsa-miR-4741, and miR-3619-3p is hsa -miR-3619-3p, and miR-6824-5p is hsa-miR-6824 -5p, and miR-5698 is hsa-miR-5698, and miR-371a -5p is hsa-miR-371a-5p, and miR-4488 is hsa-miR- 4488, and miR-1233-5p is hsa-miR-1233-5p, and m iR-4723-5p is hsa-miR-4723-5p, and miR-24-3p is hsa-miR-24-3p, and miR-1238-5p is hsa-miR-123 8-5p, miR-4442 is hsa-miR-4442, and miR-392 8-3p is hsa-miR-3928-3p, and miR-6716-5p is hsa- miR-6716-5p, miR-6089 is hsa-miR-6089, and miR-6124 is hsa-miR-6124, and miR-6778-5p is hsa -miR-6778-5p, miR-557 is hsa-miR-557, and moreover, miR-6090 is hsa-miR-6090, the kit according to (7).

[0036] (9) The nucleic acid is a polynucleotide represented by the following (k) to (o): (k) A polynucleotide consisting of a base sequence represented by any of SEQ ID NOs: 184 to 224 or a base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 1 5 or more consecutive bases, (l) A polynucleotide containing a base sequence represented by any of SEQ ID NOs: 184 to 224, (m) A polynucleotide consisting of a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 184 to 224 or a base sequence in which u is t in the base sequence, a variant thereof, (n) A polynucleotide consisting of a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 184 to 224 or a base sequence in which u is t in the base sequence, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases, (o) A polynucleotide that hybridizes under stringent conditions with any of the polynucleotides of (k) to (n), (p) A polynucleotide selected from the group consisting of, the kit according to (7) or (8). (q) A polynucleotide selected from the group consisting of, the kit according to (7) or (8). (r) A polynucleotide selected from the group consisting of, the kit according to (7) or (8). (s) A polynucleotide selected from the group consisting of, the kit according to (7) or (8). (t) A polynucleotide selected from the group consisting of, the kit according to (7) or (8). A polynucleotide selected from the group consisting of, the kit according to (7) or (8).

[0037] (10) The kit is selected from all of the liver cancer markers described in (1) or (2), and contains at least two or more nucleic acids that can specifically bind to each of at least two or more polynucleotides described in any one of (1) to (9).

[0038] (11) miR-1343-3p, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, m iR-6131, miR-6766-3p, miR-7641, miR-1249, mi R-3679-3p, miR-6787-5p, miR-4454, miR-3135b , miR-6765-3p, miR-7975, miR-204-3p, miR-797 7, miR-7110-5p, miR-6717-5p, miR-6870-5p, mi R-663b, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, m iR-7108-5p, miR-4433b-3p, miR-6893-5p, miR- 6857-5p, miR-1227-5p, miR-6741-5p, miR-451a , miR-8063, miR-3622a-5p, miR-615-5p, miR-12 8-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p , miR-4665-5p, miR-7845-5p, miR-1908-5p, miR -6840-3p, miR-6765-5p, miR-296-5p, miR-3675 -3p, miR-6781-5p, miR-423-5p, miR-3663-3p, m iR-6784-5p, miR-6749-5p, miR-1231, miR-4746 -3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p , miR-3184-5p, miR-6125, miR-6721-5p, miR-67 91-5p, miR-3185, miR-1260a, miR-3197, miR-68 45-5p, miR-6887-5p, miR-6738-5p, miR-6872-3 p, miR-4497, miR-1229-5p, miR-6820-5p, miR-6 777-5p, miR-3917, miR-5787, miR-4286, miR-68 77-5p, miR-1225-3p, miR-6088, miR-6800-5p, m iR-1246, miR-4467, miR-4419b, miR-1914-3p, m iR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1 185-2-3p, miR-6746-5p, miR-5001-5p, miR-122 8-5p, miR-5572, miR-4327, miR-4638-5p, miR-6 799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808-5p, miR-4449, miR-119 9-5p, miR-1275, miR-4792, miR-4443, miR-6891 -5p, miR-6826-5p, miR-6807-5p, miR-7150, miR -4534, miR-4476, miR-4649-5p, miR-4525, miR- 1915-3p, miR-4516, miR-4417, miR-642b-3p, mi R-3141, miR-5100, miR-6848-5p, miR-4739, miR -4459, miR-1237-5p, miR-296-3p, miR-4665-3p , miR-6786-5p, miR-4258, miR-6510-5p, miR-13 43-5p, miR-1247-3p, miR-6805-5p, miR-4492, m iR-1469, miR-1268b, miR-6858-5p, miR-3937, m iR-939-5p, miR-3656, miR-744-5p, miR-4687-3 p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6 842-5p, miR-4707-5p, miR-642a-3p, miR-7113- 3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p , miR-6774-5p, miR-8059, miR-3131, miR-7847- 3p, miR-4463, miR-128-2-5p, miR-4508, miR-68 06-5p, miR-7111-5p, miR-6782-5p, miR-4734, m iR-3162-5p, miR-887-3p, miR-6752-5p, miR-67 24-5p, miR-6757-5p, miR-4448, miR-671-5p, mi R-3178, miR-4725-3p, miR-940, miR-6789-5p, m iR-4484, miR-4634, miR-4745-5p, miR-4730, mi R-6803-5p, miR-6798-5p, miR-3648, miR-4783- At least one polynucleotide selected from the group consisting of 3p and miR-6836-3p, and a nucleic acid capable of specifically binding thereto. A device for detecting liver cancer, comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of 3p and miR-6836-3p.

[0039] (12) miR-1343-3p is hsa-miR-1343-3p, and miR-6 726-5p is hsa-miR-6726-5p, and miR-6515-3p is hs a-miR-6515-3p, and miR-4651 is hsa-miR-4651 and miR-4257 is hsa-miR-4257, and miR-3188 is hsa- miR-3188, and miR-6131 is hsa-miR-6131, and miR -6766-3p is hsa-miR-6766-3p, and miR-7641 is hsa -miR-7641, and miR-1249 is hsa-miR-1249, and mi R-3679-3p is hsa-miR-3679-3p, and miR-6787-5p is hsa-miR-6787-5p, and miR-4454 is hsa-miR-445 4, and miR-3135b is hsa-miR-3135b, and miR-6765 -3p is hsa-miR-6765-3p, and miR-7975 is hsa-miR- 7975, and miR-204-3p is hsa-miR-204-3p, and miR -7977 is hsa-miR-7977, and miR-7110-5p is hsa-mi R-7110-5p, and miR-6717-5p is hsa-miR-6717-5p and miR-6870-5p is hsa-miR-6870-5p, and miR-6 63b is hsa-miR-663b, and miR-6875-5p is hsa-miR- 6875-5p, and miR-8072 is hsa-miR-8072, and miR- 6816-5p is hsa-miR-6816-5p, and miR-4281 is hsa- miR-4281, where miR-6729-5p is hsa-miR-6729-5p and miR-8069 is hsa-miR-8069, miR-4706 is hsa -miR-4706, miR-7108-5p is hsa-miR-7108-5p and miR-4433b-3p is hsa-miR-4433b-3p, miR -6893-5p is hsa-miR-6893-5p, miR-6857-5p is hsa-miR-6857-5p, miR-1227-5p is hsa-miR-1 227-5p, miR-6741-5p is hsa-miR-6741-5p and miR-451a is hsa-miR-451a, miR-8063 is hsa-m iR-8063, miR-3622a-5p is hsa-miR-3622a-5p and miR-615-5p is hsa-miR-615-5p, miR-128 -1-5p is hsa-miR-128-1-5p, miR-6825-5p is hs a-miR-6825-5p, miR-1260b is hsa-miR-1260b and miR-4433-3p is hsa-miR-4433-3p, miR-4 665-5p is hsa-miR-4665-5p, miR-7845-5p is hs a-miR-7845-5p, miR-1908-5p is hsa-miR-190 8-5p, miR-6840-3p is hsa-miR-6840-3p, m iR-6765-5p is hsa-miR-6765-5p, miR-296-5p is hsa-miR-296-5p, miR-3675-3p is hsa-miR-3 675-3p, miR-6781-5p is hsa-miR-6781-5p and miR-423-5p is hsa-miR-423-5p, miR-3663-3 p is hsa-miR-3663-3p, miR-6784-5p is hsa-miR -6784-5p, miR-6749-5p is hsa-miR-6749-5p, miR-1231 is hsa-miR-1231, miR-4746-3p is hsa-miR-4746-3p, miR-6780b-5p is hsa-miR- 6780b-5p, miR-4758-5p is hsa-miR-4758-5p, miR-3679-5p is hsa-miR-3679-5p, miR-31 84-5p is hsa-miR-3184-5p, miR-6125 is hsa-mi R-6125, miR-6721-5p is hsa-miR-6721-5p, miR-6791-5p is hsa-miR-6791-5p, miR-3185 is hsa-miR-3185, miR-1260a is hsa-miR-1260a miR-3197 is hsa-miR-3197, miR-6845-5p is hsa-miR-6845-5p, miR-6887-5p is hsa-miR- 6887-5p, miR-6738-5p is hsa-miR-6738-5p, miR-6872-3p is hsa-miR-6872-3p, miR-449 7 is hsa-miR-4497, miR-1229-5p is hsa-miR-12 29-5p, miR-6820-5p is hsa-miR-6820-5p, miR-6777-5p is hsa-miR-6777-5p, miR-3917 is hsa-miR-3917, where miR-5787 is hsa-miR-5787 , miR-4286 is hsa-miR-4286, and miR-6877-5p is hs a-miR-6877-5p, and miR-1225-3p is hsa-miR-122 5-3p, miR-6088 is hsa-miR-6088, and miR-680 0-5p is hsa-miR-6800-5p, miR-1246 is hsa-miR -1246, miR-4467 is hsa-miR-4467, and miR-44 19b is hsa-miR-4419b, miR-1914-3p is hsa-miR -1914-3p, miR-4632-5p is hsa-miR-4632-5p , miR-1915-5p is hsa-miR-1915-5p, and miR-39 40-5p is hsa-miR-3940-5p, miR-1185-2-3p is h sa-miR-1185-2-3p, miR-6746-5p is hsa-miR- 6746-5p, miR-5001-5p is hsa-miR-5001-5p , miR-1228-5p is hsa-miR-1228-5p, and miR-557 2 is hsa-miR-5572, miR-4327 is hsa-miR-4327 , miR-4638-5p is hsa-miR-4638-5p, and miR-67 99-5p is hsa-miR-6799-5p, miR-6861-5p is hsa -miR-6861-5p, miR-6727-5p is hsa-miR-6727 -5p, miR-4513 is hsa-miR-4513, and miR-6805 -3p is hsa-miR-6805-3p, miR-6808-5p is hsa-m iR-6808-5p, miR-4449 is hsa-miR-4449, m iR-1199-5p is hsa-miR-1199-5p, miR-1275 is h sa-miR-1275, miR-4792 is hsa-miR-4792, miR-4443 is hsa-miR-4443, miR-6891-5p is hsa -miR-6891-5p, miR-6826-5p is hsa-miR-6826 -5p, miR-6807-5p is hsa-miR-6807-5p, mi R-7150 is hsa-miR-7150, miR-4534 is hsa-miR- 4534, miR-4476 is hsa-miR-4476, miR-464 9-5p is hsa-miR-4649-5p, miR-4525 is hsa-miR -4525, miR-1915-3p is hsa-miR-1915-3p, miR-4516 is hsa-miR-4516, miR-4417 is hsa-mi R-4417, miR-642b-3p is hsa-miR-642b-3p and miR-3141 is hsa-miR-3141, miR-5100 is hsa-m iR-5100, miR-6848-5p is hsa-miR-6848-5p and miR-4739 is hsa-miR-4739, miR-4459 is hsa- miR-4459, miR-1237-5p is hsa-miR-1237-5p and miR-296-3p is hsa-miR-296-3p, miR-4665 -3p is hsa-miR-4665-3p, miR-6786-5p is hsa-m It is iR-6786-5p, miR-4258 is hsa-miR-4258, m iR-6510-5p is hsa-miR-6510-5p, miR-1343-5 p is hsa-miR-1343-5p, miR-1247-3p is hsa-miR -1247-3p, miR-6805-5p is hsa-miR-6805-5p, miR-4492 is hsa-miR-4492, miR-1469 is hsa -miR-1469, miR-1268b is hsa-miR-1268b, miR-6858-5p is hsa-miR-6858-5p, miR-3937 is hsa-miR-3937, miR-939-5p is hsa-miR-939-5 p, miR-3656 is hsa-miR-3656, miR-744-5p is hsa-miR-744-5p, miR-4687-3p is hsa-miR-4 687-3p, miR-4763-3p is hsa-miR-4763-3p, miR-3620-5p is hsa-miR-3620-5p, miR-3195 is hsa-miR-3195, miR-6842-5p is hsa-miR-684 2-5p, miR-4707-5p is hsa-miR-4707-5p, m iR-642a-3p is hsa-miR-642a-3p, miR-7113-3 p is hsa-miR-7113-3p, miR-4728-5p is hsa-miR -4728-5p, miR-5195-3p is hsa-miR-5195-3p, miR-1185-1-3p is hsa-miR-1185-1-3p, mi R-6774-5p is hsa-miR-6774-5p, miR-8059 is hs a-miR-8059, miR-3131 is hsa-miR-3131, m iR-7847-3p is hsa-miR-7847-3p, miR-4463 is h sa-miR-4463, miR-128-2-5p is hsa-miR-128- 2-5p, miR-4508 is hsa-miR-4508, miR-680 6-5p is hsa-miR-6806-5p, miR-7111-5p is hsa- miR-7111-5p, miR-6782-5p is hsa-miR-6782- 5p, miR-4734 is hsa-miR-4734, miR-3162- 5p is hsa-miR-3162-5p, miR-887-3p is hsa-miR -887-3p, miR-6752-5p is hsa-miR-6752-5p, and miR-6724-5p is hsa-miR-6724-5p, miR-675 7-5p is hsa-miR-6757-5p, miR-4448 is hsa-miR -4448, miR-671-5p is hsa-miR-671-5p, mi R-3178 is hsa-miR-3178, miR-4725-3p is hsa-m iR-4725-3p, miR-940 is hsa-miR-940, miR -6789-5p is hsa-miR-6789-5p, miR-4484 is hsa -miR-4484, miR-4634 is hsa-miR-4634, mi R-4745-5p is hsa-miR-4745-5p, miR-4730 is hs a-miR-4730, miR-6803-5p is hsa-miR-6803-5 p, where miR-6798-5p is hsa-miR-6798-5p, miR- 3648 is hsa-miR-3648, miR-4783-3p is hsa-miR -4783-3p, and miR-6836-3p is hsa-miR-6836- 3p, the device according to (11).

[0040] (13) The nucleic acid is a polynucleotide shown in the following (a) to (e): (a) A polynucleotide consisting of a base sequence represented by any of SEQ ID NOs: 1 to 167 and 714 to 729 or a base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases, (b) A polynucleotide containing a base sequence represented by any of SEQ ID NOs: 1 to 167 and 714 to 729, (c) A polynucleotide consisting of a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 1 to 167 and 714 to 729 or a base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases, (d) A polynucleotide containing a base sequence represented by any of SEQ ID NOs: 1 to 167 and 714 to 729 or a base sequence complementary to the base sequence in which u is t in the base sequence, (e) A polynucleotide that hybridizes with any of the polynucleotides of (a) to (d) under stringent conditions, a polynucleotide selected from the group consisting of, the device according to (11) or (12). (14) The device is miR-23b-3p, miR, which is another liver cancer marker a polynucleotide, and and (e) A polynucleotide that hybridizes with any of the polynucleotides of (a) to (d) under stringent conditions, a polynucleotide, selected from the group consisting of, the device according to (11) or (12). ice.

[0041] (14) The device is miR-23b-3p, miR -23a-3p, miR-625-3p, miR-1228-3p, miR-614, m iR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5 p, miR-92b-3p, miR-150-3p, miR-564, miR-125a -3p, miR-92b-5p, miR-92a-3p, and miR-663a selected from the group consisting of at least one or more polynucleotides capable of specifically binding to a nucleic acid, and further contained in the device according to any one of (11)-(13).

[0042] (15) miR-23b-3p is hsa-miR-23b-3p, miR-23a -3p is hsa-miR-23a-3p, miR-625-3p is hsa-miR -625-3p, miR-1228-3p is hsa-miR-1228-3p, miR-614 is hsa-miR-614, miR-1913 is hsa-mi R-1913, miR-92a-2-5p is hsa-miR-92a-2-5p and miR-187-5p is hsa-miR-187-5p, miR-16-5 p is hsa-miR-16-5p, miR-92b-3p is hsa-miR-92 b-3p, miR-150-3p is hsa-miR-150-3p, miR -564 is hsa-miR-564, miR-125a-3p is hsa-miR- 125a-3p, miR-92b-5p is hsa-miR-92b-5p, miR-92a-3p is hsa-miR-92a-3p, and miR-663a is hsa-miR-663a, the device according to (14).

[0043] (16) The nucleic acid is a polynucleotide represented by any of the following (f) to (j): (f) A polynucleotide consisting of a base sequence represented by any of SEQ ID NOs: 168 to 183 or a base sequence in which u is t in the base sequence, its variant, its derivative, or a fragment thereof containing 15 or more consecutive bases, (g) A polynucleotide containing a base sequence represented by any of SEQ ID NOs: 168 to 183, (h) A polynucleotide consisting of a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 168 to 183 or a base sequence in which u is t in the base sequence, its variant, its derivative, or a fragment thereof containing 15 or more consecutive bases, (i) A polynucleotide containing a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 168 to 183 or a base sequence in which u is t in the base sequence, and (j) A polynucleotide that hybridizes with any of the polynucleotides of (f) to (i) under stringent conditions, The device according to (14) or (15), which is a polynucleotide selected from the group consisting of

[0044] (17) The device is miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR-6087, miR-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486-3p, miR-4466, miR-30c-1-3p, miR-36, which are other liver cancer markers, ​​​​​​​​​​​​21, miR-6743-5p, miR-4298, miR-4741, miR-361 9-3p, miR-6824-5p, miR-5698, miR-371a-5p, mi R-4488, miR-1233-5p, miR-4723-5p, miR-24-3p , miR-1238-5p, miR-4442, miR-3928-3p, miR-67 16-5p, miR-6089, miR-6124, miR-6778-5p, miR- 557, and at least one or more polynucleotides selected from the group consisting of miR-6090, and a nucleic acid capable of specifically binding to the polynucleotide, according to any one of (11)-(16). The device described in any of (11)-(16) further comprising a nucleic acid capable of specifically binding to the polynucleotide. Device.

[0045] (18) miR-4688 is hsa-miR-4688, miR-4648 is hs a-miR-4648, miR-6085 is hsa-miR-6085, m iR-6126 is hsa-miR-6126, miR-6880-5p is hsa- miR-6880-5p, miR-328-5p is hsa-miR-328-5p , miR-6768-5p is hsa-miR-6768-5p, miR-3 180 is hsa-miR-3180, miR-6087 is hsa-miR-608 7, miR-1273g-3p is hsa-miR-1273g-3p, mi R-1225-5p is hsa-miR-1225-5p, miR-3196 is hs a-miR-3196, miR-4695-5p is hsa-miR-4695-5 p, miR-6732-5p is hsa-miR-6732-5p, miR- 638 is hsa-miR-638, miR-6813-5p is hsa-miR-6 813 - 5p, where miR - 665 is hsa - miR - 665, miR - 486 -3p is hsa - miR - 486 - 3p, miR - 4466 is hsa - miR - 4 466, miR - 30c - 1 - 3p is hsa - miR - 30c - 1 - 3p, miR - 3621 is hsa - miR - 3621, miR - 6743 - 5p is hsa -miR - 6743 - 5p, miR - 4298 is hsa - miR - 4298 , miR - 4741 is hsa - miR - 4741, miR - 3619 - 3p is hs a - miR - 3619 - 3p, miR - 6824 - 5p is hsa - miR - 682 4 - 5p, miR - 5698 is hsa - miR - 5698, miR - 371 a - 5p is hsa - miR - 371a - 5p, miR - 4488 is hsa - miR -4488, miR - 1233 - 5p is hsa - miR - 1233 - 5p, miR - 4723 - 5p is hsa - miR - 4723 - 5p, miR - 24 - 3p is hsa - miR - 24 - 3p, miR - 1238 - 5p is hsa - miR - 12 38 - 5p, miR - 4442 is hsa - miR - 4442, miR - 39 28 - 3p is hsa - miR - 3928 - 3p, miR - 6716 - 5p is hsa -miR - 6716 - 5p, miR - 6089 is hsa - miR - 6089 , miR - 6124 is hsa - miR - 6124, miR - 6778 - 5p is hs a - miR - 6778 - 5p, miR - 557 is hsa - miR - 557, and miR - 6090 is hsa - miR - 6090, the device according to (17) .

[0046] (19) The nucleic acid is a polynucleotide represented by the following (k) to (o): (k) A polynucleotide consisting of a base sequence represented by any of SEQ ID NOs: 184 to 224 or a base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases, (l) A polynucleotide containing a base sequence represented by any of SEQ ID NOs: 184 to 224, (m) A polynucleotide consisting of a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 184 to 224 or a base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases, (n) A polynucleotide containing a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 184 to 224 or a base sequence in which u is t in the base sequence, and (o) A polynucleotide that hybridizes with any of the polynucleotides of (k) to (n) under stringent conditions, The device according to (17) or (18), which is a polynucleotide selected from the group consisting of

[0047] (20) The device according to any of (11) to (19), which is a device for measurement by hybridization technology.

[0048] (21) The device according to (20), wherein the hybridization technology is nucleic acid array technology.

[0049] (22) The device according to (11) or (12), which is capable of specifically binding to each of at least two or more polynucleotides selected from all liver cancer markers described therein. ​​​​​​​​​​The device according to any one of (11) to (21), comprising at least two nucleic acids.

[0050] (23) Using the kit according to any one of (1) to (10) or the device according to any one of (11) to (22) to measure the expression level of a target nucleic acid in a specimen of a subject, and using the measured expression level and the control expression level of a healthy subject measured in the same manner, to evaluate in vitro whether the subject has liver cancer or does not have liver cancer A method for detecting liver cancer, comprising: (24) The method according to (23), wherein the subject is a human. (25) The method according to (23) or (24), wherein the specimen is blood, serum or plasma.

[0051] (24) The method according to (23), wherein the subject is a human. (25) The method according to (23) or (24), wherein the specimen is blood, serum or plasma.

[0052] <Definition of Terms> The terms used in this specification have the following definitions. The representations by abbreviations such as nucleotide, polynucleotide, DNA, RNA, etc. shall follow the "Guidelines for the Preparation of Specifications, etc. Containing Base Sequences or Amino Acid Sequences" (edited by the Japan Patent Office) and the common practice in the technical field. and the common practice in the technical field. In this specification, the term "polynucleotide" is used for nucleic acids including any of RNA, DNA, and RNA / DNA (chimera). The above DNA includes cDNA, genomic DNA, and synthetic DNA. The above RNA includes total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. In this specification, "synthetic DNA" and "synthetic RNA" refer to nucleic acids having a predetermined base sequence (natural sequence

[0053] In this specification, the term "polynucleotide" is used for nucleic acids including any of RNA, DNA, and RNA / DNA (chimera). The above DNA includes cDNA, genomic DNA, and synthetic DNA. The above RNA includes total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. In this specification, the term "polynucleotide" is used for nucleic acids including any of RNA, DNA, and RNA / DNA (chimera). The above DNA includes cDNA, genomic DNA, and synthetic DNA. The above RNA includes total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. In this specification, the term "polynucleotide" is used for nucleic acids including any of RNA, DNA, and RNA / DNA (chimera). The above DNA includes cDNA, genomic DNA, and synthetic DNA. The above RNA includes total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. In this specification, the term "polynucleotide" is used for nucleic acids including any of RNA, DNA, and RNA / DNA (chimera). The above DNA includes cDNA, genomic DNA, and synthetic DNA. The above RNA includes total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. It may be either a natural or non-natural sequence. Based on this, for example, using an automated nucleic acid synthesizer, human refers to artificially produced DNA and RNA. In this specification, "non-natural sequence" is intended to be used in a broad sense, and includes sequences that are different from natural sequences, such as sequences containing substitutions, deletions, insertions, and / or additions of one or more nucleotides (i.e., mutant sequences), sequences containing one or more modified nucleotides (i.e., modified sequences), and so on. Also, in this specification, polynucleotides are used interchangeably with nucleic acids.

[0054] In this specification, a "fragment" is a polynucleotide having a base sequence of a continuous part of a polynucleotide, and desirably has a length of 15 bases or more, preferably 17 bases or more, more preferably 1 9 bases or more.

[0055] In this specification, "gene" is used to include not only RNA and double-stranded DNA, but also each single-stranded DNA such as the positive strand (or sense strand) or complementary strand (or antisense strand) that constitutes it. It is not particularly limited by its length. Therefore, in this specification, "gene" includes double-stranded DNA containing human genomic DNA, single-stranded DNA (positive strand), single-stranded DNA having a sequence complementary to the positive strand

[0056] (complementary strand. including cDNA), microRNA (miRNA), and fragments thereof, and also any transcription products. Also, the "gene" is not only the "gene" represented by a specific base sequence (or SEQ ID NO), but also RNA having the same biological function as the RNA encoded by these, such as homologs (i.e., homologs or orthologs), gene families (complementary strand. including cDNA), microRNA (miRNA), and fragments thereof, and also any transcription products. Also, the "gene" is not only the "gene" represented by a specific base sequence (or SEQ ID NO), but also RNA having the same biological function as the RNA encoded by these, such as homologs (i.e., homologs or orthologs), gene families and RNA that is equivalent to the RNA encoded by these, for example, homologs (i.e., homologs or orthologs), gene families and RNA that is equivalent to the RNA encoded by these, for example, homologs (i.e., homologs or orthologs), gene families It includes "nucleic acids" encoding homologs, mutants such as types, and derivatives. Such homologs, mutants or as derivatives, the "nucleic acids" encoding them specifically include, under the stringent conditions described later, the base sequences represented by any of SEQ ID NOs: 1 to 765, or the base sequences in which u is t, and the "nucleic acids" having a base sequence that hybridizes with the complementary sequence can be mentioned. Note that a "gene" is not limited by the separation of functional regions and can include, for example, an expression control region, a coding region, an exon or an intron. Also, a "gene" may be contained in a cell, may exist alone outside the cell, or may be encapsulated in vesicles called exosomes.

[0057] In this specification, "exosome" (also known as "exosome") is a vesicle encapsulated by a lipid bilayer secreted from cells. Exosomes are derived from multivesicular endosomes and contain "genes" such as RNA and DNA and biological substances such as proteins inside when released into the extracellular environment. Exosomes are known to be contained in body fluids such as blood, serum, plasma, and lymph.

[0058] In this specification, "transcript" refers to RNA synthesized using the DNA sequence of a gene as a template. RNA polymerase binds to a site called a promoter upstream of the gene and binds ribonucleotides to the 3' end so as to be complementary to the base sequence of DNA, and RNA is synthesized in such a way that it binds sequentially. This RNA contains not only the gene itself but also the entire sequence from the transcription start point, including the expression control region, coding region, exon or intron, to the end of the polyA sequence.

[0059] In addition, in this specification, "microRNA (miRNA)" refers to, unless otherwise specified, RNA precursors with a hairpin-like structure that are transcribed and cleaved by dsRNA cleavage enzymes with RNase III cleavage activity and incorporated into a protein complex called RISC, and are intentionally used to refer to non-coding RNAs of 15 to 25 bases involved in the translational repression of mRNA. Also, "miRNA" as used in this specification includes not only "miRNA" represented by a specific base sequence (or SEQ ID NO.), but also precursors of the "miRNA" (pre-miRNA, pri-miRNA), and miRNAs with biological functions equivalent to these, such as homologs (i.e., homologs or orthologs), mutants such as gene polymorphisms, and derivatives. Specific examples of such precursors, homologs, mutants or derivatives can be identified by miRBase release 20 (http: / / www.mirbase.org / ) and hybridize with the complementary sequence of any specific base sequence represented by any of SEQ ID NOs. 1 to 765 under the stringent conditions described later. Furthermore, "miRNA" as used in this specification may be a gene product of the miR gene, and such a gene product includes mature miRNA (e.g., non-coding RNAs of 15 to 25 bases, or 19 to 25 bases, involved in the translational repression of mRNA as described above) or miRNA precursors (e.g., pre-miRNA or pri-miRNA as described above).

[0060] In this specification, "probe" refers to RNA generated by the expression of a gene or Polynucleotides used to specifically detect incoming polynucleotides and / or include polynucleotides complementary thereto.

[0061] As used herein, a "primer" refers to a polynucleotide that specifically recognizes and amplifies an RNA produced by gene expression or a polynucleotide derived therefrom and / or a polynucleotide complementary thereto. include polynucleotides complementary thereto.

[0062] Here, the complementary polynucleotide (complementary strand, reverse strand) refers to a polynucleotide having a base sequence defined by any of SEQ ID NOs: 1 to 765, or a base sequence in which u is t in the said base sequence, or the full-length sequence of a polynucleotide consisting thereof, or a partial sequence thereof, (herein referred to as the sense strand for convenience) is based on the base pair relationship such as A:T(U), G:C, and is a polynucleotide having a base complementary relationship. However, such a complementary strand is not limited to forming a completely complementary sequence with the base sequence of the target sense strand, and may have a complementary relationship to such an extent that it can hybridize with the target sense strand under stringent conditions. As used herein, "stringent conditions" refer to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (e.g., a measurement value of the average of the background measurement value + the standard error of the background measurement value × 2 or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " As used herein, "stringent conditions" refer to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (e.g., a measurement value of the average of the background measurement value + the standard error of the background measurement value × 2 or more) than to other sequences. Stringent

[0063] As used herein, "stringent conditions" refer to conditions under which a nucleic acid probe hybridizes to its target sequence to a greater extent (e.g., a measurement value of the average of the background measurement value + the standard error of the background measurement value × 2 or more) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " conditions are sequence-dependent and vary depending on the environment in which hybridization is performed. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the nucleic acid probe can be identified. " Specific examples of "stringent conditions" will be described later.

[0064] In this specification, the "Tm value" means the temperature at which the double-stranded portion of a polynucleotide denatures into single strands and the double strands and single strands are present in a 1:1 ratio.

[0065] In this specification, the "variant" in the case of nucleic acids refers to natural variants caused by polymorphisms, mutations, etc., or the nucleotide sequences of any of SEQ ID NOs: 1 to 765, or the nucleotide sequences in which u is t in the said nucleotide sequences, or variants containing deletions, substitutions, additions or insertions of one or more bases in the partial sequences thereof, or variants showing % identity of about 90 % or more, about 95% or more, about 97% or more, about 98% or more, about 99% or more with each of the said nucleotide sequences or their partial sequences, or nucleic acids that hybridize with polynucleotides or oligonucleotides containing the said nucleotide sequences or their partial sequences under the stringent conditions defined above.

[0066] In this specification, "several" means an integer of about 10, 9, 8, 7, 6, 5, 4, 3 or 2.

[0067] In this specification, variants can be prepared using well-known techniques such as site-directed mutagenesis and mutagenesis introduction methods using the PCR method.

[0068] In this specification, "% identity" can be determined using the protein or gene search systems such as BLAST and FASTA above, with or without introducing gaps (Zheng Zhang et al., 2000, J. Comput. B iol., 7, p203-214; Altschul, S.F. et al., 1990, Jo Journal of Molecular Biology, Vol. 215, p403 - 41 0; Pearson, W. R. et al., 1988, Proc. Natl. Acad. Sci . U.S.A., Vol. 85, p2444 - 2448).

[0069] As used herein, "derivative" refers to a modified nucleic acid, including, but not limited to, derivatives labeled with a fluorophore, etc., modified nucleotides (e.g., nucleotides containing groups such as alkyls such as halogen, methyl, alkoxys such as methoxy, thio, carboxymethyl, etc., and reconstruction of bases), nucleotides that have undergone saturation of double bonds, deamination, substitution of oxygen molecules with sulfur molecules, etc., and derivatives containing such), PNA (peptide nucleic acid; Niels en, P. E. et al., 1991, Science, Vol. 254, p1497 - 500), L NA (locked nucleic acid; Obika, S. et al., 1998, Tetrahedron Lett., Vol. 39, p5401 - 5404), etc. is meant to include.

[0070] The "nucleic acid" that can specifically bind to a polynucleotide selected from the group of miRNAs that are the above - mentioned liver cancer markers herein is a synthesized or prepared nucleic acid, specifically it includes "nucleic acid probes" or "primers", and is used directly or indirectly for detecting the presence or absence of liver cancer in a subject, or for diagnosing the presence or absence of liver cancer, the degree of disease, the presence or absence of improvement of liver cancer and the degree of improvement, the sensitivity to the treatment of liver cancer, or for screening candidate substances useful for the prevention, improvement or treatment of liver cancer. These are related to the sequence in vivo, especially in samples of body fluids such as blood, urine, etc., in relation to the development of liver cancer ​​​​ Specifically recognize a transcript represented by any of numbers 1 to 765 or a cDNA-synthesized nucleic acid thereof and include nucleotides, oligonucleotides, and polynucleotides that can bind thereto. These nucleotides, oligonucleotides, and polynucleotides are based on the above properties and can be effectively used as a probe for detecting the above gene expressed in vivo, in tissues, cells, etc., and as a primer for amplifying the above gene expressed in vivo

[0071] As used herein, the term "detection" can be replaced with the terms inspection, measurement, detection, or assistance in determination. Also, as used herein, the term "evaluation" is used in the sense of including assisting in diagnosis or evaluation based on inspection results or measurement results

[0072] As used herein, the "subject" means mammals such as humans, primates including chimpanzees, pet animals such as dogs and cats, livestock animals such as cows, horses, sheep, and goats, and rodents such as mice and rats. Also, a "healthy subject" also means such a mammal that is not suffering from the cancer to be detected

[0073] As used herein, "liver cancer" means "primary liver cancer" that originates in the liver, and includes, for example, "hepatocellular carcinoma" in which liver cells have become cancerous and "hepatocellular-cholangiocarcinoma mixed cancer"

[0074] As used herein, "P" or "P value" refers to the probability that a statistic more extreme than the statistic actually calculated from the data is observed under the null hypothesis in a statistical test. Thus ​​​​​​​​​​Thus, the smaller the "P" or "P value", the more significant the difference between the comparison targets can be considered.

[0075] In this specification, "sensitivity" is the value of (the number of true positives) / (the number of true positives + the number of false negatives) and means. If the sensitivity is high, it becomes possible to detect liver cancer at an early stage, leading to resection of the entire cancerous part and a reduction in the recurrence rate.

[0076] In this specification, "specificity" means (the number of true negatives) / (the number of true negatives + the number of false positives). If the specificity is high, it prevents the unnecessary additional tests due to misclassifying a healthy body as a liver cancer patient, leading to a reduction in the burden on the patient and a reduction in medical costs.

[0077] In this specification, "accuracy" means the value of (the number of true positives + the number of true negatives) / (the total number of cases). Accuracy indicates the proportion of correct discrimination results for all specimens and is the first indicator for evaluating the detection performance.

[0078] In this specification, the "specimen" to be the subject of determination, detection or diagnosis refers to tissues and biological materials in which the gene of the present invention undergoes expression changes along with the occurrence, progression of liver cancer, and the exertion of therapeutic effects on liver cancer. Specifically, it refers to liver tissues and their surrounding blood vessels, lymph nodes and organs, as well as organs suspected of metastasis, skin, and body fluids such as blood, urine, saliva, sweat, tissue exudates, serum, plasma prepared from blood, and others, feces, hair, etc. Furthermore, biological samples extracted from these, specifically referring to genes such as RNA and miRNA.

[0079] The term "hsa-miR-1343-3p gene" or "hsa-miR-1343-3p" used in this specification refers to hsa-miR-1343-3 described in SEQ ID NO: 1. The p gene (miRBase Accession No. MIMAT0019776) and include other species homologs or orthologs, etc. hsa-miR-1343- 3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71, p 78 - 86. Also, "hsa-miR-13 43-3p" has a hairpin-like structure as its precursor, "hsa-mir-1343" (miRBase Accession No. MI0017320, SEQ ID NO: 225) is known.

[0080] As used herein, the term "hsa-miR-6726-5p gene" or "hsa-mi R-6726-5p" refers to the hsa-miR-6726-5 p gene (miRBase Accession No. MIMAT0027353) described in SEQ ID NO: 2 and includes other species homologs or orthologs, etc. hsa-miR-6726- 5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p 1634 - 1645. Also, "hsa-mi R-6726-5p" has a hairpin-like structure as its precursor, "hsa-mir-6 726" (miRBase Accession No. MI0022571, SEQ ID NO: 226) is known.

[0081] As used herein, the term "hsa-miR-6515-3p gene" or "hsa-mi R-6515-3p" refers to the hsa-miR-6515-3 p gene (miRBase Accession No. MIMAT0025487) described in SEQ ID NO: 3 and It includes other species homologs or orthologs, etc. hsa-miR-6515- The 3p gene can be obtained by the method described by Joyce CE et al., 2011, Hum Mol Genet, Vol. 20 , pp. 4025-4040. Also, "hsa- miR-6515-3p" has a hairpin-like structure as its precursor, "hsa-mir -6515" (miRBase Accession No. MI0022227, sequence number 227) is known.

[0082] As used herein, the term "hsa-miR-4651 gene" or "hsa-miR-4 651" includes the hsa-miR-4651 gene (miRB ase Accession No. MIMAT0019715) described in SEQ ID NO: 4 and other species homologs or orthologs, etc. The hsa-miR-4651 gene can be obtained by the method described by Perss on H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Also, "hsa-miR-4651" has a hairpin-like structure as its precursor "hsa-mir-4651" (miRBase Access ion No. MI0017279, SEQ ID NO: 228) is known.

[0083] As used herein, the term "hsa-miR-4257 gene" or "hsa-miR-4 257" includes the hsa-miR-4257 gene (miRB ase Accession No. MIMAT0016878) described in SEQ ID NO: 5 and other species homologs or orthologs, etc. The hsa-miR-4257 gene is described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192, can be obtained by the method described therein. Also, "hsa-miR-4257" has a hairpin-like structure as its precursor, namely "hsa-mir-4257" (miRBase Accession No. .MI0015856, SEQ ID NO: 229) is known. The term "hsa-miR-3188 gene" or "hsa-miR-3 188" as used herein encompasses the hsa-miR-3188 gene (miRBase Accession No. MIMAT0015070) described in SEQ ID NO: 6, as well as homologs or orthologs of other species. The hsa-miR-3188 gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Also, "hsa-miR-3188" has a hairpin-like structure as its precursor, namely "hsa-mir-3188" (miRBase Accession No.

[0084] MI0014232, SEQ ID NO: 230) is known. The term "hsa-miR-6131 gene" or "hsa-miR-6 131" as used herein encompasses the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in SEQ ID NO: 7, as well as homologs or orthologs of other species. The hsa-miR-6131 gene can be obtained by the method described by Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, p552-5 64. Also, "hsa-miR-6131" The term "hsa-miR-3188 gene" or "hsa-miR-3188" as used herein encompasses the hsa-miR-3188 gene (miRBase Accession No. MIMAT0015070) described in SEQ ID NO: 6, as well as homologs or orthologs of other species. The hsa-miR-3188 gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e9685. Also, "hsa-miR-3188" has a hairpin-like structure as its precursor, namely "hsa-mir-3188" (miRBase Accession No. The term "hsa-miR-6131 gene" or "hsa-miR-6131" as used herein encompasses the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in SEQ ID NO: 7, as well as homologs or orthologs of other species. The hsa-miR-6131 gene can be obtained by the method described by Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, p552-5 MI0014232, SEQ ID NO: 230) is known. The term "hsa-miR-6131 gene" or "hsa-miR-6131" as used herein encompasses the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in SEQ ID NO: 7, as well as homologs or orthologs of other species. The hsa-miR-6131 gene can be obtained by the method described by Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, p552-5

[0085] The term "hsa-miR-6131 gene" or "hsa-miR-6131" as used herein encompasses the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in SEQ ID NO: 7, as well as homologs or orthologs of other species. The hsa-miR-6131 gene can be obtained by the method described by Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, p552-5 The term "hsa-miR-6131 gene" or "hsa-miR-6131" as used herein encompasses the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in SEQ ID NO: 7, as well as homologs or orthologs of other species. The hsa-miR-6131 gene can be obtained by the method described by Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, p552-5 The term "hsa-miR-6131 gene" or "hsa-miR-6131" as used herein encompasses the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in SEQ ID NO: 7, as well as homologs or orthologs of other species. The hsa-miR-6131 gene can be obtained by the method described by Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, p552-5 The hsa-miR-6131 gene can be obtained by the method described by Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, p552-5 64. Also, "hsa-miR-6131" The term "hsa-miR-6131 gene" or "hsa-miR-6131" as used herein encompasses the hsa-miR-6131 gene (miRBase Accession No. MIMAT0024615) described in SEQ ID NO: 7, as well as homologs or orthologs of other species. The hsa-miR-6131 gene can be obtained by the method described by Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, p552-5 "hsa-mir-6131" (miRBa), which has a hairpin-like structure as its precursor, is known (miRBase Accession No. MI0021276, SEQ ID NO: 231).

[0086] As used herein, the term "hsa-miR-6766-3p gene" or "hsa-miR-6766-3p" refers to the hsa-miR-6766-3p gene (miRBase Accession No. MIMAT0027433) described in SEQ ID NO: 8, as well as other species homologs or orthologs, etc. The hsa-miR-6766-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-miR-6766-3p" has a hairpin-like structure as its precursor, "hsa-mir-6766" (miRBase Accession No. MI0022611, SEQ ID NO: 232) is known.

[0087] As used herein, the term "hsa-miR-7641 gene" or "hsa-miR-7641" refers to the hsa-miR-7641 gene (miRBase Accession No. MIMAT0029782) described in SEQ ID NO: 9, as well as other species homologs or orthologs, etc. The hsa-miR-7641 gene can be obtained by the method described in Yoo JK et al., 2013, Arch Pharm Res, 36, p353-358. Also, "hsa-miR-7641" has a hairpin-like structure as its precursor, "hsa-mir-7641-1", "hsa-mir- ​​​​​​"7641-2" (miRBase Accession No. MI0024975, M I0024976, SEQ ID NO: 233, 234) is known.

[0088] As used herein, the term "hsa-miR-1249 gene" or "hsa-miR-1 249" refers to the hsa-miR-1249 gene described in SEQ ID NO: 10 (miR Base Accession No. MIMAT0005901) and other homologs or orthologs of other species. The hsa-miR-1249 gene can be obtained by the method described by Mori n RD et al., 2008, Genome Res, Vol. 18, p610-621. Also, "hsa-miR-1249" is the precursor which takes a hairpin-like structure, "hsa-mir-1249" (miRBase Acce ssion No. MI0006384, SEQ ID NO: 235) is known. As used herein, the term "hsa-miR-3679-3p gene" or "hsa-mi R-3679-3p" refers to the hsa-miR-3679-

[0089] 3p gene described in SEQ ID NO: 11 (miRBase Accession No. MIMAT0018105) and other homologs or orthologs of other species. The hsa-miR-3679 -3p gene can be obtained by the method described by Creighton CJ et al., 2010, PLoS One, Vol. 5, e9637. Also, "hsa-miR-36 79-3p" is the precursor which takes a hairpin-like structure, "hsa-mir-3679" which takes a hairpin-like structure, "hsa-mir-3679" 79-3p" is the precursor which takes a hairpin-like structure, "hsa-mir-3679" (miRBase Accession No. MI0016080, SEQ ID NO: 236) is known.

[0090] As used herein, the term "hsa-miR-6787-5p gene" or "hsa-mi R-6787-5p" includes the hsa-miR-6787- 5p gene (miRBase Accession No. MIMAT0027474) described in SEQ ID NO: 12 and other homologs or orthologs of other species. The hsa-miR-6787 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6787-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6787" (miRBase Accession No. MI0022632, SEQ ID NO 237) is known.

[0091] As used herein, the term "hsa-miR-4454 gene" or "hsa-miR-4 454" includes the hsa-miR-4454 gene (miR Base Accession No. MIMAT0018976) described in SEQ ID NO: 13 and other homologs or orthologs of other species. The hsa-miR-4454 gene can be obtained by the method described in Jima DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-4454" has a hairpin-like structure as its precursor, "hsa-mir-4454" (miRBase Accessio n No. MI0016800, SEQ ID NO: 238) is known. n No. MI0016800, SEQ ID NO: 238) is known. n No. MI0016800, SEQ ID NO: 238) is known.

[0092] As used herein, the term "hsa-miR-3135b gene" or "hsa-miR- The term "3135b" encompasses the hsa-miR-3135b gene described in SEQ ID NO: 14 ( miRBase Accession No. MIMAT0018985) and other homologs or orthologs of organisms. The hsa-miR-3135b gene can be obtained by the method described in Jima DD et al., 2010, Blood, Vol. 116, pp. e118-e127. Also, "hsa-miR-3135b" has a hairpin-like structure as its precursor, "hsa-mir-3135b" (miRBase Ac cession No. MI0016809, SEQ ID NO: 239).

[0093] As used herein, the term "hsa-miR-6765-3p gene" or "hsa-mi R-6765-3p" encompasses the hsa-miR-6765- 3p gene described in SEQ ID NO: 15 (miRBase Accession No. MIMAT0027431) and other homologs or orthologs of organisms. The hsa-miR-6765 -3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. p1634-1645. Also, "hsa-m iR-6765-3p" has a hairpin-like structure as its precursor, "hsa-mir- 6765" (miRBase Accession No. MI0022610, SEQ ID NO No: 240).

[0094] As used herein, the term "hsa-miR-7975 gene" or "hsa-miR-7 975" encompasses the hsa-miR-7975 gene described in SEQ ID NO: 16 (miR ​​Base Accession No. (MIMAT0031178) and other homologous genes of other species include logs or orthologs, etc. The hsa-miR-7975 gene was identified by Velt hut-Meikas A et al., 2013, Mol Endocrinol, online version, and can be obtained by the methods described therein. Also, "hsa-miR-7975" has a hairpin-like structure as its precursor, "hsa-mir-7975" (miRBa se Accession No. MI0025751, SEQ ID NO: 241) is known .

[0095] As used herein, the term "hsa-miR-204-3p gene" or "hsa-miR -204-3p" includes the hsa-miR-204-3p gene described in SEQ ID NO: 17 (miRBase Accession No. MIMAT0022693) and other homologous genes or orthologs of other species. The hsa-miR-204-3p gene can be obtained by the methods described by Lim LP et al., 2003, Science, 299, p1540. Also, "hsa-miR-204-3p" has a hairpin-like structure as its precursor, "hsa-mir-204" (miRBase Ac cession No. MI0000284, SEQ ID NO: 242) is known.

[0096] As used herein, the term "hsa-miR-7977 gene" or "hsa-miR-7 977" includes the hsa-miR-7977 gene described in SEQ ID NO: 18 (miR Base Accession No. MIMAT0031180) and other homologous genes of other species ​​Including logs or orthologs, etc. The hsa-miR-7977 gene is Velt Hut-Meikas A et al., 2013, Mol Endocrinol, online edition, can be obtained by the method described therein. Also, "hsa-miR-7977" has a hairpin-like structure as its precursor, "hsa-mir-7977" (miRBa se Accession No. MI0025753, SEQ ID NO: 243) is known to be.

[0097] As used herein, the term "hsa-miR-7110-5p gene" or "hsa-mi R-7110-5p" refers to the hsa-miR-7110- 5p gene (miRBase Accession No. MIMAT0028117) described in SEQ ID NO: 19 and other species homologs or orthologs, etc. The hsa-miR-7110 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-7110-5p" has a hairpin-like structure as its precursor, "hsa-mir- 7110" (miRBase Accession No. MI0022961, SEQ ID NO 244) is known.

[0098] As used herein, the term "hsa-miR-6717-5p gene" or "hsa-mi R-6717-5p" refers to the hsa-miR-6717- 5p gene (miRBase Accession No. MIMAT0025846) described in SEQ ID NO: 20 and other species homologs or orthologs, etc. The hsa-miR-6717 The -5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp330-335. Also, "hsa-miR-6717-5p" has a hairpin-like structure as its precursor, "hsa-mir-6717" (miRBase Accession No. MI0022551, SEQ ID NO: 245) is known.

[0099] The term "hsa-miR-6870-5p gene" or "hsa-miR-6870-5p" used in this specification includes the hsa-miR-6870-5p gene (miRBase Accession No. MIMAT0027640) described in SEQ ID NO: 21, and other homologs or orthologs of other species. The hsa-miR-6870-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp1634-1645. Also, "hsa-miR-6870-5p" has a hairpin-like structure as its precursor, "hsa-mir-6870" (miRBase Accession No. MI0022717, SEQ ID NO: 246) is known.

[0100] The term "hsa-miR-663b gene" or "hsa-miR-663b" used in this specification includes the hsa-miR-663b gene (miRBase Accession No. MIMAT0005867) described in SEQ ID NO: 22, and other homologs or orthologs of other species. The hsa-miR-663b gene is described in Takada S et al., 2008, Leukemia, Vol. 22, pp1274-1278. ​​​​​​​​​​​​​​​​can be obtained by the method. Also, "hsa-miR-663b" is its precursor "hsa-mir-663b" (miRBase Acce ssion No.MI0006336, SEQ ID NO: 247) which has a hairpin-like structure as

[0101] As used herein, the term "hsa-miR-6875-5p gene" or "hsa-mi R-6875-5p" refers to the hsa-miR-6875- 5p gene (miRBase Accession No.MIMAT0027650) described in SEQ ID NO: 23 and also includes other species homologs or orthologs, etc. The hsa-miR-6875 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6875-5p" has a hairpin-like structure as its precursor "hsa-mir- 6875" (miRBase Accession No.MI0022722, SEQ ID NO: 248) which is known.

[0102] As used herein, the term "hsa-miR-8072 gene" or "hsa-miR-8 072" refers to the hsa-miR-8072 gene (miR Base Accession No.MIMAT0030999) described in SEQ ID NO: 24 and also includes other species homologs or orthologs, etc. The hsa-miR-8072 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, 39, p480-487. Also, "hsa-miR-8072" has a hairpin as its precursor "hsa-mir-8072" (miRBase Accession No. MI0025908, SEQ ID NO: 249) having a hairpin-like structure is known.

[0103] As used herein, the term "hsa-miR-6816-5p gene" or "hsa-mi R-6816-5p" refers to the hsa-miR-6816- 5p gene (miRBase Accession No. MIMAT0027532) described in SEQ ID NO: 25 and includes other species homologs or orthologs, etc. The hsa-miR-6816 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6816-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6816" (miRBase Accession No. MI0022661, SEQ ID NO: 250) is known.

[0104] As used herein, the term "hsa-miR-4281 gene" or "hsa-miR-4 281" refers to the hsa-miR-4281 gene (miR Base Accession No. MIMAT0016907) described in SEQ ID NO: 26 and includes other species homo logs or orthologs, etc. The hsa-miR-4281 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, 4, e7192. Also, "hsa-miR-4281" has a hairpin -like structure as its precursor, "hsa-mir-4281" (miRBase Accession N o. MI0015885, SEQ ID NO: 251) is known. ​

[0105] As used herein, the term "hsa-miR-6729-5p gene" or "hsa-mi R-6729-5p" refers to the hsa-miR-6729- 5p gene (miRBase Accession No. MIMAT0027359) described in SEQ ID NO: 27 and includes other species homologs or orthologs, etc. The hsa-miR-6729 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, pp1634-1645. Also, "hsa-m iR-6729-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6729" (miRBase Accession No. MI0022574, SEQ ID NO: 252) is known.

[0106] As used herein, the term "hsa-miR-8069 gene" or "hsa-miR-8 069" refers to the hsa-miR-8069 gene (miR Base Accession No. MIMAT0030996) described in SEQ ID NO: 28 and includes other species homo logs or orthologs, etc. The hsa-miR-8069 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, 39, pp480-487. Also, "hsa-miR-8069" has a hairpin structure as its precursor, "hsa-mir-8069" (miRBase Accession No. MI0025905, SEQ ID NO: 253) is known. No.MI0025905, SEQ ID NO: 253) is known.

[0107] As used herein, the term "hsa-miR-4706 gene" or "hsa-miR-4 The term "706" includes the hsa-miR-4706 gene described in SEQ ID NO: 29 (miR Base Accession No. MIMAT0019806) and other homologs or orthologs of other species. The hsa-miR-4706 gene can be obtained by the method described by Pers son H et al., 2011, Cancer Res, Vol. 71, p78-86. Also, "hsa-miR-4706" is known as "hsa-mir-4706" (miRBase Acces sion No. MI0017339, SEQ ID NO: 254) which takes a hairpin-like structure as its precursor.

[0108] As used herein, the term "hsa-miR-7108-5p gene" or "hsa-mi R-7108-5p" includes the hsa-miR-7108- 5p gene described in SEQ ID NO: 30 (miRBase Accession No. MIMAT0028113) and other homologs or orthologs of other species. The hsa-miR-7108 -5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. Also, "hsa-m iR-7108-5p" is known as "hsa-mir- 7108" (miRBase Accession No. MI0022959, SEQ ID NO: 255) which takes a hairpin-like structure as its precursor.

[0109] As used herein, the term "hsa-miR-4433b-3p gene" or "hsa-m iR-4433b-3p" includes the hsa-miR-443 ​​​3b-3p gene (miRBase Accession No. MIMAT00304 14) and other species homologs or orthologs, etc. are included. hsa-miR-4 The 433b-3p gene can be obtained by the method described by Ple H et al., 2012, PLoS One, 7, e50 746. Also, "hsa-miR-4433 b-3p" has a hairpin-like structure as its precursor, "hsa-mir-4433b" (miRBase Accession No. MI0025511, SEQ ID NO: 256) is known.

[0110] As used herein, the term "hsa-miR-6893-5p gene" or "hsa-mi R-6893-5p" refers to the hsa-miR-6893- 5p gene (miRBase Accession No. MIMAT0027686) described in SEQ ID NO: 32 and other species homologs or orthologs, etc. are included. hsa-miR-6893 -5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6893-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6893" (miRBase Accession No. MI0022740, SEQ ID NO: 257) is known.

[0111] As used herein, the term "hsa-miR-6857-5p gene" or "hsa-mi R-6857-5p" refers to the hsa-miR-6857- 5p gene (miRBase Accession No. MIMAT0027614) described in SEQ ID NO: 33 It includes other species homologs or orthologs, etc. hsa-miR-6857 The -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, pp. 1634-1645. Also, "hsa-m iR-6857-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6857" (miRBase Accession No. MI0022703, SEQ ID No. 258) is known.

[0112] As used herein, the term "hsa-miR-1227-5p gene" or "hsa-mi R-1227-5p" refers to the hsa-miR-1227- 5p gene described in SEQ ID NO: 34 (miRBase Accession No. MIMAT0022941) and includes other species homologs or orthologs, etc. hsa-miR-1227 The -5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, 28, pp. 328-336. Also, "hsa-miR -1227-5p" has a hairpin-like structure as its precursor, "hsa-mir-12 27" (miRBase Accession No. MI0006316, SEQ ID No. 259) is known.

[0113] As used herein, the term "hsa-miR-6741-5p gene" or "hsa-mi R-6741-5p" refers to the hsa-miR-6741- 5p gene described in SEQ ID NO: 35 (miRBase Accession No. MIMAT0027383) and includes other species homologs or orthologs, etc. hsa-miR-6741 The -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, pp1634-1645. Also, "hsa-m iR-6741-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6741" (miRBase Accession No. MI0022586, SEQ ID No. 260) is known.

[0114] As used herein, the term "hsa-miR-451a gene" or "hsa-miR-4 51a" includes the hsa-miR-451a gene described in SEQ ID NO: 36 (miR Base Accession No. MIMAT0001631) and other homologs or orthologs of other species. The hsa-miR-451a gene can be obtained by the method described in Altu via Y et al., 2005, Nucleic Acids Res, 33, p2697 -2706. Also, "hsa-miR-45 1a" has a hairpin-like structure as its precursor, "hsa-mir-451a" (mi RBase Accession No. MI0001729, SEQ ID NO: 261) is known to be.

[0115] As used herein, the term "hsa-miR-8063 gene" or "hsa-miR-8 063" includes the hsa-miR-8063 gene described in SEQ ID NO: 37 (miR Base Accession No. MIMAT0030990) and other homologs or orthologs of other species. The hsa-miR-8063 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, 39, pp480-487 by It can be obtained. Also, "hsa-miR-8063" has a hairpin-like structure as its precursor, "hsa-mir-8063" (miRBase Accession No.MI0025899, SEQ ID NO: 262) is known.

[0116] As used herein, the term "hsa-miR-3622a-5p gene" or "hsa-m iR-3622a-5p" includes the hsa-miR-3622a-5p gene (miRBase Accession No.MIMAT00180 03) described in SEQ ID NO: 38 and other homologs or orthologs of other species. The hsa-miR-3 622a-5p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, 8, p58. Also, "hsa-miR-3622 a-5p" has a hairpin-like structure as its precursor, "hsa-mir-3622a" (miRBase Accession No.MI0016013, SEQ ID NO: 263) is known.

[0117] As used herein, the term "hsa-miR-615-5p gene" or "hsa-miR -615-5p" includes the hsa-miR-615-5p gene (miRBase Accession No.MIMAT0004804) described in SEQ ID NO: 39 and other homologs or orthologs of other species. The hsa-miR-615-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci U S A, 103, p3687-3692. Also, "hsa-miR-615-5p" has a hairpin-like structure as its precursor and can be obtained by the method described in USA, 103, p3687-3692. Also, "hsa-miR-615-5p" has a hairpin-like structure as its precursor ​ The "hsa-mir-615" (miRBase Accession No. MI0 003628, SEQ ID NO: 264) is known.

[0118] As used herein, the term "hsa-miR-128-1-5p gene" or "hsa-m iR-128-1-5p" includes the hsa-miR-128 -1-5p gene (miRBase Accession No. MIMAT00264 77) described in SEQ ID NO: 40 and other homologs or orthologs of other species. hsa-miR-1 28-1-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, Vol. 12, p735-739. Also, "hsa-miR-128-1-5p" has a hairpin-like structure as its precursor and is the "hsa-mir-128-1" (miRBase Accession No. MI0 000447, SEQ ID NO: 265) which is known.

[0119] As used herein, the term "hsa-miR-6825-5p gene" or "hsa-mi R-6825-5p" includes the hsa-miR-6825- 5p gene (miRBase Accession No. MIMAT0027550) and other homologs or orthologs of other species. hsa-miR-6825 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, p1634-1645. Also, "hsa-m iR-6825-5p" has a hairpin-like structure as its precursor and is the "hsa-mir- ​"6825" (miRBase Accession No. MI0022670, sequence number 266) is known.

[0120] As used herein, the term "hsa-miR-1260b gene" or "hsa-miR- 1260b" refers to the hsa-miR-1260b gene described in SEQ ID NO: 42 ( miRBase Accession No. MIMAT0015041) and other homologous or orthologous genes of other species, etc. The hsa-miR-1260b gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, 5, e9685. Also, "hsa-miR-1260b" refers to "hsa-mir-1260b" which forms a hairpin-like structure as its precursor (miRBase Acce ssion No. MI0014197, SEQ ID NO: 267) is known.

[0121] As used herein, the term "hsa-miR-4433-3p gene" or "hsa-mi R-4433-3p" refers to the hsa-miR-4433- 3p gene described in SEQ ID NO: 43 (miRBase Accession No. MIMAT0018949) and other homologous or orthologous genes of other species, etc. The hsa-miR-4433-3p gene can be obtained by the method described by Jima DD et al., 2010, Blood, 116, e118-e 127. Also, "hsa-miR-4433-3p" refers to "hsa-mir-4433" which forms a hairpin-like structure as its precursor (miRBase Accession No. MI0016773, SEQ ID NO: 268) is known.

[0122] As used herein, the term "hsa-miR-4665-5p gene" or "hsa-mi R-4665-5p" refers to the hsa-miR-4665- 5p gene (miRBase Accession No. MIMAT0019739) described in SEQ ID NO: 44 and includes other species homologs or orthologs, etc. The hsa-miR-4665 -5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71, pp78-86. Also, "hsa-miR-4 665-5p" has a hairpin-like structure as its precursor, "hsa-mir-4665 " (miRBase Accession No. MI0017295, SEQ ID NO: 269 ).

[0123] As used herein, the term "hsa-miR-7845-5p gene" or "hsa-mi R-7845-5p" refers to the hsa-miR-7845- 5p gene (miRBase Accession No. MIMAT0030420) and includes other species homologs or orthologs, etc. The hsa-miR-7845 -5p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, 7, e50746 . Also, "hsa-miR-7845-5p" has a hairpin-like structure as its precursor, "hsa-mir-7845" (miRBa se Accession No. MI0025515, SEQ ID NO: 270) is known .

[0124] As used herein, the term "hsa-miR-1908-5p gene" or "hsa-mi The term "R-1908-5p" includes the hsa-miR-1908- 5p gene (miRBase Accession No. MIMAT0007881) and other species homologs or orthologs, etc. The hsa-miR-1908 -5p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, 26, p249 6-2505. Also, "hsa-miR-1 908-5p" has a hairpin-like structure as its precursor, "hsa-mir-1908 " (miRBase Accession No. MI0008329, SEQ ID NO: 271 ).

[0125] As used herein, the term "hsa-miR-6840-3p gene" or "hsa-mi R-6840-3p" includes the hsa-miR-6840- 3p gene (miRBase Accession No. MIMAT0027583) and other species homologs or orthologs, etc. The hsa-miR-6840 -3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6840-3p" has a hairpin-like structure as its precursor, "hsa-mir- 6840" (miRBase Accession No. MI0022686, SEQ ID NO : 272).

[0126] As used herein, the term "hsa-miR-6765-5p gene" or "hsa-mi R-6765-5p" includes the hsa-miR-6765- The 5p gene (miRBase Accession No. MIMAT0027430) and other homologs or orthologs of other species are also included. hsa-miR-6765 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, pp1634-1645. Also, "hsa-m iR-6765-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6765" (miRBase Accession No. MI0022610, SEQ ID No. 240) is known.

[0127] As used herein, the term "hsa-miR-296-5p gene" or "hsa-miR -296-5p" includes the hsa-miR-296-5p gene described in SEQ ID NO: 49 (miRBase Accession No. MIMAT0000690) and its homologs or orthologs of other species. The hsa-miR-296-5p gene can be obtained by the method described in Houbaviy HB et al., 2003, Dev Cell, 5, p351- 358. Also, "hsa-miR-296- 5p" has a hairpin-like structure as its precursor, "hsa-mir-296" (miR Base Accession No. MI0000747, SEQ ID NO: 273) is known to exist.

[0128] As used herein, the term "hsa-miR-3675-3p gene" or "hsa-mi R-3675-3p" includes the hsa-miR-3675- 3p gene described in SEQ ID NO: 50 (miRBase Accession No. MIMAT0018099)​ including other species homologs or orthologs, etc. hsa-miR-3675 -3p gene can be obtained by the method described in Vaz C et al., 2010, BMC Genomics, 11, p2 88. Also, "hsa-miR-3675- 3p" has a hairpin-like structure as its precursor, "hsa-mir-3675" (mi RBase Accession No. MI0016076, SEQ ID NO: 274) is known to be.

[0129] As used herein, the term "hsa-miR-6781-5p gene" or "hsa-mi R-6781-5p" refers to the hsa-miR-6781- 5p gene (miRBase Accession No. MIMAT0027462) described in SEQ ID NO: 51 including other species homologs or orthologs, etc. hsa-miR-6781 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634 - 1645. Also, "hsa-m iR-6781-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6781" (miRBase Accession No. MI0022626, SEQ ID NO: 275) is known.

[0130] As used herein, the term "hsa-miR-423-5p gene" or "hsa-miR -423-5p" refers to the hsa-miR-423-5p gene described in SEQ ID NO: 52 (miRBase Accession No. MIMAT0004748) and its other species homologs or orthologs, etc. hsa-miR-423-5p gene The gene can be obtained by the method described in Kasashima K et al., 2004, Biochem Biophys Res Commun, 322, p403-410. Also, "hsa-miR-423-5p" has a hairpin-like structure as its precursor "hsa-mir-423" (miRBase Accession No. MI 0001445, SEQ ID NO: 276) is known.

[0131] As used herein, the term "hsa-miR-3663-3p gene" or "hsa-mi R-3663-3p" refers to the hsa-miR-3663- 3p gene (miRBase Accession No. MIMAT0018085) described in SEQ ID NO: 53 and also includes other species homologs or orthologs, etc. The hsa-miR-3663 -3p gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, 5, e1056 3. Also, "hsa-miR-3663-3 p" has a hairpin-like structure as its precursor "hsa-mir-3663" (miR Base Accession No. MI0016064, SEQ ID NO: 277) is known .

[0132] As used herein, the term "hsa-miR-6784-5p gene" or "hsa-mi R-6784-5p" refers to the hsa-miR-6784- 5p gene (miRBase Accession No. MIMAT0027468) described in SEQ ID NO: 54 and also includes other species homologs or orthologs, etc. The hsa-miR-6784 The -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6784-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6784" (miRBase Accession No. MI0022629, SEQ ID No. 278) is known.

[0133] As used herein, the term "hsa-miR-6749-5p gene" or "hsa-mi R-6749-5p" refers to the hsa-miR-6749- 5p gene (miRBase Accession No. MIMAT0027398) described in SEQ ID NO: 55 and also includes homologs or orthologs of other species. The hsa-miR-6749 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6749-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6749" (miRBase Accession No. MI0022594, SEQ ID No. 279) is known.

[0134] As used herein, the term "hsa-miR-1231 gene" or "hsa-miR-1 231" refers to the hsa-miR-1231 gene (miR Base Accession No. MIMAT0005586) described in SEQ ID NO: 56 and also includes homologs of other species or orthologs, etc. The hsa-miR-1231 gene is described in Bere zikov E et al., 2007, Mol Cell, 28, p328-336 It can be obtained by the method described. Also, "hsa-miR-1231" has a hairpin-like structure as its precursor, "hsa-mir-1231" (miRBase Acc ession No.MI0006321, SEQ ID NO: 280) is known. ession No.MI0006321, SEQ ID NO: 280) is known.

[0135] As used herein, the term "hsa-miR-4746-3p gene" or "hsa-mi R-4746-3p" refers to the hsa-miR-4746- 3p gene (miRBase Accession No.MIMAT0019881) described in SEQ ID NO: 57 and also includes other species homologs or orthologs, etc. The hsa-miR-4746 -3p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, pp78-86. Also, "hsa-miR-4 746-3p" has a hairpin-like structure as its precursor, "hsa-mir-4746 " (miRBase Accession No.MI0017385, SEQ ID NO: 281 ) is known.

[0136] As used herein, the term "hsa-miR-6780b-5p gene" or "hsa-m iR-6780b-5p" refers to the hsa-miR-678 0b-5p gene (miRBase Accession No.MIMAT00275 72) and also includes other species homologs or orthologs, etc. The hsa-miR-6 780b-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, pp1634-1645. Also, "h "sa-miR-6780b-5p" has a hairpin-like structure as its precursor, "hsa" -mir-6780b (miRBase Accession No. MI00226 81, SEQ ID NO: 282) is known.

[0137] As used herein, the term "hsa-miR-4758-5p gene" or "hsa-mi R-4758-5p" refers to the hsa-miR-4758- 5p gene (miRBase Accession No. MIMAT0019903) and also includes other species homologs or orthologs, etc. The hsa-miR-4758 -5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71, pp78-86. Also, "hsa-miR-4 758-5p" has a hairpin-like structure as its precursor, "hsa-mir-4758 " (miRBase Accession No. MI0017399, SEQ ID NO: 283 ) is known.

[0138] As used herein, the term "hsa-miR-3679-5p gene" or "hsa-mi R-3679-5p" refers to the hsa-miR-3679- 5p gene (miRBase Accession No. MIMAT0018104) and also includes other species homologs or orthologs, etc. The hsa-miR-3679 -5p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, 5, e9637. Also, "hsa-miR-36 79-5p" has a hairpin-like structure as its precursor, "hsa-mir-3679" (miRBase Accession No.MI0016080, SEQ ID NO: 236) is known.

[0139] As used herein, the term "hsa-miR-3184-5p gene" or "hsa-mi R-3184-5p" refers to the hsa-miR-3184- 5p gene (miRBase Accession No.MIMAT0015064) described in SEQ ID NO: 61 and includes other species homologs or orthologs, etc. The hsa-miR-3184 -5p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, 5, e968 5. Also, "hsa-miR-3184-5 p" has a hairpin-like structure as its precursor, "hsa-mir-3184" (miR Base Accession No.MI0014226, SEQ ID NO: 284) is known .

[0140] As used herein, the term "hsa-miR-6125 gene" or "hsa-miR-6 125" refers to the hsa-miR-6125 gene (miR Base Accession No.MIMAT0024598) described in SEQ ID NO: 62 and includes other species homo logs or orthologs, etc. The hsa-miR-6125 gene can be obtained by the method described in Smit h JL et al., 2012, J Virol, 86, p5278-5287 . Also, "hsa-miR-6125" has a hairpin-like structure as its precursor, "hsa-mir-6125" (miRBase Acces sion No.MI0021259, SEQ ID NO: 285) is known. ​

[0141] As used herein, the term "hsa-miR-6721-5p gene" or "hsa-mi R-6721-5p" includes the hsa-miR-6721- 5p gene (miRBase Accession No. MIMAT0025852) described in SEQ ID NO: 63 and other homologs or orthologs of other species. The hsa-miR-6721 -5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335. Also, "hsa-miR-6721-5p" has a hairpin-like structure as its precursor, "hsa-mir-6721" (miRBas e Accession No. MI0022556, SEQ ID NO: 286) is known .

[0142] As used herein, the term "hsa-miR-6791-5p gene" or "hsa-mi R-6791-5p" includes the hsa-miR-6791- 5p gene (miRBase Accession No. MIMAT0027482) and other homologs or orthologs of other species. The hsa-miR-6791 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22, pp. 1634-1645. Also, "hsa-m iR-6791-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6791" (miRBase Accession No. MI0022636, SEQ ID NO: 287) is known.

[0143] As used herein, the term "hsa-miR-3185 gene" or "hsa-miR-3​ The term "185" includes the hsa-miR-3185 gene described in SEQ ID NO: 65 (miR Base Accession No. MIMAT0015065) and other homologous or orthologous genes of other species. The hsa-miR-3185 gene can be obtained by the method described by Star k MS et al., 2010, PLoS One, Vol. 5, e9685. Also, "hsa-miR-3185" has a hairpin-like structure as its precursor, "hsa-mir-3185" (miRBase Accession No. MI0014227, SEQ ID NO: 288) is known.

[0144] As used herein, the term "hsa-miR-1260a gene" or "hsa-miR- 1260a" includes the hsa-miR-1260a gene described in SEQ ID NO: 66 ( miRBase Accession No. MIMAT0005911) and other homologous or orthologous genes of other species. The hsa-miR-1260a gene can be obtained by the method described by Morin RD et al., 2008, Genome Res, Vol. 18, p610-621. Also, "hsa-miR-1260a" has a hairpin-like structure as its precursor, "hsa-mir-1260a" (miRBas e Accession No. MI0006394, SEQ ID NO: 289) is known. e Accession No. MI0006394, SEQ ID NO: 289) is known .

[0145] As used herein, the term "hsa-miR-3197 gene" or "hsa-miR-3 197" includes the hsa-miR-3197 gene described in SEQ ID NO: 67 (miR ​​​​​Base Accession No. (MIMAT0015082) and other homologous genes of other species include logs or orthologs, etc. The hsa-miR-3197 gene was obtained by the method described by Star k MS et al. in 2010, PLoS One, Volume 5, e9685. In addition, "hsa-miR-3197" has a hairpin-like structure as its precursor, "hsa-mir-3197" (miRBase Accession No. MI0014245, SEQ ID NO: 290) is known.

[0146] As used herein, the term "hsa-miR-6845-5p gene" or "hsa-miR-6845-5p" refers to the hsa-miR-6845-5p gene described in SEQ ID NO: 68 (miRBase Accession No. MIMAT0027590) and includes other homologous genes or orthologs of other species. The hsa-miR-6845-5p gene can be obtained by the method described by Ladewig E et al. in 2012, Genome Res, Volume 22, p1634 - 1645. In addition, "hsa-miR-6845-5p" has a hairpin-like structure as its precursor, "hsa-mir-6845" (miRBase Accession No. MI0022691, SEQ ID NO: 291) is known.

[0147] As used herein, the term "hsa-miR-6887-5p gene" or "hsa-miR-6887-5p" refers to the hsa-miR-6887-5p gene described in SEQ ID NO: 69 (miRBase Accession No. MIMAT0027674) It includes other species homologs or orthologs, etc. hsa-miR-6887 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, pp. 1634-1645. Also, "hsa-m iR-6887-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6887" (miRBase Accession No. MI0022734, SEQ ID No. 292) is known.

[0148] As used herein, the term "hsa-miR-6738-5p gene" or "hsa-mi R-6738-5p" refers to the hsa-miR-6738- 5p gene (miRBase Accession No. MIMAT0027377) described in SEQ ID NO: 70 and includes other species homologs or orthologs, etc. hsa-miR-6738 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, pp. 1634-1645. Also, "hsa-m iR-6738-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6738" (miRBase Accession No. MI0022583, SEQ ID No. 293) is known.

[0149] As used herein, the term "hsa-miR-6872-3p gene" or "hsa-mi R-6872-3p" refers to the hsa-miR-6872- 3p gene (miRBase Accession No. MIMAT0027645) described in SEQ ID NO: 71 and includes other species homologs or orthologs, etc. hsa-miR-6872 The -3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6872-3p" has a hairpin-like structure as its precursor, "hsa-mir- 6872" (miRBase Accession No. MI0022719, SEQ ID No. 294) is known.

[0150] As used herein, the term "hsa-miR-4497 gene" or "hsa-miR-4 497" refers to the hsa-miR-4497 gene described in SEQ ID NO: 72 (miR Base Accession No. MIMAT0019032) and other homologs or orthologs of other species. The hsa-miR-4497 gene can be obtained by the method described in Jima DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-4497" has a he hairpin-like structure as its precursor, "hsa-mir-4497" (miRBase Accessio n No. MI0016859, SEQ ID NO: 295) is known.

[0151] As used herein, the term "hsa-miR-1229-5p gene" or "hsa-mi R-1229-5p" refers to the hsa-miR-1229- 5p gene described in SEQ ID NO: 73 (miRBase Accession No. MIMAT0022942) and other homologs or orthologs of other species. The hsa-miR-1229 -5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, 28, ​​It can be obtained by the method described in p328-336. Also, "hsa-miR -1229-5p" has a hairpin-like structure as its precursor, "hsa-mir-12 29" (miRBase Accession No. MI0006319, SEQ ID NO: 296) is known.

[0152] As used herein, the term "hsa-miR-6820-5p gene" or "hsa-mi R-6820-5p" refers to the hsa-miR-6820- 5p gene described in SEQ ID NO: 74 (miRBase Accession No. MIMAT0027540) and also includes other species homologs or orthologs, etc. The hsa-miR-6820 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6820-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6820" (miRBase Accession No. MI0022665, SEQ ID NO: 297) is known.

[0153] As used herein, the term "hsa-miR-6777-5p gene" or "hsa-mi R-6777-5p" refers to the hsa-miR-6777- 5p gene described in SEQ ID NO: 75 (miRBase Accession No. MIMAT0027454) and also includes other species homologs or orthologs, etc. The hsa-miR-6777 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m "iR-6777-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6777" (miRBase Accession No. MI0022622, SEQ ID NO: 298) is known.

[0154] As used herein, the term "hsa-miR-3917 gene" or "hsa-miR-3 917" refers to the hsa-miR-3917 gene described in SEQ ID NO: 76 (miR Base Accession No. MIMAT0018191) and other homologs or orthologs in other species. The hsa-miR-3917 gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, 5, e9637. Also, "hsa-miR-3917" has a hairpin-like structure as its precursor, "hsa-mir-3917" (miRBase Access ion No. MI0016423, SEQ ID NO: 299) is known. As used herein, the term "hsa-miR-5787 gene" or "hsa-miR-5 787" refers to the hsa-miR-5787 gene described in SEQ ID NO: 77 (miR Base Accession No. MIMAT0023252) and other homologs or orthologs in other species. The hsa-miR-5787 gene can be obtained by the method described in Yoo H et al., 2011, Biochem Biophys Res Commun, 415,

[0155] p567-572. Also, "hsa-miR-5787" has a hairpin-like structure as its precursor, "hsa-mir-5787" " (miRBase Accession No. MI0019797, SEQ ID NO: 300 ) is known.

[0156] As used herein, "hsa-miR-4286 gene" or "hsa-miR-4 The term "miR-4286" refers to the hsa-miR-4286 gene (miR Base Accession No. MIMAT0016916) and other species The hsa-miR-4286 gene is a member of the Goff By the method described in LA et al., 2009, PLoS One, vol. 4, e7192. In addition, "hsa-miR-4286" can be obtained by integrating a hairpin "hsa-mir-4286" (miRBase Accession No. o.MI0015894, sequence number 301) is known.

[0157] As used herein, the term "hsa-miR-6877-5p gene" or "hsa-mi The term "hsa-miR-6877-5p" refers to hsa-miR-6877- 5p gene (miRBase Accession No. MIMAT0027654) and other species homologs or orthologs. -5p gene, Ladewig E et al., 2012, Genome Res, vol. 22, It can be obtained by the method described in p. 1634-1645. iR-6877-5p is a precursor of the hairpin-like structure known as hsa-mir- 6877" (miRBase Accession No. MI0022724, sequence no. No. 302) is known.

[0158] As used herein, the term "hsa-miR-1225-3p gene" or "hsa-mi R-1225-3p" refers to the hsa-miR-1225- 3p gene (miRBase Accession No. MIMAT0005573) described in SEQ ID NO: 80 and also includes homologs or orthologs of other species. The hsa-miR-1225 -3p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Also, "hsa-miR -1225-3p" has a hairpin-like structure as its precursor, "hsa-mir-12 25" (miRBase Accession No. MI0006311, SEQ ID NO: 3 03) is known.

[0159] As used herein, the term "hsa-miR-6088 gene" or "hsa-miR-6 088" refers to the hsa-miR-6088 gene (miR Base Accession No. MIMAT0023713) described in SEQ ID NO: 81 and also includes homologs of other species or orthologs. The hsa-miR-6088 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, Vol. 21, pp. 2049-2057. Also, "hsa-miR-6088" has a hairpin-like structure as its precursor, "hsa-mir-6088" (miRBase Accession No. MI0020365, SEQ ID NO: 304) is known.

[0160] As used herein, the term "hsa-miR-6800-5p gene" or "hsa-mi The term "R-6800-5p" refers to the hsa-miR-6800- 5p gene (miRBase Accession No. MIMAT0027500) and includes other species homologs or orthologs, etc. hsa-miR-6800 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6800-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6800" (miRBase Accession No. MI0022645, SEQ ID No. 305) is known.

[0161] As used herein, the term "hsa-miR-1246 gene" or "hsa-miR-1 246" refers to the hsa-miR-1246 gene (miR Base Accession No. MIMAT0005898) described in SEQ ID NO: 83 and includes other species homo logs or orthologs, etc. The hsa-miR-1246 gene can be obtained by the method described in Mori n RD et al., 2008, Genome Res, 18, p610-621. Also, "hsa-miR-1246" has a hairpin-like structure as its precursor "hsa-mir-1246" (miRBase Acce ssion No. MI0006381, SEQ ID No. 306) is known.

[0162] As used herein, the term "hsa-miR-4467 gene" or "hsa-miR-4 467" refers to the hsa-miR-4467 gene (miR Base Accession No. (MIMAT0018994) and other orthologs or homologs of other species are included. The hsa-miR-4467 gene can be obtained by the method described by Jima DD et al. in Blood, Vol. 116, e118 - e127, 2010. Also, "hsa-miR-4467" has a hairpin-like structure as its precursor, "hsa-mir-4467" (miRBase Accession No. MI0016818, SEQ ID NO: 307) is known. Logs or orthologs, etc. are included. The hsa-miR-4467 gene can be obtained by the method described by Jima DD et al. in Blood, Vol. 116, e118 - e127, 2010. Also, "hsa-miR-4467" has a hairpin-like structure as its precursor, "hsa-mir-4467" (miRBase Accession No. MI0016818, SEQ ID NO: 307) is known. DD et al., 2010, Blood, Vol. 116, e118 - e127. and can be obtained by the method described in Blood, Vol. 116, e118 - e127, 2010. Also, "hsa-miR-4467" has a hairpin-like structure as its precursor, "hsa-mir-4467" (miRBase Accession No. MI0016818, SEQ ID NO: 307) is known. "hsa-mir-4467" which has a hairpin-like structure as its precursor (miRBase Accession No. MI0016818, SEQ ID NO: 307) is known. n No. MI0016818, SEQ ID NO: 307) is known.

[0163] As used herein, the term "hsa-miR-4419b gene" or "hsa-miR- 4419b" includes the hsa-miR-4419b gene described in SEQ ID NO: 85 ( miRBase Accession No. MIMAT0019034) and other orthologs or homologs of other species. The hsa-miR-4419b gene can be obtained by the method described by Jima DD et al. in Blood, Vol. 116, e118 - e127, 2010. Also, "hsa-miR-4419b" has a hairpin-like structure as its precursor, "hsa-mir-4419b" (miRBase Ac cession No. MI0016861, SEQ ID NO: 308) is known. DD et al., 2010, Blood, Vol. 116, e118 - e127. and can be obtained by the method described in Blood, Vol. 116, e118 - e127, 2010. Also, "hsa-miR-4419b" has a hairpin-like structure as its precursor, "hsa-mir-4419b" (miRBase Ac cession No. MI0016861, SEQ ID NO: 308) is known. cession No. MI0016861, SEQ ID NO: 308) is known.

[0164] As used herein, the term "hsa-miR-1914-3p gene" or "hsa-mi R-1914-3p" includes the hsa-miR-1914- 3p gene described in SEQ ID NO: 86 (miRBase Accession No. MIMAT0007890) and other orthologs or homologs of other species. The hsa-miR-1914 The -3p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, p249 and can be obtained by the method described in 6-2505. Also, "hsa-miR-1 914-3p" has a hairpin-like structure as its precursor, "hsa-mir-1914 "(miRBase Accession No. MI0008335, SEQ ID NO: 309 ) is known.

[0165] As used herein, the term "hsa-miR-4632-5p gene" or "hsa-mi R-4632-5p" refers to the hsa-miR-4632- 5p gene described in SEQ ID NO: 87 (miRBase Accession No. MIMAT0022977) and includes other species homologs or orthologs, etc. The hsa-miR-4632 -5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, p78-86. Also, "hsa-miR-4 632-5p" has a hairpin-like structure as its precursor, "hsa-mir-4632 "(miRBase Accession No. MI0017259, SEQ ID NO: 310 ) is known.

[0166] As used herein, the term "hsa-miR-1915-5p gene" or "hsa-mi R-1915-5p" refers to the hsa-miR-1915- 5p gene described in SEQ ID NO: 88 (miRBase Accession No. MIMAT0007891) and includes other species homologs or orthologs, etc. The hsa-miR-1915 -5p gene is described in Bar M et al., 2008, Stem Cells, Vol. 26, p249 It can be obtained by the method described in 6-2505. Also, "hsa-miR-1" "915-5p" has a hairpin-like structure as its precursor, "hsa-mir-1915" "(miRBase Accession No. MI0008336, SEQ ID NO: 311)" is known.

[0167] As used herein, the term "hsa-miR-3940-5p gene" or "hsa-mi" "R-3940-5p" refers to the hsa-miR-3940- 5p gene (miRBase Accession No. MIMAT0019229) described in SEQ ID NO: 89 and also includes other species homologs or orthologs, etc. The hsa-miR-3940 -5p gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, 5, e1056 3. Also, "hsa-miR-3940-5" "p" has a hairpin-like structure as its precursor, "hsa-mir-3940" (miR Base Accession No. MI0016597, SEQ ID NO: 312) is known .

[0168] As used herein, the term "hsa-miR-1185-2-3p gene" or "hsa-" "miR-1185-2-3p" refers to the hsa-miR-1 1185-2-3p gene (miRBase Accession No. MIMAT00 22713) described in SEQ ID NO: 90 and also includes other species homologs or orthologs, etc. The hsa-mi R-1185-2-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, 16, p1289-1298 and can be obtained by the method described in Berezikov E et al., 2006, Genome Res, 16, p1289-1298 。In addition, "hsa-miR-1185-2-3p" has a hairpin-like structure as its precursor "hsa-mir-1185-2" (miRBase Accession No .MI0003821, SEQ ID NO: 313) which forms such a structure is known.

[0169] As used herein, the term "hsa-miR-6746-5p gene" or "hsa-mi R-6746-5p" refers to the hsa-miR-6746- 5p gene (miRBase Accession No. MIMAT0027392) described in SEQ ID NO: 91 and also includes homologs or orthologs of other species. The hsa-miR-6746 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. In addition, "hsa-m iR-6746-5p" has a hairpin-like structure as its precursor "hsa-mir- 6746" (miRBase Accession No. MI0022591, SEQ ID NO: 314) which is known.

[0170] As used herein, the term "hsa-miR-5001-5p gene" or "hsa-mi R-5001-5p" refers to the hsa-miR-5001- 5p gene (miRBase Accession No. MIMAT0021021) described in SEQ ID NO: 92 and also includes homologs or orthologs of other species. The hsa-miR-5001 -5p gene can be obtained by the method described in Hansen TB et al., 2011, RNA Biol, 8, p37 8-383. In addition, "hsa-miR-50 "01-5p" has, as its precursor, "hsa-mir-5001" which takes a hairpin-like structure (miRBase Accession No. MI0017867, SEQ ID NO: 315) and is known.

[0171] As used herein, the term "hsa-miR-1228-5p gene" or "hsa-mi R-1228-5p" refers to the hsa-miR-1228- 5p gene (miRBase Accession No. MIMAT0005582) described in SEQ ID NO: 93 and also includes other species homologs or orthologs, etc. The hsa-miR-1228 -5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28, pp328 - 336. Also, "hsa-miR -1228-5p" has, as its precursor, "hsa-mir-12 28" (miRBase Accession No. MI0006318, SEQ ID NO: 3 16) and is known.

[0172] As used herein, the term "hsa-miR-5572 gene" or "hsa-miR-5 572" refers to the hsa-miR-5572 gene (miR Base Accession No. MIMAT0022260) described in SEQ ID NO: 94 and also includes other species homo logs or orthologs, etc. The hsa-miR-5572 gene can be obtained by the method described in Tandon M et al., 2012, Oral Dis, Vol. 18, pp127 - 131. Also, "hsa-miR-5572" has, as its precursor, a "hsa-mir-5572" which takes a hairpin-like structure (miRBase Access Ion No. MI0019117, SEQ ID NO: 317) is known.

[0173] As used herein, the term "hsa-miR-4327 gene" or "hsa-miR-4 327" refers to the hsa-miR-4327 gene described in SEQ ID NO: 95 (miR Base Accession No. MIMAT0016889) and other homologs or orthologs of other species. The hsa-miR-4327 gene can be obtained by the method described by Goff LA et al., 2009, PLoS One, Vol. 4, e7192. Also, "hsa-miR-4327" has a hairpin -like structure as its precursor, "hsa-mir-4327" (miRBase Accession N o. MI0015867, SEQ ID NO: 318) is known.

[0174] As used herein, the term "hsa-miR-4638-5p gene" or "hsa-mi R-4638-5p" refers to the hsa-miR-4638- 5p gene described in SEQ ID NO: 96 (miRBase Accession No. MIMAT0019695) and other homologs or orthologs of other species. The hsa-miR-4638 -5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, p78-86. Also, "hsa-miR-4 638-5p" has a hairpin-like structure as its precursor, "hsa-mir-4638 " (miRBase Accession No. MI0017265, SEQ ID NO: 319 ) is known.

[0175] As used herein, the term "hsa-miR-6799-5p gene" or "hsa-mi R-6799-5p" includes the hsa-miR-6799- 5p gene (miRBase Accession No. MIMAT0027498) described in SEQ ID NO: 97 and other homologs or orthologs of other species. The hsa-miR-6799 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, pp1634-1645. Also, "hsa-m iR-6799-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6799" (miRBase Accession No. MI0022644, SEQ ID NO: 320) is known.

[0176] As used herein, the term "hsa-miR-6861-5p gene" or "hsa-mi R-6861-5p" includes the hsa-miR-6861- 5p gene (miRBase Accession No. MIMAT0027623) described in SEQ ID NO: 98 and other homologs or orthologs of other species. The hsa-miR-6861 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, pp1634-1645. Also, "hsa-m iR-6861-5p" has a hairpin-like structure as its precursor, "hsa-mir- 6861" (miRBase Accession No. MI0022708, SEQ ID NO: 321) is known.

[0177] As used herein, the term "hsa-miR-6727-5p gene" or "hsa-mi The term "R-6727-5p" refers to the hsa-miR-6727- 5p gene (miRBase Accession No. MIMAT0027355) and includes other species homologs or orthologs, etc. hsa-miR-6727 -5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa-m iR-6727-5p" takes a hairpin-like structure as its precursor, "hsa-mir- 6727" (miRBase Accession No. MI0022572, SEQ ID No. 322) is known.

[0178] As used herein, the term "hsa-miR-4513 gene" or "hsa-miR-4 513" refers to the hsa-miR-4513 gene described in SEQ ID NO: 100 (mi RBase Accession No. MIMAT0019050) and includes other species ho mologs or orthologs, etc. The hsa-miR-4513 gene can be obtained by the method described in Jim a DD et al., 2010, Blood, 116, e118-e127 . Also, "hsa-miR-4513" takes a hairpin-like structure as its precursor "hsa-mir-4513" (miRBase Accessi on No. MI0016879, SEQ ID NO: 323) is known.

[0179] As used herein, the term "hsa-miR-6805-3p gene" or "hsa-mi R-6805-3p" refers to hsa-miR-6805 described in SEQ ID NO: 101 -3p gene (miRBase Accession No. MIMAT0027511 ) and other homologs or orthologs of other species are included. hsa-miR-680 The 5-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 , pp. 1634-1645. Also, "hsa- miR-6805-3p" has a hairpin-like structure as its precursor, "hsa-mir -6805" (miRBase Accession No. MI0022650, sequence No. 324) is known.

[0180] As used herein, the term "hsa-miR-6808-5p gene" or "hsa-mi R-6808-5p" refers to the hsa-miR-6808 -5p gene (miRBase Accession No. MIMAT0027516 ) and other homologs or orthologs of other species are included. hsa-miR-680 The 8-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 , pp. 1634-1645. Also, "hsa- miR-6808-5p" has a hairpin-like structure as its precursor, "hsa-mir -6808" (miRBase Accession No. MI0022653, sequence No. 325) is known.

[0181] As used herein, the term "hsa-miR-4449 gene" or "hsa-miR-4 449" refers to the hsa-miR-4449 gene described in SEQ ID NO: 103 (mi RBase Accession No. MIMAT0018968) and other homologs of other species Includes homologs or orthologs, etc. The hsa-miR-4449 gene was described by Jim a DD et al. in 2010, Blood, Vol. 116, pp. e118 - e127 and can be obtained by the method described therein. Also, "hsa-miR-4449" has a hairpin-like structure as its precursor, "hsa-mir-4449" (miRBase Accessi on No. MI0016792, SEQ ID NO: 326) is known.

[0182] As used herein, the term "hsa-miR-1199-5p gene" or "hsa-mi R-1199-5p" includes the hsa-miR-1199-5p gene described in SEQ ID NO: 104 (miRBase Accession No. MIMAT0031119 ) and other species homologs or orthologs, etc. The hsa-miR-119 9-5p gene can be obtained by the method described by Salvi A et al. in 2013, Int J Oncol, Vol. 42, pp. 391 - 402. Also, "hsa-miR -1199-5p" has a hairpin-like structure as its precursor, "hsa-mir-11 99" (miRBase Accession No. MI0020340, SEQ ID NO: 3 27) is known.

[0183] As used herein, the term "hsa-miR-1275 gene" or "hsa-miR-1 275" includes the hsa-miR-1275 gene described in SEQ ID NO: 105 (mi RBase Accession No. MIMAT0005929) and other species homologs or orthologs, etc. The hsa-miR-1275 gene was described by Mor ​​​It can be obtained by the method described in RD et al., 2008, Genome Res, 18, p610-621. Also, "hsa-miR-1275" has a hairpin-like structure as its precursor, "hsa-mir-1275" (miRBase Accession No. MI0006415, SEQ ID NO: 328). is known. The term "hsa-miR-4792 gene" or "hsa-miR-4792" as used in this specification includes the hsa-miR-4792 gene described in SEQ ID NO: 106 (miRBase Accession No. MIMAT0019964) and other orthologs or paralogs of other species. The hsa-miR-4792 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71, p78-86. Also, "hsa-miR-4792" has a hairpin-like structure as its precursor, "hsa-mir-4792" (miRBase Accession No. MI0017439, SEQ ID NO: 329). is known.

[0184] The term "hsa-miR-4792 gene" or "hsa-miR-4792" as used in this specification includes the hsa-miR-4792 gene described in SEQ ID NO: 106 (miRBase Accession No. MIMAT0019964) and other orthologs or paralogs of other species. The hsa-miR-4792 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71, p78-86. Also, "hsa-miR-4792" has a hairpin-like structure as its precursor, "hsa-mir-4792" (miRBase Accession No. MI0017439, SEQ ID NO: 329). is known. The term "hsa-miR-4443 gene" or "hsa-miR-4443" as used in this specification includes the hsa-miR-4443 gene described in SEQ ID NO: 107 (miRBase Accession No. MIMAT0018961) and other orthologs or paralogs of other species. The hsa-miR-4443 gene can be obtained by the method described in Jima DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-4443" has a hairpin-like structure as its precursor, is known. The term "hsa-miR-4443 gene" or "hsa-miR-4443" as used in this specification includes the hsa-miR-4443 gene described in SEQ ID NO: 107 (miRBase Accession No. MIMAT0018961) and other orthologs or paralogs of other species. The hsa-miR-4443 gene can be obtained by the method described in Jima DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-4443" has a hairpin-like structure as its precursor, is known. The term "hsa-miR-4443 gene" or "hsa-miR-4443" as used in this specification includes the hsa-miR-4443 gene described in SEQ ID NO: 107 (miRBase Accession No. MIMAT0018961) and other orthologs or paralogs of other species. The hsa-miR-4443 gene can be obtained by the method described in Jima DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-4443" has a hairpin-like structure as its precursor, is known.

[0185] The term "hsa-miR-4443 gene" or "hsa-miR-4443" as used in this specification includes the hsa-miR-4443 gene described in SEQ ID NO: 107 (miRBase Accession No. MIMAT0018961) and other orthologs or paralogs of other species. The hsa-miR-4443 gene can be obtained by the method described in Jima DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-4443" has a hairpin-like structure as its precursor, is known. The term "hsa-miR-4443 gene" or "hsa-miR-4443" as used in this specification includes the hsa-miR-4443 gene described in SEQ ID NO: 107 (miRBase Accession No. MIMAT0018961) and other orthologs or paralogs of other species. The hsa-miR-4443 gene can be obtained by the method described in Jima DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-4443" has a hairpin-like structure as its precursor, is known. The hsa-miR-4443 gene can be obtained by the method described in Jima DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-4443" has a hairpin-like structure as its precursor, is known. "hsa-mir-4443" (miRBase Accessi on No. MI0016786, SEQ ID NO: 330) with a hairpin-like structure is known.

[0186] As used herein, the term "hsa-miR-6891-5p gene" or "hsa-mi R-6891-5p" includes the hsa-miR-6891 -5p gene (miRBase Accession No. MIMAT0027682 ) described in SEQ ID NO: 108, as well as homologs or orthologs of other species. The hsa-miR-689 1-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 , p1634-1645. Also, "hsa- miR-6891-5p" has a hairpin-like structure as its precursor, "hsa-mir -6891" (miRBase Accession No. MI0022738, sequence No. 331) is known.

[0187] As used herein, the term "hsa-miR-6826-5p gene" or "hsa-mi R-6826-5p" includes the hsa-miR-6826 -5p gene (miRBase Accession No. MIMAT0027552 ) described in SEQ ID NO: 109, as well as homologs or orthologs of other species. The hsa-miR-682 6-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 , p1634-1645. Also, "hsa- miR-6826-5p" has a hairpin-like structure as its precursor, "hsa-mir -6826」(miRBase Accession No. MI0022671, sequence number 332) is known.

[0188] As used herein, the term "hsa-miR-6807-5p gene" or "hsa-mi R-6807-5p" refers to the hsa-miR-6807 -5p gene (miRBase Accession No. MIMAT0027514 ) described in SEQ ID NO: 110, as well as homologs or orthologs of other species. The hsa-miR-680 7-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 , p1634-1645. Also, "hsa- miR-6807-5p" has a hairpin-like structure as its precursor, "hsa-mir -6807" (miRBase Accession No. MI0022652, sequence number 333) is known.

[0189] As used herein, the term "hsa-miR-7150 gene" or "hsa-miR-7 150" refers to the hsa-miR-7150 gene (mi RBase Accession No. MIMAT0028211) described in SEQ ID NO: 111, as well as homologs or orthologs of other species. The hsa-miR-7150 gene can be obtained by the method described in Oulas A et al., 2009, Nucleic Acids Res, 37, p3276- 3287. Also, "hsa-miR-715 0" has a hairpin-like structure as its precursor, "hsa-mir-7150" (miR Base Accession No. MI0023610, SEQ ID NO: 334) is known . ​ is present.

[0190] As used herein, the term "hsa-miR-4534 gene" or "hsa-miR-4 534" includes the hsa-miR-4534 gene (mi RBase Accession No. MIMAT0019073) described in SEQ ID NO: 112 and other orthologs or paralogs of other species. The hsa-miR-4534 gene can be obtained by the method described in Jim a DD et al., 2010, Blood, Vol. 116, pp. e118-e127. Also, "hsa-miR-4534" has, as its precursor, "hsa-mir-4534" (miRBase Accessi on No. MI0016901, SEQ ID NO: 335) which has a hairpin-like structure. is known.

[0191] As used herein, the term "hsa-miR-4476 gene" or "hsa-miR-4 476" includes the hsa-miR-4476 gene (mi RBase Accession No. MIMAT0019003) described in SEQ ID NO: 113 and other orthologs or paralogs of other species. The hsa-miR-4476 gene can be obtained by the method described in Jim a DD et al., 2010, Blood, Vol. 116, pp. e118-e127. Also, "hsa-miR-4476" has, as its precursor, "hsa-mir-4476" (miRBase Accessi on No. MI0016828, SEQ ID NO: 336) which has a hairpin-like structure. is known.

[0192] As used herein, the term "hsa-miR-4649-5p gene" or "hsa-mi The term "R-4649-5p" includes the hsa-miR-4649 gene (miRBase Accession No. MIMAT0019711) described in SEQ ID NO: 114, as well as homologs or orthologs of other species. The hsa-miR-4649-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71, p78-86. Also, "hsa-miR-4649-5p" has a hairpin-like structure as its precursor, "hsa-mir-4649" (miRBase Accession No. MI0017276, SEQ ID NO: 337). -5p gene (miRBase Accession No. MIMAT0019711 ) and homologs or orthologs of other species, etc. are included. hsa-miR-464 9-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71 volume, p78-86. Also, "hsa-miR- 4649-5p" has a hairpin-like structure as its precursor, "hsa-mir-464 9" (miRBase Accession No. MI0017276, SEQ ID NO: 33 7) is known.

[0193] As used herein, the term "hsa-miR-4525 gene" or "hsa-miR-4 525" includes the hsa-miR-4525 gene (mi RBase Accession No. MIMAT0019064) described in SEQ ID NO: 115 and homologs or orthologs of other species. The hsa-miR-4525 gene can be obtained by the method described in Jim a DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-4525" has a hairpin-like structure as its precursor, "hsa-mir-4525" (miRBase Accessi on No. MI0016892, SEQ ID NO: 338) is known. "hsa-mir-4525" (miRBase Accessi on No. MI0016892, SEQ ID NO: 338) is known.

[0194] As used herein, the term "hsa-miR-1915-3p gene" or "hsa-mi R-1915-3p" includes the hsa-miR-1915 described in SEQ ID NO: 116 -3p gene (miRBase Accession No. MIMAT0007892 ) and also includes other species homologs or orthologs, etc. hsa-miR-191 The 5-3p gene can be obtained by the method described by Bar M et al., 2008, Stem Cells, 26, p24 96 - 2505. Also, "hsa-miR- 191 5-3p" has a hairpin-like structure as its precursor, "hsa-mir-191 5" (miRBase Accession No. MI0008336, SEQ ID NO: 31 1) is known.

[0195] As used herein, the term "hsa-miR-4516 gene" or "hsa-miR-4 516" includes the hsa-miR-4516 gene described in SEQ ID NO: 117 (mi RBase Accession No. MIMAT0019053) and other species homologs or orthologs, etc. The hsa-miR-4516 gene can be obtained by the method described by Jim a DD et al., 2010, Blood, 116, e118 - e127 . Also, "hsa-miR-4516" has a hairpin-like structure as its precursor "hsa-mir-4516" (miRBase Accessi on No. MI0016882, SEQ ID NO: 339) is known.

[0196] As used herein, the term "hsa-miR-4417 gene" or "hsa-miR-4 417" includes the hsa-miR-4417 gene described in SEQ ID NO: 118 (mi RBase Accession No. MIMAT0018929) and other species homologs or orthologs, etc. ​It includes homologs or orthologs, etc. The hsa-miR-4417 gene was described by Jim a DD et al. in 2010, Blood, Volume 116, e118-e127 by the method described therein. Also, "hsa-miR-4417" has, as its precursor, "hsa-mir-4417" which takes on a hairpin-like structure (miRBase Accessi on No. MI0016753, SEQ ID NO: 340) is known.

[0197] As used herein, the term "hsa-miR-642b-3p gene" or "hsa-mi R-642b-3p" includes the hsa-miR-642b-3p gene described in SEQ ID NO: 119 (miRBase Accession No. MIMAT0018444 ) and other species homologs or orthologs, etc. The hsa-miR-642 b-3p gene can be obtained by the method described by Witten D et al. in 2010, BMC Biol, Volume 8, p58 . Also, "hsa-miR-642b-3p " has, as its precursor, "hsa-mir-642b" which takes on a hairpin-like structure (miRB ase Accession No. MI0016685, SEQ ID NO: 341) is known .

[0198] As used herein, the term "hsa-miR-3141 gene" or "hsa-miR-3 141" includes the hsa-miR-3141 gene described in SEQ ID NO: 120 (mi RBase Accession No. MIMAT0015010) and other species hom ologs or orthologs, etc. The hsa-miR-3141 gene can be obtained by the method described by Sta rk MS et al. in 2010, PLoS One, Volume 5, e9685 by the method​ can be obtained. Also, "hsa-miR-3141" has a hairpin-like structure as its precursor, "hsa-mir-3141" (miRBase Accession No.MI0014165, SEQ ID NO: 342) is known.

[0199] As used herein, the term "hsa-miR-5100 gene" or "hsa-miR-5 100" includes the hsa-miR-5100 gene (miRBase Accession No.MIMAT0022259) described in SEQ ID NO: 121 and other homologous or orthologous genes of other species. The hsa-miR-5100 gene can be obtained by the method described by Tandon M et al., 2012, Oral Dis, 18, p127-131. Also, "hsa-miR-5100" has a hairpin-like structure as its precursor, "hsa-mir-5100" (miRBase Accession No.MI0019116, SEQ ID NO: 343) is known.

[0200] As used herein, the term "hsa-miR-6848-5p gene" or "hsa-mi R-6848-5p" includes the hsa-miR-6848-5p gene (miRBase Accession No.MIMAT0027596 ) described in SEQ ID NO: 122 and other homologous or orthologous genes of other species. The hsa-miR-6848-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, 22 , p1634-1645. Also, "hsa-miR-6848-5p" has a hairpin-like structure as its precursor, "hsa-mir -6848-5p" ​​​​​​​​-6848」(miRBase Accession No.MI0022694, sequence No. 344) is known.

[0201] As used herein, the term "hsa-miR-4739 gene" or "hsa-miR-4 739" refers to the hsa-miR-4739 gene described in SEQ ID NO: 123 (mi RBase Accession No.MIMAT0019868) and other orthologs or homologs of other species. The hsa-miR-4739 gene can be obtained by the method described by Per sson H et al., 2011, Cancer Res, Vol. 71, p78-86. Also, "hsa-miR-4739" has a hairpin-like structure as its precursor "hsa-mir-4739" (miRBase Acce ssion No.MI0017377, SEQ ID NO: 345) is known.

[0202] As used herein, the term "hsa-miR-4459 gene" or "hsa-miR-4 459" refers to the hsa-miR-4459 gene described in SEQ ID NO: 124 (mi RBase Accession No.MIMAT0018981) and other orthologs or homologs of other species. The hsa-miR-4459 gene can be obtained by the method described by Jim a DD et al., 2010, Blood, Vol. 116, e118-e127. Also, "hsa-miR-4459" has a hairpin-like structure as its precursor "hsa-mir-4459" (miRBase Accessi on No.MI0016805, SEQ ID NO: 346) is known.

[0203] ​​As used herein, the term "hsa-miR-1237-5p gene" or "hsa-mi R-1237-5p" includes the hsa-miR-1237 -5p gene (miRBase Accession No. MIMAT0022946 ) described in SEQ ID NO: 125, as well as homologs or orthologs of other species. The hsa-miR-123 7-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28 , pp. 328-336. Also, "hsa-mi R-1237-5p" has a hairpin-like structure as its precursor, "hsa-mir-1 237" (miRBase Accession No. MI0006327, SEQ ID NO: 347).

[0204] As used herein, the term "hsa-miR-296-3p gene" or "hsa-miR -296-3p" includes the hsa-miR-296-3p gene (miRBase Accession No. MIMAT0004679) described in SEQ ID NO: 126, as well as homologs or orthologs of other species. The hsa-miR-296-3p gene can be obtained by the method described in Houbaviy HB et al., 2003, Dev Cell, Vol. 5, pp. 351 -358. Also, "hsa-miR-296 -3p" has a hairpin-like structure as its precursor, "hsa-mir-296" (mi RBase Accession No. MI0000747, SEQ ID NO: 273) is known .

[0205] As used herein, the term "hsa-miR-4665-3p gene" or "hsa-mi ​The term "R-4665-3p" encompasses the hsa-miR-4665 described in SEQ ID NO: 127 -3p gene (miRBase Accession No. MIMAT0019740 ), as well as homologs or orthologs of other species. The hsa-miR-466 5-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71 , pp. 78 - 86. Also, "hsa-miR- 4665-3p" has a hairpin-like structure as its precursor, "hsa-mir-466 5" (miRBase Accession No. MI0017295, SEQ ID NO: 26 9) is known.

[0206] As used herein, the term "hsa-miR-6786-5p gene" or "hsa-mi R-6786-5p" encompasses the hsa-miR-6786 described in SEQ ID NO: 128 -5p gene (miRBase Accession No. MIMAT0027472 ), as well as homologs or orthologs of other species. The hsa-miR-678 6-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22 , pp. 1634 - 1645. Also, "hsa- miR-6786-5p" has a hairpin-like structure as its precursor, "hsa-mir -6786" (miRBase Accession No. MI0022631, SEQ ID NO: 348) is known.

[0207] As used herein, the term "hsa-miR-4258 gene" or "hsa-miR-4 258" encompasses the hsa-miR-4258 gene described in SEQ ID NO: 129 (mi RBase Accession No. (MIMAT0016879) and other homologs or orthologs of other species are included. The hsa-miR-4258 gene can be obtained by the method described by Gof f LA et al. in 2009, PLoS One, Volume 4, e7192. Also, "hsa-miR-4258" has a hairpin-like structure as its precursor, "hsa-mir-4258" (miRBase Accession No. MI0015857, SEQ ID NO: 349) is known. including homologs or orthologs such as paralogs or orthologs. The hsa-miR-4258 gene can be obtained by the method described by Gof f LA et al. in 2009, PLoS One, Volume 4, e7192. f LA et al., 2009, PLoS One, Volume 4, e7192. and can be obtained by the method described by Gof f LA et al. in 2009, PLoS One, Volume 4, e7192. Also, "hsa-miR-4258" has a hairpin-like structure as its precursor, "hsa-mir-4258" (miRBase Accession No. MI0015857, SEQ ID NO: 349) is known. with a hairpin-like structure as its precursor, "hsa-mir-4258" (miRBase Accession No. MI0015857, SEQ ID NO: 349) is known. No. MI0015857, SEQ ID NO: 349).

[0208] As used herein, the term "hsa-miR-6510-5p gene" or "hsa-miR-6510-5p" includes the hsa-miR-6510-5p gene described in SEQ ID NO: 130 (miRBase Accession No. MIMAT0025476) and other homologs or orthologs of other species. The hsa-miR-6510-5p gene can be obtained by the method described by Joyce CE et al. in 2011, Hum Mol Genet, Volume 20, p4025 - 4040. Also, "hsa-miR-6510-5p" has a hairpin-like structure as its precursor, "hsa-mir-6510" (miRBase Accession No. MI0022222, SEQ ID NO: 350) is known. As used herein, the term "hsa-miR-6510-5p gene" or "hsa-miR-6510-5p" includes the hsa-miR-6510-5p gene described in SEQ ID NO: 130 (miRBase Accession No. MIMAT0025476) and other homologs or orthologs of other species. No. MIMAT0025476) and other homologs or orthologs of other species are included. The hsa-miR-6510-5p gene can be obtained by the method described by Joyce CE et al. in 2011, Hum Mol Genet, Volume 20, p4025 - 4040. Also, "hsa-miR-6510-5p" has a hairpin-like structure as its precursor, "hsa-mir-6510" (miRBase Accession No. MI0022222, SEQ ID NO: 350) is known. The hsa-miR-6510-5p gene can be obtained by the method described by Joyce CE et al. in 2011, Hum Mol Genet, Volume 20, p4025 - 4040. et al., 2011, Hum Mol Genet, Volume 20, p4025 - 4040. Also, "hsa-miR-6510-5p" has a hairpin-like structure as its precursor, "hsa-mir-6510" (miRBase Accession No. MI0022222, SEQ ID NO: 350) is known. "hsa-miR-6510-5p" has a hairpin-like structure as its precursor, "hsa-mir-6510" (miRBase Accession No. MI0022222, SEQ ID NO: 350) is known. "hsa-mir-6510" (miRBase Accession No. MI0022222, SEQ ID NO: 350) is known. SEQ ID NO: 350) is known.

[0209] As used herein, the term "hsa-miR-1343-5p gene" or "hsa-miR-1343-5p" includes the hsa-miR-1343-5p gene described in SEQ ID NO: 131 (miRBase Accession No. MIMAT0027038) and other homologs or orthologs of other species. As used herein, the term "hsa-miR-1343-5p gene" or "hsa-miR-1343-5p" includes the hsa-miR-1343-5p gene described in SEQ ID NO: 131 (miRBase Accession No. MIMAT0027038) and other homologs or orthologs of other species. No. MIMAT0027038) and other homologs or orthologs of other species. ) and also includes other species homologs or orthologs, etc. hsa-miR-134 The 3-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71 , pp. 78-86. Also, "hsa-miR- 134 3-5p" has a hairpin-like structure as its precursor, "hsa-mir-134 3" (miRBase Accession No. MI0017320, SEQ ID NO: 22 5) is known.

[0210] As used herein, the term "hsa-miR-1247-3p gene" or "hsa-mi R-1247-3p" refers to the hsa-miR-1247 -3p gene described in SEQ ID NO: 132 (miRBase Accession No. MIMAT0022721 ) and also includes other species homologs or orthologs, etc. The hsa-miR-124 7-3p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, Vol. 18, pp. 610-621. Also, "hsa-miR -1247-3p" has a hairpin-like structure as its precursor, "hsa-mir-12 47" (miRBase Accession No. MI0006382, SEQ ID NO: 3 51) is known.

[0211] As used herein, the term "hsa-miR-6805-5p gene" or "hsa-mi R-6805-5p" refers to the hsa-miR-6805 -5p gene described in SEQ ID NO: 133 (miRBase Accession No. MIMAT0027510 ) and also includes other species homologs or orthologs, etc. hsa-miR-680 The 5-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22 , pages 1634-1645. Also, "hsa- miR-6805-5p" has a hairpin-like structure as its precursor, "hsa-mir -6805" (miRBase Accession No. MI0022650, sequence number 324) is known.

[0212] As used herein, the term "hsa-miR-4492 gene" or "hsa-miR-4 492" includes the hsa-miR-4492 gene described in SEQ ID NO: 134 (mi RBase Accession No. MIMAT0019027) and other homologs or orthologs of other species. The hsa-miR-4492 gene can be obtained by the method described in Jim a DD et al., 2010, Blood, Vol. 116, e118-e127 . Also, "hsa-miR-4492" has a hairpin-like structure as its precursor, "hsa-mir-4492" (miRBase Accessi on No. MI0016854, SEQ ID NO: 352) is known.

[0213] As used herein, the term "hsa-miR-1469 gene" or "hsa-miR-1 469" includes the hsa-miR-1469 gene described in SEQ ID NO: 135 (mi RBase Accession No. MIMAT0007347) and other homologs or orthologs of other species. The hsa-miR-1469 gene can be obtained by the method described in Kawaji H et al., 2008, BMC Genomics, Vol. 9, p157 . ​​It can be obtained by a method. Also, "hsa-miR-1469" has a hairpin-like structure as its precursor, "hsa-mir-1469" (miRBase Access ion No.MI0007074, SEQ ID NO: 353) is known.

[0214] As used herein, the term "hsa-miR-1268b gene" or "hsa-miR- 1268b" includes the hsa-miR-1268b gene described in SEQ ID NO: 136 (miRBase Accession No.MIMAT0018925) and other biological species homologs or orthologs, etc. The hsa-miR-1268b gene can be obtained by the method described in Jima DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-1268b" has a hairpin-like structure as its precursor, "hsa-mir-1268b" (miRBase A ccession No.MI0016748, SEQ ID NO: 354) is known.

[0215] As used herein, the term "hsa-miR-6858-5p gene" or "hsa-mi R-6858-5p" includes the hsa-miR-6858-5p gene described in SEQ ID NO: 137 (miRBase Accession No.MIMAT0027616 ) and other biological species homologs or orthologs, etc. The hsa-miR-685 8-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22, p1634-1645. Also, "hsa- miR-6858-5p" has a hairpin-like structure as its precursor, "hsa-mir -6858」(miRBase Accession No. MI0022704, sequence number 355) is known.

[0216] As used herein, the term "hsa-miR-3937 gene" or "hsa-miR-3 937" refers to the hsa-miR-3937 gene described in SEQ ID NO: 138 (mi RBase Accession No. MIMAT0018352) and other homologs or orthologs of other species. The hsa-miR-3937 gene can be obtained by the method described by Lia o JY et al., 2010, PLoS One, Vol. 5, e10563. Also, "hsa-miR-3937" has a hairpin-like structure as its precursor, "hsa-mir-3937" (miRBase Accession No. MI0016593, SEQ ID NO: 356) is known.

[0217] As used herein, the term "hsa-miR-939-5p gene" or "hsa-miR -939-5p" refers to the hsa-miR-939-5p gene described in SEQ ID NO: 139 (miRBase Accession No. MIMAT0004982) and other homologs or orthologs of other species. The hsa-miR-939-5p gene can be obtained by the method described by Lui WO et al., 2007, Cancer Res, Vol. 67, p6031- 6043. Also, "hsa-miR-939 -5p" has a hairpin-like structure as its precursor, "hsa-mir-939" (mi RBase Accession No. MI0005761, SEQ ID NO: 357) is known.

[0218] ​​​​ As used herein, the term "hsa-miR-3656 gene" or "hsa-miR-3 656" includes the hsa-miR-3656 gene described in SEQ ID NO: 140 (mi RBase Accession No. MIMAT0018076), as well as homologs or orthologs of other species. The hsa-miR-3656 gene can be obtained by the method described by Mei ri E et al., 2010, Nucleic Acids Res, Vol. 38, p6234- 6246. Also, "hsa-miR-365 6" is known to have a hairpin-like structure as its precursor, "hsa-mir-3656" (mi RBase Accession No. MI0016056, SEQ ID NO: 358). It is known.

[0219] As used herein, the term "hsa-miR-744-5p gene" or "hsa-miR -744-5p" includes the hsa-miR-744-5p gene described in SEQ ID NO: 141 (mi RBase Accession No. MIMAT0004945), as well as homologs or orthologs of other species. The hsa-miR-744-5p gene can be obtained by the method described by Berezikov E et al., 2006, Genome Res, Vol. 16, p 1289-1298. Also, "hsa-mi R-744-5p" is known to have a hairpin-like structure as its precursor, "hsa-mir-74 4" (miRBase Accession No. MI0005559, SEQ ID NO: 35 9). It is known.

[0220] As used herein, the term "hsa-miR-4687-3p gene" or "hsa-mi ​​The term "R-4687-3p" encompasses the hsa-miR-4687 described in SEQ ID NO: 142 -3p gene (miRBase Accession No. MIMAT0019775 ), as well as homologs or orthologs of other species. The hsa-miR-468 7-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71 , pp78-86. Also, "hsa-miR- 4687-3p" has a hairpin-like structure as its precursor, "hsa-mir-468 7" (miRBase Accession No. MI0017319, SEQ ID NO: 36 0) is known.

[0221] As used herein, the term "hsa-miR-4763-3p gene" or "hsa-mi R-4763-3p" encompasses the hsa-miR-4763 described in SEQ ID NO: 143 -3p gene (miRBase Accession No. MIMAT0019913 ), as well as homologs or orthologs of other species. The hsa-miR-476 3-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71 , pp78-86. Also, "hsa-miR- 4763-3p" has a hairpin-like structure as its precursor, "hsa-mir-476 3" (miRBase Accession No. MI0017404, SEQ ID NO: 36 1) is known.

[0222] As used herein, the term "hsa-miR-3620-5p gene" or "hsa-mi R-3620-5p" encompasses the hsa-miR-3620 described in SEQ ID NO: 144 -5p gene (miRBase Accession No. MIMAT0022967 ) and other species homologs or orthologs, etc. are included. hsa-miR-362 The 0-5p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, Vol. 8, p58 . Also, "hsa-miR-3620-5p " has, as its precursor, "hsa-mir-3620" which takes a hairpin-like structure (miR Base Accession No. MI0016011, SEQ ID NO: 362) and is known .

[0223] As used herein, the term "hsa-miR-3195 gene" or "hsa-miR-3 195" includes the hsa-miR-3195 gene described in SEQ ID NO: 145 (mi RBase Accession No. MIMAT0015079) and other species homologs or orthologs, etc. The hsa-miR-3195 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, Vol. 5, e9685 . Also, "hsa-miR-3195" has, as its precursor, a hair pin-like structure "hsa-mir-3195" (miRBase Accession No. MI0014240, SEQ ID NO: 363) and is known .

[0224] As used herein, the term "hsa-miR-6842-5p gene" or "hsa-mi R-6842-5p" includes the hsa-miR-6842 -5p gene described in SEQ ID NO: 146 (miRBase Accession No. MIMAT0027586 ) and other species homologs or orthologs, etc. hsa-miR-684​ The 2-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22 , pp. 1634-1645. Also, "hsa- miR-6842-5p" has a hairpin-like structure as its precursor, "hsa-mir -6842" (miRBase Accession No. MI0022688, sequence No. 364) is known.

[0225] As used herein, the term "hsa-miR-4707-5p gene" or "hsa-mi R-4707-5p" includes the hsa-miR-4707 -5p gene (miRBase Accession No. MIMAT0019807 ) described in SEQ ID NO: 147, as well as homologs or orthologs of other species. The hsa-miR-470 7-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71 , pp. 78-86. Also, "hsa-miR- 4707-5p" has a hairpin-like structure as its precursor, "hsa-mir-470 7" (miRBase Accession No. MI0017340, sequence number 36 5) is known.

[0226] As used herein, the term "hsa-miR-642a-3p gene" or "hsa-mi R-642a-3p" includes the hsa-miR-642a -3p gene (miRBase Accession No. MIMAT0020924 ) described in SEQ ID NO: 148, as well as homologs or orthologs of other species. The hsa-miR-642 a-3p gene was described by Cummins JM et al., 2006, Proc Natl Aca It can be obtained by the method described in d Sci U S A, Vol. 103, pp. 3687 - 3692. In addition, "hsa-miR-642a-3p" has a hairpin-like structure as its precursor, "hsa-mir-642a" (miRBase Accession No. MI0003657, SEQ ID NO: 366) is known.

[0227] As used herein, the term "hsa-miR-7113-3p gene" or "hsa-miR-7113-3p" refers to the hsa-miR-7113-3p gene described in SEQ ID NO: 149 (miRBase Accession No. MIMAT0028124 ) and also includes other species homologs or orthologs, etc. The hsa-miR-7113-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22 , pp. 1634 - 1645. In addition, "hsa-miR-7113-3p" has a hairpin-like structure as its precursor, "hsa-mir-7113" (miRBase Accession No. MI0022964, sequence number 367) is known.

[0228] As used herein, the term "hsa-miR-4728-5p gene" or "hsa-miR-4728-5p" refers to the hsa-miR-4728-5p gene described in SEQ ID NO: 150 (miRBase Accession No. MIMAT0019849 ) and also includes other species homologs or orthologs, etc. The hsa-miR-4728-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71 , can be obtained by the method described in p78 - 86. Also, "hsa - miR - 4728 - 5p" has a hairpin - like structure as its precursor, "hsa - mir - 472 8" (miRBase Accession No.MI0017365, SEQ ID NO: 36 8) is known.

[0229] As used herein, the term "hsa - miR - 5195 - 3p gene" or "hsa - mi R - 5195 - 3p" includes the hsa - miR - 5195 - 3p gene described in SEQ ID NO: 151 (miRBase Accession No.MIMAT0021127 ), as well as homologs or orthologs of other species. The hsa - miR - 519 5 - 3p gene can be obtained by the method described in Schotte D et al., 2011, Leukemia, 25, p 1389 - 1399. Also, "hsa - mi R - 5195 - 3p" has a hairpin - like structure as its precursor, "hsa - mir - 5 195" (miRBase Accession No.MI0018174, SEQ ID NO: 369) is known.

[0230] As used herein, the term "hsa - miR - 1185 - 1 - 3p gene" or "hsa - miR - 1185 - 1 - 3p" includes the hsa - miR - 1185 - 1 - 3p gene described in SEQ ID NO: 152 (miRBase Accession No.MIMAT0 022838), as well as homologs or orthologs of other species. The hsa - m iR - 1185 - 1 - 3p gene can be obtained by the method described in Berezikov E et al., 2006, Geno me Res, 16, p1289 - 1298. It also exists. "hsa-miR-1185-1-3p" has a hairpin-like structure as its precursor, "hsa-mir-1185-1" (miRBase Accession N o.MI0003844, SEQ ID NO: 370). is known.

[0231] As used herein, the term "hsa-miR-6774-5p gene" or "hsa-mi R-6774-5p" refers to the hsa-miR-6774 -5p gene described in SEQ ID NO: 153 (miRBase Accession No. MIMAT0027448 ), as well as other species homologs or orthologs, etc. The hsa-miR-677 4-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 , pp. 1634-1645. Also, "hsa- miR-6774-5p" has a hairpin-like structure as its precursor, "hsa-mir -6774" (miRBase Accession No. MI0022619, sequence No. 371) is known.

[0232] As used herein, the term "hsa-miR-8059 gene" or "hsa-miR-8 059" refers to the hsa-miR-8059 gene described in SEQ ID NO: 154 (mi RBase Accession No. MIMAT0030986) and other species homologs or orthologs, etc. The hsa-miR-8059 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, 39 , pp. 480-487. Also, "hsa-miR-8059" has a hairpin as its precursor ... ... "hsa-mir-8059" (miRBase Accession No. MI0025895, SEQ ID NO: 372) with a pin-like structure is known.

[0233] As used herein, the term "hsa-miR-3131 gene" or "hsa-miR-3 131" includes the hsa-miR-3131 gene (mi RBase Accession No. MIMAT0014996) described in SEQ ID NO: 155 and other homologs or orthologs of other species. The hsa-miR-3131 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, 5, e9685. Also, "hsa-miR-3131" has, as its precursor, "hsa-mir-3131" (miRBase Accession No. MI0014151, SEQ ID NO: 373) with a hairpin-like structure. rk MS et al., 2010, PLoS One, 5, e9685 and is known. "hsa-mir-3131" (miRBase Accession No. MI0014151, SEQ ID NO: 373) with a hairpin-like structure is known.

[0234] As used herein, the term "hsa-miR-7847-3p gene" or "hsa-mi R-7847-3p" includes the hsa-miR-7847 -3p gene (miRBase Accession No. MIMAT0030422 ) described in SEQ ID NO: 156 and other homologs or orthologs of other species. The hsa-miR-784 7-3p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, 7, e50746. Also, "hsa-miR-7847-3p " has, as its precursor, "hsa-mir-7847" (miRB ase Accession No. MI0025517, SEQ ID NO: 374) with a hairpin-like structure. is known.

[0235] As used herein, "hsa-miR-4463 gene" or "hsa-miR-4 The term "miR-4463" refers to the hsa-miR-4463 gene (miR-4463) set forth in SEQ ID NO: 157. RBase Accession No. MIMAT0018987) and other species The hsa-miR-4463 gene is a member of the Jim a Method described in DD et al., 2010, Blood, vol. 116, e118-e127 In addition, "hsa-miR-4463" can be obtained as its precursor. The hairpin-like structure of "hsa-mir-4463" (miRBase Accession No. on No. MI0016811, sequence number 375) is known.

[0236] As used herein, "hsa-miR-128-2-5p gene" or "hsa-m The term "hsa-miR-128-2-5p" refers to the hsa-miR-12 8-2-5p gene (miRBase Accession No. MIMAT0031 095) and other species homologs or orthologs. The 128-2-5p gene was identified in Lagos-Quintana M et al., 2002, Cur It can be obtained by the method described in rBiol, vol. 12, p735-739. In addition, "hsa-miR-128-2-5p" has a hairpin-like structure as its precursor. "hsa-mir-128-2" (miRBase Accession No. MI 0000727, sequence number 376) is known.

[0237] As used herein, "hsa-miR-4508 gene" or "hsa-miR-4 The term "508" includes the hsa-miR-4508 gene described in SEQ ID NO: 159 (mi RBase Accession No. MIMAT0019045) and other homologs or orthologs of other species. The hsa-miR-4508 gene can be obtained by the method described by Jim a DD et al., 2010, Blood, Vol. 116, pp. e118-e127. Also, "hsa-miR-4508" has, as its precursor, "hsa-mir-4508" (miRBase Accessi on No. MI0016872, SEQ ID NO: 377) which takes a hairpin-like structure.

[0238] As used herein, the term "hsa-miR-6806-5p gene" or "hsa-mi R-6806-5p" includes the hsa-miR-6806 -5p gene described in SEQ ID NO: 160 (miRBase Accession No. MIMAT0027512 ) and other homologs or orthologs of other species. The hsa-miR-680 6-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22 , pp. 1634-1645. Also, "hsa- miR-6806-5p" has, as its precursor, "hsa-mir -6806" (miRBase Accession No. MI0022651, sequence NO: 378) which takes a hairpin-like structure.

[0239] As used herein, the term "hsa-miR-7111-5p gene" or "hsa-mi R-7111-5p" includes the hsa-miR-7111 described in SEQ ID NO: 161 ​​-5p gene (miRBase Accession No. MIMAT0028119 ) and other species homologs or orthologs, etc. are included. hsa-miR-711 The 1-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22 , pp. 1634-1645. Also, "hsa- miR-7111-5p" has a hairpin-like structure as its precursor, "hsa-mir -7111" (miRBase Accession No. MI0022962, sequence No. 379) is known.

[0240] As used herein, the term "hsa-miR-6782-5p gene" or "hsa-mi R-6782-5p" refers to the hsa-miR-6782 -5p gene (miRBase Accession No. MIMAT0027464 ) described in SEQ ID NO: 162 and other species homologs or orthologs, etc. are included. hsa-miR-678 The 2-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22 , pp. 1634-1645. Also, "hsa- miR-6782-5p" has a hairpin-like structure as its precursor, "hsa-mir -6782" (miRBase Accession No. MI0022627, sequence No. 380) is known.

[0241] As used herein, the term "hsa-miR-4734 gene" or "hsa-miR-4 734" refers to the hsa-miR-4734 gene (mi RBase Accession No. MIMAT0019859) described in SEQ ID NO: 163 and other species homologs Includes morologs or orthologs, etc. The hsa-miR-4734 gene is Per sson H et al., 2011, Cancer Res, Vol. 71, p78-86, and can be obtained by the method described therein. Also, "hsa-miR-4734" has a hairpin-like structure as its precursor, "hsa-mir-4734" (miRBase Acce ssion No. MI0017371, SEQ ID NO: 381).

[0242] As used herein, the term "hsa-miR-3162-5p gene" or "hsa-mi R-3162-5p" includes the hsa-miR-3162-5p gene (miRBase Accession No. MIMAT0015036 ) described in SEQ ID NO: 164 and other species homologs or orthologs, etc. The hsa-miR-316 2-5p gene can be obtained by the method described by Stark MS et al., 2010, PLoS One, Vol. 5, e96 85. Also, "hsa-miR-3162- 5p" has a hairpin-like structure as its precursor, "hsa-mir-3162" (mi RBase Accession No. MI0014192, SEQ ID NO: 382).

[0243] As used herein, the term "hsa-miR-887-3p gene" or "hsa-miR -887-3p" includes the hsa-miR-887-3p gene (miRBase Accession No. MIMAT0004951) described in SEQ ID NO: 165 and other species homologs or orthologs, etc. The hsa-miR-887-3p ​​​​​​The gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, 16, p 1289 - 1298. Also, "hsa-mi R-887-3p" has a hairpin-like structure as its precursor, "hsa-mir-88 7" (miRBase Accession No. MI0005562, SEQ ID NO: 38 3) is known.

[0244] As used herein, the term "hsa-miR-6752-5p gene" or "hsa-mi R-6752-5p" includes the hsa-miR-6752 -5p gene (miRBase Accession No. MIMAT0027404 ) described in SEQ ID NO: 166, as well as homologs or orthologs of other species. The hsa-miR-675 2-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 , p1634 - 1645. Also, "hsa- miR-6752-5p" has a hairpin-like structure as its precursor, "hsa-mir -6752" (miRBase Accession No. MI0022597, sequence NO: 384) is known.

[0245] As used herein, the term "hsa-miR-6724-5p gene" or "hsa-mi R-6724-5p" includes the hsa-miR-6724 -5p gene (miRBase Accession No. MIMAT0025856 ) described in SEQ ID NO: 167, as well as homologs or orthologs of other species. The hsa-miR-672 4-5p gene is described in Li Y et al., 2012, Gene, 497, p330 - 335 can be obtained by the methods described. Also, "hsa-miR-6724-5p" has a hairpin-like structure as its precursor, "hsa-mir-6724" (miRBa se Accession No. MI0022559, SEQ ID NO: 385) is known to be.

[0246] As used herein, the term "hsa-miR-23b-3p gene" or "hsa-miR -23b-3p" refers to the hsa-miR-23b-3p gene described in SEQ ID NO: 168 (miRBase Accession No. MIMAT0000418) and other homologs or orthologs of other species, etc. The hsa-miR-23b-3p gene can be obtained by the methods described by Lagos-Quintana M et al., 2002, Curr Biol, 1 2, p735-739. Also, "hsa- miR-23b-3p" has a hairpin-like structure as its precursor, "hsa-mir- 23b" (miRBase Accession No. MI0000439, SEQ ID NO: 386) is known.

[0247] As used herein, the term "hsa-miR-23a-3p gene" or "hsa-miR -23a-3p" refers to the hsa-miR-23a-3p gene described in SEQ ID NO: 169 (miRBase Accession No. MIMAT0000078) and other homologs or orthologs of other species, etc. The hsa-miR-23a-3p gene can be obtained by the methods described by Lagos-Quintana M et al., 2001, Science, 294 vol., p853-858. Also, "hsa-m "iR-23a-3p" has a hairpin-like structure as its precursor, "hsa-mir-2" 3a" (miRBase Accession No. MI0000079, SEQ ID NO: 3 87) is known.

[0248] As used herein, the term "hsa-miR-625-3p gene" or "hsa-miR -625-3p" refers to the hsa-miR-625-3p gene described in SEQ ID NO: 170 (miRBase Accession No. MIMAT0004808) and its homologs or orthologs in other species, etc. The hsa-miR-625-3p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sc i U.S.A., Vol. 103, p3687 - 3692. Also, "hsa-miR-625-3p" has a hairpin-like structure as its precursor, "hsa-mir-625" (miRBase Accession No. M I0003639, SEQ ID NO: 388) is known.

[0249] As used herein, the term "hsa-miR-1228-3p gene" or "hsa-mi R-1228-3p" refers to the hsa-miR-1228-3p gene described in SEQ ID NO: 171 (miRBase Accession No. MIMAT0005583 ) and its homologs or orthologs in other species, etc. The hsa-miR-122 8-3p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28 , p328 - 336. Also, "hsa-mi R-1228-3p" has a hairpin-like structure as its precursor, "hsa-mir-1" "228" (miRBase Accession No. MI0006318, SEQ ID NO: 316) is known.

[0250] As used herein, the term "hsa-miR-614 gene" or "hsa-miR-61 4" refers to the hsa-miR-614 gene described in SEQ ID NO: 172 (miRBa se Accession No. MIMAT0003282) and other species homologs or orthologs, etc. The hsa-miR-614 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci U S A, Vol. 103 , p3687-3692. Also, "hsa- miR-614" has a hairpin-like structure as its precursor, "hsa-mir-614 " (miRBase Accession No. MI0003627, SEQ ID NO: 389 ) is known.

[0251] As used herein, the term "hsa-miR-1913 gene" or "hsa-miR-1 913" refers to the hsa-miR-1913 gene described in SEQ ID NO: 173 (mi RBase Accession No. MIMAT0007888) and other species homologs or orthologs, etc. The hsa-miR-1913 gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, p2496-2505 . Also, "hsa-miR-1913" has a hairpin-like structure as its precursor "hsa-mir-1913" (miRBase Acce ssion No. MI0008334, SEQ ID NO: 390) is known.

[0252] As used herein, the term "hsa-miR-92a-2-5p gene" or "hsa-m iR-92a-2-5p" includes the hsa-miR-92 a-2-5p gene (miRBase Accession No. MIMAT0004 508) described in SEQ ID NO: 174, as well as homologs or orthologs of other species. The hsa-miR- 92a-2-5p gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes D ev, 16, p720-728. Also, " hsa-miR-92a-2-5p" has a hairpin-like structure as its precursor, "hs a-mir-92a-2" (miRBase Accession No. MI0000 094, SEQ ID NO: 391) is known.

[0253] As used herein, the term "hsa-miR-187-5p gene" or "hsa-miR -187-5p" includes the hsa-miR-187-5p gene (miRBase Accession No. MIMAT0004561) described in SEQ ID NO: 175, and homologs or orthologs of other species. The hsa-miR-187-5p gene can be obtained by the method described in Lim LP et al., 2003, Science, 299, p1540. Also, "hsa-miR-187-5p" has a hairpin-like structure as its precursor, "hsa-mir-187" (miRBase A ccession No. MI0000274, SEQ ID NO: 392) is known. As used herein, the term "hsa-miR-16-5p gene" or "hsa-miR- ccession No. MI0000274, SEQ ID NO: 392) is known.

[0254] As used herein, the term "hsa-miR-16-5p gene" or "hsa-miR- The term "16-5p" refers to the hsa-miR-16-5p gene described in SEQ ID NO: 176 (miRBase Accession No. MIMAT0000069) and other homologous or orthologous genes of other species, etc. The hsa-miR-16-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, Vol. 294, p8 53-858. Also, "hsa-miR-1 6-5p" has, as its precursor, "hsa-mir-16-1" which has a hairpin-like structure, "hsa-mir-16-2" (miRBase Accession No. MI00 00070, MI0000115, SEQ ID NO: 393, 394) is known.

[0255] As used herein, the term "hsa-miR-92b-3p gene" or "hsa-miR -92b-3p" refers to the hsa-miR-92b-3p gene described in SEQ ID NO: 177 (miRBase Accession No. MIMAT0003218) and other homologous or orthologous genes of other species, etc. The hsa-miR-92b-3p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sc i USA, Vol. 103, p3687-3692. Also, "hsa-miR-92b-3p" has, as its precursor, a hairpin-like structure "hsa-mir-92b" (miRBase Accession No. MI 0003560, SEQ ID NO: 395) is known.

[0256] As used herein, the term "hsa-miR-150-3p gene" or "hsa-miR The term "-150-3p" refers to hsa-miR-150-3p described in SEQ ID NO: 178 gene (miRBase Accession No. MIMAT0004610), and other homologs or orthologs of other species, etc. are included. The hsa-miR-150-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, 1 2, p735-739. Also, "hsa- miR-150-3p" has a hairpin-like structure as its precursor, "hsa-mir- 150" (miRBase Accession No. MI0000479, SEQ ID NO: 396) is known.

[0257] As used herein, the term "hsa-miR-564 gene" or "hsa-miR-56 4" refers to the hsa-miR-564 gene described in SEQ ID NO: 179 (miRBa se Accession No. MIMAT0003228) and other homologs or orthologs of other species, etc. are included. The hsa-miR-564 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci U S A, 103 volumes , p3687-3692. Also, "hsa- miR-564" has a hairpin-like structure as its precursor, "hsa-mir-564 " (miRBase Accession No. MI0003570, SEQ ID NO: 397

[0258] As used herein, the term "hsa-miR-125a-3p gene" or "hsa-mi R-125a-3p" refers to hsa-miR-125a described in SEQ ID NO: 180 -3p gene (miRBase Accession No. MIMAT0004602 ) and other homologs or orthologs of other species are included. hsa-miR-125 a-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Bi ol, 12, p735-739. Also, " hsa-miR-125a-3p" takes a hairpin-like structure as its precursor, "hsa -mir-125a" (miRBase Accession No. MI000046 9, SEQ ID NO: 398) is known.

[0259] As used herein, the term "hsa-miR-92b-5p gene" or "hsa-miR -92b-5p" refers to the hsa-miR-92b-5p gene described in SEQ ID NO: 181 (miRBase Accession No. MIMAT0004792) and other homologs or orthologs of other species. hsa-miR-92b-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sc i U S A, 103, p3687-3692. Also, "hsa-miR-92b-5p" takes a hairpin-like structure as its precursor, "hsa-mir-92b" (miRBase Accession No. MI 0003560, SEQ ID NO: 395) is known.

[0260] As used herein, the term "hsa-miR-92a-3p gene" or "hsa-miR -92a-3p" refers to the hsa-miR-92a-3p Genes (miRBase Accession No. MIMAT0000092) and other homologous or orthologous genes of other species are included. hsa-miR-92a-3p gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev, 16, p 720-728. Also, "hsa-miR- 92a-3p" has a hairpin-like structure as its precursor, "hsa-mir-92a- 1", "hsa-mir-92a-2" (miRBase Accession No. MI0000093, MI0000094, SEQ ID NO: 399, 391) is known.

[0261] As used herein, the term "hsa-miR-663a gene" or "hsa-miR-6 63a" refers to the hsa-miR-663a gene described in SEQ ID NO: 183 (mi RBase Accession No. MIMAT0003326) and other homologous or orthologous genes of other species. The hsa-miR-663a gene can be obtained by the method described in Cum mins JM et al., 2006, Proc Natl Acad Sci U S A, 103, p3687-3692. Also, " hsa-miR-663a" has a hairpin-like structure as its precursor, "hsa-mi r-663a" (miRBase Accession No. MI0003672, seq quence number 400) is known.

[0262] As used herein, the term "hsa-miR-4688 gene" or "hsa-miR-4 688" refers to the hsa-miR-4688 gene described in SEQ ID NO: 184 (mi ​​RBase Accession No. (MIMAT0019777) and other homologous genes or orthologs of other species are included. The hsa-miR-4688 gene can be obtained by the method described by Persson H et al. in Cancer Res, Vol. 71, p78-86 in 2011. Also, "hsa-miR-4688" has a precursor "hsa-mir-4688" (miRBase Accession No. MI0017321, SEQ ID NO: 401) that forms a hairpin-like structure. It includes homologs or orthologs, etc. The hsa-miR-4688 gene can be obtained by the method described by Persson H et al. in Cancer Res, Vol. 71, p78-86 in 2011. Also, "hsa-miR-4688" has a precursor "hsa-mir-4688" (miRBase Accession No. MI0017321, SEQ ID NO: 401) that forms a hairpin-like structure.

[0263] The term "hsa-miR-4648 gene" or "hsa-miR-4648" used in this specification refers to the hsa-miR-4648 gene (miRBase Accession No. MIMAT0019710) described in SEQ ID NO: 185 and other homologous genes or orthologs of other species are included. The hsa-miR-4648 gene can be obtained by the method described by Persson H et al. in Cancer Res, Vol. 71, p78-86 in 2011. Also, "hsa-miR-4648" has a precursor "hsa-mir-4648" (miRBase Accession No. MI0017275, SEQ ID NO: 402) that forms a hairpin-like structure. is known.

[0264] The term "hsa-miR-6085 gene" or "hsa-miR-6085" used in this specification refers to the hsa-miR-6085 gene (miRBase Accession No. MIMAT0023710) described in SEQ ID NO: 186 and other homologous genes or orthologs of other species are included. The hsa-miR-6085 gene can be obtained by the method described by Voe The method described by llenkle C et al. in 2012, RNA, Vol. 18, pp. 472-484 can be used to obtain it. Also, "hsa-miR-6085" has a hairpin-like structure as its precursor, namely "hsa-mir-6085" (miRBase Accession No. MI0020362, SEQ ID NO: 403) which is known. The term "hsa-miR-6126 gene" or "hsa-miR-6126" used in this specification includes the hsa-miR-6126 gene described in SEQ ID NO: 187 (miRBase Accession No. MIMAT0024599), as well as homologs or orthologs of other species. The hsa-miR-6126 gene can be obtained by the method described by Smith JL et al. in 2012, J Virol, Vol. 86, pp. 5278-5287. Also, "hsa-miR-6126" has a hairpin-like structure as its precursor, namely "hsa-mir-6126" (miRBase Accession No. MI0021260, SEQ ID NO: 404) which is known. The term "hsa-miR-6880-5p gene" or "hsa-miR-6880-5p" used in this specification includes the hsa-miR-6880-5p gene described in SEQ ID NO: 188 (miRBase Accession No. MIMAT0027660) and homologs or orthologs of other species. The hsa-miR-6880-5p gene can be obtained by the method described by Ladewig E et al. in 2012, Genome Res, Vol. 22, pp. 1634-1645. ion No.MI0020362, SEQ ID NO: 403) is known.

[0265] The term "hsa-miR-6126 gene" or "hsa-miR-6126" used in this specification includes the hsa-miR-6126 gene described in SEQ ID NO: 187 (miRBase Accession No. MIMAT0024599), as well as homologs or orthologs of other species. The hsa-miR-6126 gene can be obtained by the method described by Smith JL et al. in 2012, J Virol, Vol. 86, pp. 5278-5287. Also, "hsa-miR-6126" has a hairpin-like structure as its precursor, namely "hsa-mir-6126" (miRBase Accession No. MI0021260, SEQ ID NO: 404) which is known. The hsa-miR-6126 gene can be obtained by the method described by Smith JL et al. in 2012, J Virol, Vol. 86, pp. 5278-5287. Also, "hsa-miR-6126" has a hairpin-like structure as its precursor, namely "hsa-mir-6126" (miRBase Accession No. MI0021260, SEQ ID NO: 404) which is known. RBase Accession No.MIMAT0024599) and homologs or orthologs of other species. The hsa-miR-6126 gene can be obtained by the method described by Smith JL et al. in 2012, J Virol, Vol. 86, pp. 5278-5287. Also, "hsa-miR-6126" has a hairpin-like structure as its precursor, namely "hsa-mir-6126" (miRBase Accession No. MI0021260, SEQ ID NO: 404) which is known. The hsa-miR-6126 gene can be obtained by the method described by Smith JL et al. in 2012, J Virol, Vol. 86, pp. 5278-5287. Also, "hsa-miR-6126" has a hairpin-like structure as its precursor, namely "hsa-mir-6126" (miRBase Accession No. MI0021260, SEQ ID NO: 404) which is known. The method described by Smith JL et al. in 2012, J Virol, Vol. 86, pp. 5278-5287 can be used to obtain it. Also, "hsa-miR-6126" has a hairpin-like structure as its precursor, namely "hsa-mir-6126" (miRBase Accession No. MI0021260, SEQ ID NO: 404) which is known. The method described by Smith JL et al. in 2012, J Virol, Vol. 86, pp. 5278-5287 can be used to obtain it. Also, "hsa-miR-6126" has a hairpin-like structure as its precursor, namely "hsa-mir-6126" (miRBase Accession No. MI0021260, SEQ ID NO: 404) which is known. The method described by Smith JL et al. in 2012, J Virol, Vol. 86, pp. 5278-5287 can be used to obtain it. Also, "hsa-miR-6126" has a hairpin-like structure as its precursor, namely "hsa-mir-6126" (miRBase Accession No. MI0021260, SEQ ID NO: 404) which is known. The method described by Smith JL et al. in 2012, J Virol, Vol. 86, pp. 5278-5287 can be used to obtain it. Also, "hsa-miR-6126" has a hairpin-like structure as its precursor, namely "hsa-mir-6126" (miRBase Accession No. MI0021260, SEQ ID NO: 404) which is known.

[0266] The term "hsa-miR-6880-5p gene" or "hsa-miR-6880-5p" used in this specification includes the hsa-miR-6880-5p gene described in SEQ ID NO: 188 (miRBase Accession No. MIMAT0027660) and homologs or orthologs of other species. The hsa-miR-6880-5p gene can be obtained by the method described by Ladewig E et al. in 2012, Genome Res, Vol. 22, pp. 1634-1645. The term "hsa-miR-6880-5p gene" or "hsa-miR-6880-5p" used in this specification includes the hsa-miR-6880-5p gene described in SEQ ID NO: 188 (miRBase Accession No. MIMAT0027660) and homologs or orthologs of other species. The hsa-miR-6880-5p gene can be obtained by the method described by Ladewig E et al. in 2012, Genome Res, Vol. 22, pp. 1634-1645. -5p gene (miRBase Accession No. MIMAT0027660 ) and homologs or orthologs of other species. The hsa-miR-6880-5p gene can be obtained by the method described by Ladewig E et al. in 2012, Genome Res, Vol. 22, pp. 1634-1645. The hsa-miR-6880-5p gene can be obtained by the method described by Ladewig E et al. in 2012, Genome Res, Vol. 22, pp. 1634-1645. The hsa-miR-6880-5p gene can be obtained by the method described by Ladewig E et al. in 2012, Genome Res, Vol. 22, pp. 1634-1645. Also, "hsa-" "miR-6880-5p" has a hairpin-like structure as its precursor, "hsa-mir" -6880" (miRBase Accession No. MI0022727, sequence number 405) is known.

[0267] As used herein, the term "hsa-miR-328-5p gene" or "hsa-miR -328-5p" refers to the hsa-miR-328-5p gene described in SEQ ID NO: 189 (miRBase Accession No. MIMAT0026486) and other homologs or orthologs of other species. The hsa-miR-328-5p gene can be obtained by the method described in Kim J et al., 2004, Proc Natl Acad Sci U S A, 101, p360-365. Also, "hsa-miR-328-5p" has a hairpin-like structure as its precursor, "hsa -mir-328" (miRBase Accession No. MI0000804 , SEQ ID NO: 406) is known.

[0268] As used herein, the term "hsa-miR-6768-5p gene" or "hsa-mi R-6768-5p" refers to the hsa-miR-6768 -5p gene described in SEQ ID NO: 190 (miRBase Accession No. MIMAT0027436 ) and other homologs or orthologs of other species. The hsa-miR-676 8-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 , p1634-1645. Also, "hsa- miR-6768-5p" has a hairpin-like structure as its precursor, "hsa-mir" -6768」(miRBase Accession No. MI0022613, sequence number 407) is known.

[0269] As used herein, the term "hsa-miR-3180 gene" or "hsa-miR-3 180" includes the hsa-miR-3180 gene described in SEQ ID NO: 191 (mi RBase Accession No. MIMAT0018178) and its homologs or orthologs in other species, etc. The hsa-miR-3180 gene can be obtained by the method described by Creighton CJ et al., 2010, PLoS One, 5, e9637. Also, "hsa-miR-3180" includes its precursors, such as "hsa-mir-3180-4" and "hsa-mir-31 80-5" (miRBase Accession No. MI0016408, MI0 016409, SEQ ID NOs: 408, 409) which form a hairpin-like structure. As used herein, the term "hsa-miR-6087 gene" or "hsa-miR-6 087" includes the hsa-miR-6087 gene described in SEQ ID NO: 192 (mi RBase Accession No. MIMAT0023712) and its homologs or orthologs in other species, etc. The hsa-miR-6087 gene can be obtained by the method described by Yoo JK et al., 2012, Stem Cells Dev, 21, p2049-2057. Also, "hsa-miR-6087" includes its precursor, "hsa-mir-6087" which forms a hairpin-like structure (miRBase

[0270] As used herein, the term "hsa-miR-6087 gene" or "hsa-miR-6 087" includes the hsa-miR-6087 gene described in SEQ ID NO: 192 (mi RBase Accession No. MIMAT0023712) and its homologs or orthologs in other species, etc. The hsa-miR-6087 gene can be obtained by the method described by Yoo JK et al., 2012, Stem Cells Dev, 21, p2049-2057 and can be obtained by the method described therein. Also, "hsa-miR-6087" includes its precursor, "hsa-mir-6087" which forms a hairpin-like structure (miRBase Accession No.). Accession No. MI0020364, SEQ ID NO: 410) is known.

[0271] As used herein, the term "hsa-miR-1273g-3p gene" or "hsa-m iR-1273g-3p" includes the hsa-miR-12 73g-3p gene (miRBase Accession No. MIMAT0022 742) described in SEQ ID NO: 193, as well as homologs or orthologs of other species. hsa-miR- The 1273g-3p gene can be obtained by the method described in Reshmi G et al., 2011, Genomics, 97 vol., p333-340. Also, "hsa-m iR-1273g-3p" has a hairpin-like structure as its precursor, "hsa-mir -1273g" (miRBase Accession No. MI0018003, SEQ ID NO: 411) is known.

[0272] As used herein, the term "hsa-miR-1225-5p gene" or "hsa-mi R-1225-5p" includes the hsa-miR-1225 -5p gene (miRBase Accession No. MIMAT0005572 ) described in SEQ ID NO: 194, as well as homologs or orthologs of other species. hsa-miR-122 The 5-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, 28 vol ., p328-336. Also, "hsa-mi R-1225-5p" has a hairpin-like structure as its precursor, "hsa-mir-1 225" (miRBase Accession No. MI0006311, SEQ ID NO: 303) is known.

[0273] As used herein, "hsa-miR-3196 gene" or "hsa-miR-3 The term "miR-3196" refers to the hsa-miR-3196 gene (miR-3196) set forth in SEQ ID NO: 195. RBase Accession No. MIMAT0015080) and other species The hsa-miR-3196 gene is a member of the Sta rk MS et al., 2010, PLoS One, vol. 5, e9685. In addition, "hsa-miR-3196" can be obtained by The pin-like structure of "hsa-mir-3196" (miRBase Accession No. MI0014241, SEQ ID NO: 412) is known.

[0274] As used herein, the term "hsa-miR-4695-5p gene" or "hsa-mi The term "miR-4695-5p" refers to hsa-miR-4695 as set forth in SEQ ID NO: 196. -5p gene (miRBase Accession No. MIMAT0019788 ) and other species homologs or orthologs. The 5-5p gene is described in Persson H et al., 2011, Cancer Res, vol. 71. The hsa-miR- 4695-5p is a precursor of hsa-mir-469, which has a hairpin-like structure. 5" (miRBase Accession No. MI0017328, SEQ ID NO: 41 3) is known.

[0275] As used herein, the term "hsa-miR-6732-5p gene" or "hsa-mi The term "R-6732-5p" encompasses the hsa-miR-6732 gene described in SEQ ID NO: 197 -5p gene (miRBase Accession No. MIMAT0027365 ), as well as homologs or orthologs in other species. The hsa-miR-673 2-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 , pp1634-1645. Also, "hsa- miR-6732-5p" has a hairpin-like structure as its precursor, "hsa-mir -6732" (miRBase Accession No. MI0022577, SEQ ID No. 414) is known.

[0276] As used herein, the term "hsa-miR-638 gene" or "hsa-miR-63 8" encompasses the hsa-miR-638 gene described in SEQ ID NO: 198 (miRBa se Accession No. MIMAT0003308), as well as homologs or orthologs in other species. The hsa-miR-638 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci U S A, 103 , pp3687-3692. Also, "hsa- miR-638" has a hairpin-like structure as its precursor, "hsa-mir-638 " (miRBase Accession No. MI0003653, SEQ ID NO: 415 ) is known.

[0277] As used herein, the term "hsa-miR-6813-5p gene" or "hsa-mi R-6813-5p" encompasses the hsa-miR-6813 described in SEQ ID NO: 199 -5p gene (miRBase Accession No. MIMAT0027526 ) and also includes other species homologs or orthologs, etc. hsa-miR-681 The 3-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, Vol. 22 , pp. 1634-1645. Also, "hsa- miR-6813-5p" has a hairpin-like structure as its precursor, "hsa-mir -6813" (miRBase Accession No. MI0022658, sequence number 416) is known.

[0278] As used herein, the term "hsa-miR-665 gene" or "hsa-miR-66 5" refers to the hsa-miR-665 gene described in SEQ ID NO: 200 (miRBa se Accession No. MIMAT0004952) and other species homologs or orthologs, etc. The hsa-miR-665 gene can be obtained by the method described in Berezik ov E et al., 2006, Genome Res, Vol. 16, pp. 1289-1298 described. Also, "hsa-miR-665" has a hairpin-like structure as its precursor "hsa-mir-665" (miRBase Acce ssion No. MI0005563, SEQ ID NO: 417) is known.

[0279] As used herein, the term "hsa-miR-486-3p gene" or "hsa-miR -486-3p" refers to the hsa-miR-486-3p gene described in SEQ ID NO: 201 (miRBase Accession No. MIMAT0004762) and so on also includes other species homologs or orthologs, etc. hsa-miR-486-3p The gene was obtained by the method described by Fu H et al., 2005, FEBS Lett, 579, p3849-38 54. Also, "hsa-miR-486-3 p" has a hairpin-like structure as its precursor, "hsa-mir-486", "hsa -mir-486-2" (miRBase Accession No.MI00024 70, MI0023622, SEQ ID NO: 418, 419) are known.

[0280] As used herein, the term "hsa-miR-4466 gene" or "hsa-miR-4 466" refers to the hsa-miR-4466 gene described in SEQ ID NO: 202 (mi RBase Accession No.MIMAT0018993) and other species homologs or orthologs, etc. The hsa-miR-4466 gene can be obtained by the method described by Jim a DD et al., 2010, Blood, 116, e118-e127. Also, "hsa-miR-4466" has a hairpin-like structure as its precursor "hsa-mir-4466" (miRBase Accessi on No.MI0016817, SEQ ID NO: 420) is known.

[0281] As used herein, the term "hsa-miR-30c-1-3p gene" or "hsa-m iR-30c-1-3p" refers to the hsa-miR-30 c-1-3p gene described in SEQ ID NO: 203 (miRBase Accession No.MIMAT0004 674) and other species homologs or orthologs, etc. hsa-miR- The 30c-1-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, 12, p735-739. Also, "hsa-miR-30c-1-3p" has a hairpin-like structure as its precursor, "hsa-mir-30c-1" (miRBase Accession No.MI 0000736, SEQ ID NO: 421) is known.

[0282] As used herein, the term "hsa-miR-3621 gene" or "hsa-miR-3 621" includes the hsa-miR-3621 gene (mi RBase Accession No.MIMAT0018002) described in SEQ ID NO: 204, as well as homologs or orthologs of other species. The hsa-miR-3621 gene can be obtained by the method described in Wit ten D et al., 2010, BMC Biol, 8, p58. Also, "hsa-miR-3621" has a hairpin -like structure as its precursor, "hsa-mir-3621" (miRBase Accession N o.MI0016012, SEQ ID NO: 422) is known.

[0283] As used herein, the term "hsa-miR-6743-5p gene" or "hsa-mi R-6743-5p" includes the hsa-miR-6743 -5p gene (miRBase Accession No.MIMAT0027387 ) described in SEQ ID NO: 205, as well as homologs or orthologs of other species. The hsa-miR-674 3-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 ​​​, can be obtained by the method described in p1634-1645. Also, "hsa- miR-6743-5p" has a hairpin-like structure as its precursor, "hsa-mir -6743" (miRBase Accession No. MI0022588, sequence No. 423) is known.

[0284] As used herein, the term "hsa-miR-4298 gene" or "hsa-miR-4 298" includes the hsa-miR-4298 gene described in SEQ ID NO: 206 (mi RBase Accession No. MIMAT0016852) and other orthologs or paralogs of other species. The hsa-miR-4298 gene can be obtained by the method described by Gof f LA et al., 2009, PLoS One, Vol. 4, e7192. Also, "hsa-miR-4298" has a hairpin -like structure as its precursor, "hsa-mir-4298" (miRBase Accession No. MI0015830, SEQ ID NO: 424) is known. -like structure as its precursor, "hsa-mir-4298" (miRBase Accession No. MI0015830, SEQ ID NO: 424) is known.

[0285] As used herein, the term "hsa-miR-4741 gene" or "hsa-miR-4 741" includes the hsa-miR-4741 gene described in SEQ ID NO: 207 (mi RBase Accession No. MIMAT0019871) and other orthologs or paralogs of other species. The hsa-miR-4741 gene can be obtained by the method described by Per sson H et al., 2011, Cancer Res, Vol. 71, p78-86. Also, "hsa-miR-4741" has its precursor -like structure as its precursor, "hsa-miR-4741" has a hairpin -like structure as its precursor, "hsa-miR-4741" has a hairpin "hsa-mir-4741", which has a hairpin-like structure, is known (miRBase Accession No. MI0017379, SEQ ID NO: 425). Sequence No. MI0017379, SEQ ID NO: 425).

[0286] As used herein, the term "hsa-miR-3619-3p gene" or "hsa-mi R-3619-3p" includes the hsa-miR-3619-3p gene described in SEQ ID NO: 208 (miRBase Accession No. MIMAT0019219 ), as well as homologs or orthologs of other species. The hsa-miR-361 ) and the like. The hsa-miR-3619-3p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, 8, p58 . Also, "hsa-miR-3619-3p " has a hairpin-like structure as its precursor, "hsa-mir-3619" (miRB ase Accession No. MI0016009, SEQ ID NO: 426) is known . known.

[0287] As used herein, the term "hsa-miR-6824-5p gene" or "hsa-mi R-6824-5p" includes the hsa-miR-6824-5p gene described in SEQ ID NO: 209 (miRBase Accession No. MIMAT0027548 ), as well as homologs or orthologs of other species. The hsa-miR-682 4-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 , p1634-1645. Also, "hsa- miR-6824-5p" has a hairpin-like structure as its precursor, "hsa-mir " -6824” (miRBase Accession No. MI0022669, sequence No. 427) is known.

[0288] As used herein, the term “hsa-miR-5698 gene” or “hsa-miR-5 698” refers to the hsa-miR-5698 gene (mi RBase Accession No. MIMAT0022491) described in SEQ ID NO: 210 and other species homologs or orthologs, etc. The hsa-miR-5698 gene can be obtained by the method described by Wat ahiki A et al., 2011, PLoS One, Vol. 6, e24950. Also, “hsa-miR-5698” has a hairpin-like structure as its precursor, “hsa-mir-5698” (miRBase Access ion No. MI0019305, SEQ ID NO: 428) is known.

[0289] As used herein, the term “hsa-miR-371a-5p gene” or “hsa-mi R-371a-5p” refers to the hsa-miR-371a -5p gene (miRBase Accession No. MIMAT0004687 ) and other species homologs or orthologs, etc. The hsa-miR-371 a-5p gene can be obtained by the method described by Suh MR et al., 2004, Dev Biol, Vol. 270, p48 8 - 498. Also, “hsa-miR-37 1a-5p” has a hairpin-like structure as its precursor, “hsa-mir-371a” (miRBase Accession No. MI0000779, SEQ ID NO: 429) is known.

[0290] As used herein, the term "hsa-miR-4488 gene" or "hsa-miR-4 488" includes the hsa-miR-4488 gene (miRBase Accession No. MIMAT0019022) described in SEQ ID NO: 212 and other species homologs or orthologs thereof. The hsa-miR-4488 gene can be obtained by the method described by Jim a DD et al., 2010, Blood, Vol. 116, pp. e118-e127. Also, "hsa-miR-4488" has a hairpin-like structure as its precursor, "hsa-mir-4488" (miRBase Accession No. MI0016849, SEQ ID NO: 430) is

[0291] As used herein, the term "hsa-miR-1233-5p gene" or "hsa-mi R-1233-5p" includes the hsa-miR-1233-5p gene (miRBase Accession No. MIMAT0022943 ) described in SEQ ID NO: 213 and other species homologs or orthologs thereof. The hsa-miR-1233-5p gene can be obtained by the method described by Berezikov E et al., 2007, Mol Cell, Vol. 28, pp. 328-336. Also, "hsa-mi R-1233-5p" has hairpin-like structures as its precursors, "hsa-mir-1233-1", "hsa-mir-1233-2" (miRBase Accession No. MI0006323, MI0015973, SEQ ID NO: 431, 432) are

[0292] As used herein, the term "hsa-miR-4723-5p gene" or "hsa-mi R-4723-5p" includes the hsa-miR-4723 -5p gene (miRBase Accession No. MIMAT0019838 ) described in SEQ ID NO: 214, as well as homologs or orthologs of other species. The hsa-miR-472 3-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71 :78-86. Also, "hsa-miR- 4723-5p" has a hairpin-like structure as its precursor, "hsa-mir-472 3" (miRBase Accession No. MI0017359, SEQ ID NO: 43 3).

[0293] As used herein, the term "hsa-miR-24-3p gene" or "hsa-miR- 24-3p" includes the hsa-miR-24-3p gene (miRBase Accession No. MIMAT0000080) described in SEQ ID NO: 215, as well as homologs or orthologs of other species. The hsa-miR-24-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, 294 :853-858. Also, "hsa-miR-2 4-3p" has a hairpin-like structure as its precursor, "hsa-mir-24-1", "hsa-mir-24-2" (miRBase Accession No. MI00 00080, MI0000081, SEQ ID NO: 434, 435).

[0294] ​As used herein, the term "hsa-miR-1238-5p gene" or "hsa-mi R-1238-5p" includes the hsa-miR-1238 -5p gene described in SEQ ID NO: 216 (miRBase Accession No. MIMAT0022947 ), as well as homologs or orthologs of other species. The hsa-miR-123 8-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, Vol. 28 , pp. 328-336. Also, "hsa-mi R-1238-5p" has a hairpin-like structure as its precursor, "hsa-mir-1 238" (miRBase Accession No. MI0006328, SEQ ID NO: 436).

[0295] As used herein, the term "hsa-miR-4442 gene" or "hsa-miR-4 442" includes the hsa-miR-4442 gene described in SEQ ID NO: 217 (mi RBase Accession No. MIMAT0018960), as well as homologs or orthologs of other species . The hsa-miR-4442 gene can be obtained by the method described in Jim a DD et al., 2010, Blood, Vol. 116, pp. e118-e127 . Also, "hsa-miR-4442" has a hairpin-like structure as its precursor "hsa-mir-4442" (miRBase Accessi on No. MI0016785, SEQ ID NO: 437).

[0296] As used herein, the term "hsa-miR-3928-3p gene" or "hsa-mi The term "R-3928-3p" encompasses the hsa-miR-3928 gene described in SEQ ID NO: 218 -3p gene (miRBase Accession No. MIMAT0018205 ), as well as homologs or orthologs of other species. The hsa-miR-392 8-3p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, Vol. 5 , e9637. Also, "hsa-miR-3 928-3p" has a hairpin-like structure as its precursor, "hsa-mir-3928 " (miRBase Accession No. MI0016438, SEQ ID NO: 438 ).

[0297] As used herein, the term "hsa-miR-6716-5p gene" or "hsa-mi R-6716-5p" encompasses the hsa-miR-6716 described in SEQ ID NO: 219 -5p gene (miRBase Accession No. MIMAT0025844 ), as well as homologs or orthologs of other species. The hsa-miR-671 6-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, Vol. 497, pp. 330-335 . Also, "hsa-miR-6716-5p" has a hairpin-like structure as its precursor, "hsa-mir-6716" (miRBa se Accession No. MI0022550, SEQ ID NO: 439) is known .

[0298] As used herein, the term "hsa-miR-6089 gene" or "hsa-miR-6 089" encompasses the hsa-miR-6089 gene described in SEQ ID NO: 220 (mi RBase Accession No. (MIMAT0023714) and other orthologs or homologs of other species are included. The hsa-miR-6089 gene can be obtained by the method described by Yoo JK et al., 2012, Stem Cells Dev, 21, p2049-2057. Also, "hsa-miR-6089" has "hsa-mir-6089-1" and "hsa-mir-6089-2" (miRBase Accession No. MI0020366, MI0023563, SEQ ID NOs: 440, 441) which take a hairpin-like structure as its precursors. including homologs or orthologs, etc. The hsa-miR-6089 gene can be obtained by the method described by Yoo JK et al., 2012, Stem Cells Dev, 21, p2049-2057. Also, "hsa-miR-6089" has "hsa-mir-6089-1" and "hsa-mir-6089-2" (miRBase Accession No. MI00203 66, MI0023563, SEQ ID NOs: 440, 441) which take a hairpin-like structure as its precursors. mir-6089-2" (miRBase Accession No. MI00203 66, MI0023563, SEQ ID NOs: 440, 441) which take a hairpin-like structure as its precursors.

[0299] As used herein, the term "hsa-miR-6124 gene" or "hsa-miR-6 124" includes the hsa-miR-6124 gene (miRBase Accession No. MIMAT0024597) described in SEQ ID NO: 221 and other orthologs or homologs of other species. The hsa-miR-6124 gene can be obtained by the method described by Smyth JL et al., 2012, J Virol, 86, p5278-5287. Also, "hsa-miR-6124" has "hsa-mir-6124" (miRBase Accession No. MI0021258, SEQ ID NO: 442) which takes a hairpin-like structure as its precursor. can be obtained by the method described by Smyth JL et al., 2012, J Virol, 86, p5278-5287. Also, "hsa-miR-6124" has "hsa-mir-6124" (miRBase Accession No. MI0021258, SEQ ID NO: 442) which takes a hairpin-like structure as its precursor. has "hsa-mir-6124" (miRBase Accession No. MI0021258, SEQ ID NO: 442) which takes a hairpin-like structure as its precursor. has "hsa-mir-6124" (miRBase Accession No. MI0021258, SEQ ID NO: 442) which takes a hairpin-like structure as its precursor.

[0300] As used herein, the term "hsa-miR-6778-5p gene" or "hsa-mi R-6778-5p" includes the hsa-miR-6778-5p gene (miRBase Accession No. MIMAT0027456 described in SEQ ID NO: 222. It includes hsa-miR-677, as well as other species homologs or orthologs, etc. The 8-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22 , on pages 1634 - 1645. Also, "hsa- miR-6778-5p" has a hairpin-like structure as its precursor, "hsa-mir -6778" (miRBase Accession No. MI0022623, sequence number 443) is known.

[0301] As used herein, the term "hsa-miR-557 gene" or "hsa-miR-55 7" refers to the hsa-miR-557 gene described in SEQ ID NO: 223 (miRBa se Accession No. MIMAT0003221), as well as other species homologs or orthologs, etc. The hsa-miR-557 gene can be obtained by the method described by Cummins JM et al., 2006, Proc Natl Acad Sci U S A, Vol. 103 , on pages 3687 - 3692. Also, "hsa- miR-557" has a hairpin-like structure as its precursor, "hsa-mir-557 " (miRBase Accession No. MI0003563, SEQ ID NO: 444 ) is known.

[0302] As used herein, the term "hsa-miR-6090 gene" or "hsa-miR-6 090" refers to the hsa-miR-6090 gene described in SEQ ID NO: 224 (mi RBase Accession No. MIMAT0023715), as well as other species homologs or orthologs, etc. The hsa-miR-6090 gene is described by Yoo JK et al., 2012, Stem Cells Dev, 21, p2049-2057 can be obtained by the method described in “hsa-miR-6090” has a hairpin-like structure as its precursor, “hsa-mir-6090” (miRBase Accession No. MI0020367, SEQ ID NO: 445) is known.

[0303] As used herein, the term “hsa-miR-6757-5p gene” or “hsa-mi R-6757-5p” includes the hsa-miR-6757-5p gene described in SEQ ID NO: 714 (miRBase Accession No. MIMAT0027414 ), as well as homologs or orthologs of other species. The hsa-miR-67 57-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., 2 2, p1634-1645. Also, “hs a-miR-6757-5p” has a hairpin-like structure as its precursor, “hsa-m ir-6757” (miRBase Accession No. MI0022602, SEQ ID NO: 730) is known.

[0304] As used herein, the term “hsa-miR-4448 gene” or “hsa-miR-4 448” includes the hsa-miR-4448 gene described in SEQ ID NO: 715 (mi RBase Accession No. MIMAT0018967) and homologs or orthologs of other species. The hsa-miR-4448 gene is described in Ji ma DD et al., 2010, Blood, 116, e118-e127 by the method described in It can be obtained by a method. Also, "hsa-miR-4448" has a hairpin-like structure as its precursor, "hsa-mir-4448" (miRBase Access ion No.MI0016791, SEQ ID NO: 731) is known. ion No.MI0016791, SEQ ID NO: 731) is known.

[0305] As used herein, the term "hsa-miR-671-5p gene" or "hsa-miR -671-5p" includes the hsa-miR-671-5p gene described in SEQ ID NO: 716 (miRBase Accession No.MIMAT0003880) and other homologous or orthologous genes of other species. The hsa-miR-671-5 p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, 16, p1289-1298. Also, "hsa-miR-671-5p" has a hairpin-like structure as its precursor, "hsa-mir-6 71" (miRBase Accession No.MI0003760, SEQ ID NO: 7 32) is known. iR-671-5p" has a hairpin-like structure as its precursor, "hsa-mir-6 71" (miRBase Accession No.MI0003760, SEQ ID NO: 7 32) is known.

[0306] As used herein, the term "hsa-miR-3178 gene" or "hsa-miR-3 178" includes the hsa-miR-3178 gene described in SEQ ID NO: 717 (mi RBase Accession No.MIMAT0015055) and other homologous or orthologous genes of other species. The hsa-miR-3178 gene can be obtained by the method described in St ark MS et al., 2010, PLoS One, 5, e9685. Also, "hsa-miR-3178" has a hairpin-like structure as its precursor, "h ark MS et al., 2010, PLoS One, 5, e9685. Also, "hsa-miR-3178" has a hairpin-like structure as its precursor, "h ark MS et al., 2010, PLoS One, 5, e9685. Also, "hsa-miR-3178" has a hairpin-like structure as its precursor, "h "hsa-mir-3178" (miRBase Accession n No.MI0014212, SEQ ID NO: 733) with an apin-like structure is known.

[0307] As used herein, the term "hsa-miR-4725-3p gene" or "hsa-mi R-4725-3p" refers to the hsa-miR-4725 -3p gene (miRBase Accession No.MIMAT0019844 ) described in SEQ ID NO: 718, as well as homologs or orthologs of other species. The hsa-miR-47 25-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71 vol., p78-86. Also, "hsa-miR -4725-3p" has a hairpin-like structure as its precursor, "hsa-mir-47 25" (miRBase Accession No.MI0017362, SEQ ID NO: 7 34) is known.

[0308] As used herein, the term "hsa-miR-940 gene" or "hsa-miR-94 0" refers to the hsa-miR-940 gene (miRBa se Accession No.MIMAT0004983) described in SEQ ID NO: 719, as well as homologs of other species or orthologs. The hsa-miR-940 gene can be obtained by the method described in Lui WO et al., 2007, A Cancer Res., 67 vol., p6031-6043 described. Also, "hsa-miR-940" has a hairpin-like structure as its precursor "hsa-mir-940" (miRBase Acces sion No.MI0005762, SEQ ID NO: 735) is known.

[0309] As used herein, the term "hsa-miR-6789-5p gene" or "hsa-mi The term "miR-6789-5p" refers to hsa-miR-6789 as set forth in SEQ ID NO: 720. -5p gene (miRBase Accession No. MIMAT0027478 ) and other species homologs or orthologs. The 89-5p gene is described in Ladewig E et al., 2012, Genome Res., 2 2, pp. 1634-1645. a-miR-6789-5p has a hairpin-like structure as its precursor, hsa-m ir-6789” (miRBase Accession No. MI0022634, SEQ ID NO: 736) is known.

[0310] As used herein, "hsa-miR-4484 gene" or "hsa-miR-4 The term "miR-4484" refers to the hsa-miR-4484 gene (miR-4484) set forth in SEQ ID NO: 721. RBase Accession No. MIMAT0019018) and other species The hsa-miR-4484 gene is a homologue or ortholog of the Ji Ma DD et al., 2010, Blood., vol. 116, e118-e127 The precursor of hsa-miR-4484 can be obtained by the method described above. The hairpin-like structure of "hsa-mir-4484" (miRBase Access sion No. MI0016845, sequence number 737) is known.

[0311] As used herein, "hsa-miR-4634 gene" or "hsa-miR-4 The term "634" includes the hsa-miR-4634 gene described in SEQ ID NO: 722 (mi RBase Accession No. MIMAT0019691) and other homologs or orthologs of other species. The hsa-miR-4634 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res., 71, p78-86. Also, "hsa-miR-4634" is preceded by "hsa-mir-4634" (miRBase Ac cession No. MI0017261, SEQ ID NO: 738) which has a hairpin-like structure as its precursor and is known. The term "hsa-miR-4745-5p gene" or "hsa-mi R-4745-5p" used in this specification includes the hsa-miR-4745 described in SEQ ID NO: 723

[0312] -5p gene (miRBase Accession No. MIMAT0019878 ) and other homologs or orthologs of other species. The hsa-miR-47 45-5p gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, 71 vol., p78-86. Also, "hsa-miR -4745-5p" is preceded by "hsa-mir-47" which has a hairpin-like structure as its precursor and is known (miRBase Accession No. MI0017384, SEQ ID NO: 7 39). The term "hsa-miR-4730 gene" or "hsa-miR-4 730" used in this specification includes the hsa-miR-4730 gene described in SEQ ID NO: 724 (mi

[0313] ​​​RBase Accession No. (MIMAT0019852) and other homologous or orthologous genes of other species are included. The hsa-miR-4730 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, p78 - 86. Also, "hsa-miR-4730" has a precursor "hsa-mir-4730" (miRBase Accession No. MI0017367, SEQ ID NO: 740) that forms a hairpin-like structure. Homologs or orthologs, etc. are included. The hsa-miR-4730 gene can be obtained by the method described by Persson H et al., 2011, Cancer Res, Vol. 71, p78 - 86. Also, "hsa-miR-4730" has a precursor "hsa-mir-4730" (miRBase Accession No. MI0017367, SEQ ID NO: 740) that forms a hairpin-like structure. Persson H et al., 2011, Cancer Res, Vol. 71, p78 - 86 can be used to obtain it. Also, "hsa-miR-4730" has a precursor "hsa-mir-4730" (miRBase Accession No. MI0017367, SEQ ID NO: 740) that forms a hairpin-like structure. Persson H et al., 2011, Cancer Res, Vol. 71, p78 - 86 can be used to obtain it. Also, "hsa-miR-4730" has a precursor "hsa-mir-4730" (miRBase Accession No. MI0017367, SEQ ID NO: 740) that forms a hairpin-like structure. Persson H et al., 2011, Cancer Res, Vol. 71, p78 - 86 can be used to obtain it. Also, "hsa-miR-4730" has a precursor "hsa-mir-4730" (miRBase Accession No. MI0017367, SEQ ID NO: 740) that forms a hairpin-like structure. Persson H et al., 2011, Cancer Res, Vol. 71, p78 - 86 can be used to obtain it. Also, "hsa-miR-4730" has a precursor "hsa-mir-4730" (miRBase Accession No. MI0017367, SEQ ID NO: 740) that forms a hairpin-like structure.

[0314] The term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" used in this specification includes the hsa-miR-6803-5p gene (miRBase Accession No. MIMAT0027506) described in SEQ ID NO: 725 and other homologous or orthologous genes of other species. The hsa-miR-6803-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, p1634 - 1645. Also, "hsa-miR-6803-5p" has a precursor "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 741) that forms a hairpin-like structure. The term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" used in this specification includes the hsa-miR-6803-5p gene (miRBase Accession No. MIMAT0027506) described in SEQ ID NO: 725 and other homologous or orthologous genes of other species. The hsa-miR-6803-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, p1634 - 1645. Also, "hsa-miR-6803-5p" has a precursor "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 741) that forms a hairpin-like structure. The term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" used in this specification includes the hsa-miR-6803-5p gene (miRBase Accession No. MIMAT0027506) described in SEQ ID NO: 725 and other homologous or orthologous genes of other species. The hsa-miR-6803-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, p1634 - 1645. Also, "hsa-miR-6803-5p" has a precursor "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 741) that forms a hairpin-like structure. The term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" used in this specification includes the hsa-miR-6803-5p gene (miRBase Accession No. MIMAT0027506) described in SEQ ID NO: 725 and other homologous or orthologous genes of other species. The hsa-miR-6803-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, p1634 - 1645. Also, "hsa-miR-6803-5p" has a precursor "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 741) that forms a hairpin-like structure. The term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" used in this specification includes the hsa-miR-6803-5p gene (miRBase Accession No. MIMAT0027506) described in SEQ ID NO: 725 and other homologous or orthologous genes of other species. The hsa-miR-6803-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, p1634 - 1645. Also, "hsa-miR-6803-5p" has a precursor "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 741) that forms a hairpin-like structure. The term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" used in this specification includes the hsa-miR-6803-5p gene (miRBase Accession No. MIMAT0027506) described in SEQ ID NO: 725 and other homologous or orthologous genes of other species. The hsa-miR-6803-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, p1634 - 1645. Also, "hsa-miR-6803-5p" has a precursor "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 741) that forms a hairpin-like structure. The term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" used in this specification includes the hsa-miR-6803-5p gene (miRBase Accession No. MIMAT0027506) described in SEQ ID NO: 725 and other homologous or orthologous genes of other species. The hsa-miR-6803-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, p1634 - 1645. Also, "hsa-miR-6803-5p" has a precursor "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 741) that forms a hairpin-like structure. The term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" used in this specification includes the hsa-miR-6803-5p gene (miRBase Accession No. MIMAT0027506) described in SEQ ID NO: 725 and other homologous or orthologous genes of other species. The hsa-miR-6803-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, p1634 - 1645. Also, "hsa-miR-6803-5p" has a precursor "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 741) that forms a hairpin-like structure. The term "hsa-miR-6803-5p gene" or "hsa-miR-6803-5p" used in this specification includes the hsa-miR-6803-5p gene (miRBase Accession No. MIMAT0027506) described in SEQ ID NO: 725 and other homologous or orthologous genes of other species. The hsa-miR-6803-5p gene can be obtained by the method described by Ladewig E et al., 2012, Genome Res, Vol. 22, p1634 - 1645. Also, "hsa-miR-6803-5p" has a precursor "hsa-mir-6803" (miRBase Accession No. MI0022648, SEQ ID NO: 741) that forms a hairpin-like structure.

[0315] The term "hsa-miR-6798-5p gene" or "hsa-miR-6798-5p" used in this specification includes the hsa-miR-6798-5p gene (miRBase Accession No. MIMAT0027496) described in SEQ ID NO: 726 and other homologous or orthologous genes of other species. The term "hsa-miR-6798-5p gene" or "hsa-miR-6798-5p" used in this specification includes the hsa-miR-6798-5p gene (miRBase Accession No. MIMAT0027496) described in SEQ ID NO: 726 and other homologous or orthologous genes of other species. The term "hsa-miR-6798-5p gene" or "hsa-miR-6798-5p" used in this specification includes the hsa-miR-6798-5p gene (miRBase Accession No. MIMAT0027496) described in SEQ ID NO: 726 and other homologous or orthologous genes of other species. ) and other species homologs or orthologs, etc. are included. hsa-miR-67 The 98-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, 22 volumes, p1634-1645. Also, "hsa -miR-6798-5p" takes a hairpin-like structure as its precursor, "hsa-mi r-6798" (miRBase Accession No. MI0022643, sequence number 742) is known.

[0316] As used herein, the term "hsa-miR-3648 gene" or "hsa-miR-3 648" refers to the hsa-miR-3648 gene described in SEQ ID NO: 727 (mi RBase Accession No. MIMAT0018068) and other species homologs or orthologs, etc. are included. The hsa-miR-3648 gene can be obtained by the method described in Me iri E et al., 2010, Nucleic Acids Res, 38 volumes, p6234 -6246. Also, "hsa-miR-36 48" takes a hairpin-like structure as its precursor, "hsa-mir-3648" (mi RBase Accession No. MI0016048, sequence number 743) is known .

[0317] As used herein, the term "hsa-miR-4783-3p gene" or "hsa-mi R-4783-3p" refers to the hsa-miR-4783 -3p gene described in SEQ ID NO: 728 (miRBase Accession No. MIMAT0019947 ) and other species homologs or orthologs, etc. are included. hsa-miR-47 The 83-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, 71 Volume, p78-86. Also, "hsa-miR -4783-3p" has a hairpin-like structure as its precursor, "hsa-mir-47 83" (miRBase Accession No. MI0017428, SEQ ID NO: 7 44) is known.

[0318] As used herein, the term "hsa-miR-6836-3p gene" or "hsa-mi R-6836-3p" refers to the hsa-miR-6836 -3p gene (miRBase Accession No. MIMAT0027575 ) described in SEQ ID NO: 729, as well as other species homologs or orthologs, etc. are included. hsa-miR-68 36-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res., 2 2nd, p1634-1645. Also, "hs a-miR-6836-3p" has a hairpin-like structure as its precursor, "hsa-m ir-6836" (miRBase Accession No. MI0022682, SEQ ID NO: 745) is known.

[0319] In addition, when the mature miRNA is excised from the RNA precursor with a hairpin-like structure as the mature miR NA, one to several bases at the front and back of the sequence may be excised shorter or longer, or base substitutions may occur to form mutants, which are called isomiR (Morin R D. et al., 2008, Genome Res., Vol. 18, p.610-621). mi RBase Release20 includes any of SEQ ID NOs: 1-224 and 714-729 In addition to the base sequences represented by, there are also numerous variants and fragments of the base sequences represented by any of SEQ ID NOs: 446 to 713 and 746 to 765, which are called isomiRs. These variants are also shown. These variants can also be obtained as miRNAs having the base sequences represented by any of SEQ ID NOs: 1 to 224 and 714 to 729. That is, SEQ ID NOs: 1, 3, 4, 6, 7, 10, 11, 13, 14, 16, 1

[0320] 7, 20, 22, 26, 29, 36, 38, 39, 40, 42, 43, 44, 46, 49 、52、59、60、62、63、65、66、67、72、76、77、78、81、 、83、84、85、86、87、88、89、90、92、93、94、96、100、 103、105、106、107、113、114、115、116、117、118、 119、120、121、123、124、125、126、130、132、134、 136、139、140、141、142、143、144、145、147、148、 150、151、152、155、157、158、159、163、164、165、 167、168、169、170、171、172、173、174、175、176、 177、178、179、180、181、182、183、184、185、187、 189、191、192、193、195、196、198、200、201、202、 203、206、207、210、211、212、213、214、215、217、 218、219、220、221、715、716、717、718、719、721、 723、724、727 and 728, or the base sequences in which u is in the base sequences represented by these SEQ ID NOs. Among the variants of the polynucleotide consisting of the nucleotide sequence that is t, for example miRBase As the longest variant registered in Release 20, SEQ ID NOs: 446 , 448, 450, 452, 454, 456, 458, 460, 462, 464, 466 , 468, 470, 472, 474, 476, 478, 480, 482, 484, 486 , 488, 490, 492, 494, 496, 498, 500, 502, 504, 506 , 508, 510, 512, 514, 516, 518, 520, 522, 524, 526 , 528, 530, 532, 534, 536, 538, 540, 542, 544, 546 , 548, 550, 552, 554, 556, 558, 560, 562, 564, 566 , 568, 570, 572, 574, 576, 578, 580, 582, 584, 586 , 588, 590, 592, 594, 596, 598, 600, 602, 604, 606 , 608, 610, 612, 614, 616, 618, 620, 622, 624, 626 , 628, 630, 632, 634, 636, 638, 640, 642, 644, 646 , 648, 650, 652, 654, 656, 658, 660, 662, 664, 666 , 668, 670, 672, 674, 676, 678, 680, 682, 684, 686 , 688, 690, 692, 694, 696, 698, 700, 702, 704, 706 , 708, 710, 712, 746, 748, 750, 752, 754, 756, 758 , polynucleotides represented by 760, 762 and 764 are included.

[0321] Also, SEQ ID NOs: 1, 3, 4, 6, 7, 10, 11, 13, 14, 16, 17 of the present invention 20, 22, 26, 29, 36, 38, 39, 40, 42, 43, 44, 46, 49, 5 2, 59, 60, 62, 63, 65, 66, 67, 72, 76, 77, 78, 81, 83 , 84, 85, 86, 87, 88, 89, 90, 92, 93, 94, 96, 100, 10 3, 105, 106, 107, 113, 114, 115, 116, 117, 118, 11 9, 120, 121, 123, 124, 125, 126, 130, 132, 134, 13 6, 139, 140, 141, 142, 143, 144, 145, 147, 148, 15 0, 151, 152, 155, 157, 158, 159, 163, 164, 165, 16 7, 168, 169, 170, 171, 172, 173, 174, 175, 176, 17 7, 178, 179, 180, 181, 182, 183, 184, 185, 187, 18 9, 191, 192, 193, 195, 196, 198, 200, 201, 202, 20 3, 206, 207, 210, 211, 212, 213, 214, 215, 217, 21 8, 219, 220, 221, 715, 716, 717, 718, 719, 721, 72 3, 724, 727 and 728, or a polynucleotide consisting of a base sequence in which u is t in the base sequence Among the variants of a polynucleotide consisting of a certain base sequence, for example, as the shortest variant registered in miRBase Release 20, SEQ ID NOs: 447, 4 49, 451, 453, 455, 457, 459, 461, 463, 465, 467, 4 69, 471, 473, 475, 477, 479, 481, 483, 485, 487, 4 69, 471, 473, 475, 477, 479, 481, 483, 485, 487, 4 89, 491, 493, 495, 497, 499, 501, 503, 505, 507, 5 09, 511, 513, 515, 517, 519, 521, 523, 525, 527, 5 29, 531, 533, 535, 537, 539, 541, 543, 545, 547, 5 49, 551, 553, 555, 557, 559, 561, 563, 565, 567, 5 69, 571, 573, 575, 577, 579, 581, 583, 585, 587, 5 89, 591, 593, 595, 597, 599, 601, 603, 605, 607, 6 09, 611, 613, 615, 617, 619, 621, 623, 625, 627, 6 29, 631, 633, 635, 637, 639, 641, 643, 645, 647, 6 49, 651, 653, 655, 657, 659, 661, 663, 665, 667, 6 69, 671, 673, 675, 677, 679, 681, 683, 685, 687, 6 89, 691, 693, 695, 697, 699, 701, 703, 705, 707, 7 09, 711, 713, 747, 749, 751, 753, 755, 757, 759, 7 Polynucleotides of the sequences represented by 761, 763 and 765 are included.

[0322] In addition to these variants and fragments, polynucleotides that are various isomiRs registered in miRBase with SEQ ID NOs. 1 to 224 and 714 to 729 are included. Furthermore, examples of polynucleotides containing the base sequences represented by any of SEQ ID NOs. 1 to 224 and 714 to 729 are polynucleotides represented by any of SEQ ID NOs. 225 to 445 and 730 to 745, which are their respective precursors.

[0323] The names of the genes represented by SEQ ID NOs. 1 to 765 and the miRBase Accession No. (registration number) are listed in Table 1.

[0324] As used herein, "specifically bindable" means that the nucleic acid probe or primer used in the present invention binds to a specific target nucleic acid and cannot substantially bind to other nucleic acids.

[0325] [Table 1] TIFF2025102846000002.tif248108TIFF2025102846000003.tif248107TIFF2025102846000004.tif247106TIFF2025102846000005.tif248107TIFF2025102846000006.tif247106TIFF2025102846000007.tif247107TIFF2025102846000008.tif247107TIFF2025102846000009.tif247108TIFF2025102846000010.tif247108TIFF2025102846000011.tif247109TIFF2025102846000012.tif246107TIFF2025102846000013.tif246107TIFF2025102846000014.tif246108TIFF2025102846000015.tif247107TIFF2025102846000016.tif246107TIFF2025102846000017.tif247107TIFF2025102846000018.tif246109TIFF2025102846000019.tif246107TIFF2025102846000020.tif246108TIFF2025102846000021.tif247108TIFF2025102846000022.tif23107This specification includes the contents described in the specification and drawings of Japanese Patent Application No. 2014-124880, which is the basis of the priority of this application. [Advantages of the Invention]

[0326] ​​​According to the present invention, it has become possible to easily and accurately detect liver cancer. For example , by using several miRNA measurement values in the blood, serum and / or plasma of patients that can be collected in a minimally invasive manner as an index , it is possible to easily detect whether or not a patient has liver cancer.

Brief Description of the Drawings

[0327]

Figure 1

Figure 2

Figure 3

Figure 4

Mode for Carrying Out the Invention

[0328] The present invention will be described in more detail below.

[0329] 1. Target Nucleic Acid for Liver Cancer Using the nucleic acid probe or primer for detecting liver cancer as defined above in the present invention, for detecting the presence and / or absence of liver cancer or liver cancer cells, the main target nucleic acids as liver cancer markers include hsa-miR-1343-3p, hsa-miR-6726- 5p, hsa-miR-6515-3p, hsa-miR-4651, hsa-miR- 4257, hsa-miR-3188, hsa-miR-6131, hsa-miR-6 766-3p, hsa-miR-7641, hsa-miR-1249, hsa-miR -3679-3p, hsa-miR-6787-5p, hsa-miR-4454, hs a-miR-3135b, hsa-miR-6765-3p, hsa-miR-7975 、hsa-miR-204-3p, hsa-miR-7977, hsa-miR-711 0-5p, hsa-miR-6717-5p, hsa-miR-6870-5p, hsa -miR-663b, hsa-miR-6875-5p, hsa-miR-8072, h sa-miR-6816-5p, hsa-miR-4281, hsa-miR-6729 -5p, hsa-miR-8069, hsa-miR-4706, hsa-miR-71 08-5p, hsa-miR-4433b-3p, hsa-miR-6893-5p, h sa-miR-6857-5p, hsa-miR-1227-5p, hsa-miR-6 741-5p, hsa-miR-451a, hsa-miR-8063, hsa-miR -3622a-5p, hsa-miR-615-5p, hsa-miR-128-1-5 p, hsa-miR-6825-5p, hsa-miR-1260b, hsa-miR- 4433-3p, hsa-miR-4665-5p, hsa-miR-7845-5p, hsa-miR-1908-5p, hsa-miR-6840-3p, hsa-miR- 6765-5p, hsa-miR-296-5p, hsa-miR-3675-3p, h sa-miR-6781-5p, hsa-miR-423-5p, hsa-miR-36 63 - 3p, hsa - miR - 6784 - 5p, hsa - miR - 6749 - 5p, hs a - miR - 1231, hsa - miR - 4746 - 3p, hsa - miR - 6780b - 5p, hsa - miR - 4758 - 5p, hsa - miR - 3679 - 5p, hsa - miR - 3184 - 5p, hsa - miR - 6125, hsa - miR - 6721 - 5p , hsa - miR - 6791 - 5p, hsa - miR - 3185, hsa - miR - 12 60a, hsa - miR - 3197, hsa - miR - 6845 - 5p, hsa - miR - 6887 - 5p, hsa - miR - 6738 - 5p, hsa - miR - 6872 - 3p , hsa - miR - 4497, hsa - miR - 1229 - 5p, hsa - miR - 68 20 - 5p, hsa - miR - 6777 - 5p, hsa - miR - 3917, hsa - m iR - 5787, hsa - miR - 4286, hsa - miR - 6877 - 5p, hsa - miR - 1225 - 3p, hsa - miR - 6088, hsa - miR - 6800 - 5 p, hsa - miR - 1246, hsa - miR - 4467, hsa - miR - 4419 b, hsa - miR - 1914 - 3p, hsa - miR - 4632 - 5p, hsa - mi R - 1915 - 5p, hsa - miR - 3940 - 5p, hsa - miR - 1185 - 2 - 3p, hsa - miR - 6746 - 5p, hsa - miR - 5001 - 5p, hsa - miR - 1228 - 5p, hsa - miR - 5572, hsa - miR - 4327, hs a - miR - 4638 - 5p, hsa - miR - 6799 - 5p, hsa - miR - 68 61 - 5p, hsa - miR - 6727 - 5p, hsa - miR - 4513, hsa - m iR-6805-3p, hsa-miR-6808-5p, hsa-miR-4449, hsa-miR-1199-5p, hsa-miR-1275, hsa-miR-479 2, hsa-miR-4443, hsa-miR-6891-5p, hsa-miR-6 826-5p, hsa-miR-6807-5p, hsa-miR-7150, hsa- miR-4534, hsa-miR-4476, hsa-miR-4649-5p, hs a-miR-4525, hsa-miR-1915-3p, hsa-miR-4516, hsa-miR-4417, hsa-miR-642b-3p, hsa-miR-314 1, hsa-miR-5100, hsa-miR-6848-5p, hsa-miR-4 739, hsa-miR-4459, hsa-miR-1237-5p, hsa-miR -296-3p, hsa-miR-4665-3p, hsa-miR-6786-5p, hsa-miR-4258, hsa-miR-6510-5p, hsa-miR-134 3-5p, hsa-miR-1247-3p, hsa-miR-6805-5p, hsa -miR-4492, hsa-miR-1469, hsa-miR-1268b, hsa -miR-6858-5p, hsa-miR-3937, hsa-miR-939-5p , hsa-miR-3656, hsa-miR-744-5p, hsa-miR-468 7-3p, hsa-miR-4763-3p, hsa-miR-3620-5p, hsa -miR-3195, hsa-miR-6842-5p, hsa-miR-4707-5 p, hsa-miR-642a-3p, hsa-miR-7113-3p, hsa-mi R-4728-5p, hsa-miR-5195-3p, hsa-miR-1185-1 -3p, hsa-miR-6774-5p, hsa-miR-8059, hsa-miR -3131, hsa-miR-7847-3p, hsa-miR-4463, hsa-m iR-128-2-5p, hsa-miR-4508, hsa-miR-6806-5p , hsa-miR-7111-5p, hsa-miR-6782-5p, hsa-miR -4734, hsa-miR-3162-5p, hsa-miR-887-3p, hsa -miR-6752-5p, hsa-miR-6724-5p, hsa-miR-675 7-5p, hsa-miR-4448, hsa-miR-671-5p, hsa-miR -3178, hsa-miR-4725-3p, hsa-miR-940, hsa-mi R-6789-5p, hsa-miR-4484, hsa-miR-4634, hsa- miR-4745-5p, hsa-miR-4730, hsa-miR-6803-5p , hsa-miR-6798-5p, hsa-miR-3648, hsa-miR-47 83-3p and at least one selected from the group consisting of hsa-miR-6836-3p or more miRNAs can be used. Furthermore, other liver cancer markers that can be combined with these miRNAs, namely, hsa-miR-23b-3p, hsa- miR-23a-3p, hsa-miR-625-3p, hsa-miR-1228-3 p, hsa-miR-614, hsa-miR-1913, hsa-miR-92a-2 -5p, hsa-miR-187-5p, hsa-miR-16-5p, hsa-miR -92b-3p, hsa-miR-150-3p, hsa-miR-564, hsa-m -92b-3p, hsa-miR-150-3p, hsa-miR-564, hsa-m iR-125a-3p, hsa-miR-92b-5p, hsa-miR-92a-3p and at least one or more miRN selected from the group consisting of hsa-miR-663a A can also be preferably used as a target nucleic acid. Furthermore, other liver cancer markers that can be combined with these miRNAs, namely, hsa-miR-4688, hsa -miR-4648, hsa-miR-6085, hsa-miR-6126, hsa- miR-6880-5p, hsa-miR-328-5p, hsa-miR-6768- 5p, hsa-miR-3180, hsa-miR-6087, hsa-miR-127 3g-3p, hsa-miR-1225-5p, hsa-miR-3196, hsa-m iR-4695-5p, hsa-miR-6732-5p, hsa-miR-638, h sa-miR-6813-5p, hsa-miR-665, hsa-miR-486-3 p, hsa-miR-4466, hsa-miR-30c-1-3p, hsa-miR- 3621, hsa-miR-6743-5p, hsa-miR-4298, hsa-mi R-4741, hsa-miR-3619-3p, hsa-miR-6824-5p, h sa-miR-5698, hsa-miR-371a-5p, hsa-miR-4488 、hsa-miR-1233-5p, hsa-miR-4723-5p, hsa-miR -24-3p, hsa-miR-1238-5p, hsa-miR-4442, hsa- miR-3928-3p, hsa-miR-6716-5p, hsa-miR-6089 、hsa-miR-6124, hsa-miR-6778-5p, hsa-miR-55 7 and at least one or more miR selected from the group consisting of hsa-miR-6090 ​ NA can also be preferably used as the target nucleic acid.

[0330] The above-mentioned miRNAs include, for example, any of SEQ ID NOs: 1 to 224 and 714 to 729 human genes containing the base sequences represented (i.e., hsa-miR-1343- 3p, hsa-miR-6726-5p, hsa-miR-6515-3p, hsa-m iR-4651, hsa-miR-4257, hsa-miR-3188, hsa-mi R-6131, hsa-miR-6766-3p, hsa-miR-7641, hsa- miR-1249, hsa-miR-3679-3p, hsa-miR-6787-5p , hsa-miR-4454, hsa-miR-3135b, hsa-miR-6765 -3p, hsa-miR-7975, hsa-miR-204-3p, hsa-miR- 7977, hsa-miR-7110-5p, hsa-miR-6717-5p, hsa -miR-6870-5p, hsa-miR-663b, hsa-miR-6875-5 p, hsa-miR-8072, hsa-miR-6816-5p, hsa-miR-4 281, hsa-miR-6729-5p, hsa-miR-8069, hsa-miR -4706, hsa-miR-7108-5p, hsa-miR-4433b-3p, h sa-miR-6893-5p, hsa-miR-6857-5p, hsa-miR-1 227-5p, hsa-miR-6741-5p, hsa-miR-451a, hsa- miR-8063, hsa-miR-3622a-5p, hsa-miR-615-5p , hsa-miR-128-1-5p, hsa-miR-6825-5p, hsa-mi R-1260b, hsa-miR-4433-3p, hsa-miR-4665-5p, hsa-miR-7845-5p, hsa-miR-1908-5p, hsa-miR- 6840-3p, hsa-miR-6765-5p, hsa-miR-296-5p, h sa-miR-3675-3p, hsa-miR-6781-5p, hsa-miR-4 23-5p, hsa-miR-3663-3p, hsa-miR-6784-5p, hs a-miR-6749-5p, hsa-miR-1231, hsa-miR-4746- 3p, hsa-miR-6780b-5p, hsa-miR-4758-5p, hsa- miR-3679-5p, hsa-miR-3184-5p, hsa-miR-6125 、hsa-miR-6721-5p, hsa-miR-6791-5p, hsa-miR -3185, hsa-miR-1260a, hsa-miR-3197, hsa-miR -6845-5p, hsa-miR-6887-5p, hsa-miR-6738-5p 、hsa-miR-6872-3p, hsa-miR-4497, hsa-miR-12 29-5p, hsa-miR-6820-5p, hsa-miR-6777-5p, hs a-miR-3917, hsa-miR-5787, hsa-miR-4286, hsa -miR-6877-5p, hsa-miR-1225-3p, hsa-miR-608 8, hsa-miR-6800-5p, hsa-miR-1246, hsa-miR-4 467, hsa-miR-4419b, hsa-miR-1914-3p, hsa-mi R-4632-5p, hsa-miR-1915-5p, hsa-miR-3940-5 p, hsa-miR-1185-2-3p, hsa-miR-6746-5p, hsa- miR-5001-5p, hsa-miR-1228-5p, hsa-miR-5572 , hsa-miR-4327, hsa-miR-4638-5p, hsa-miR-67 99-5p, hsa-miR-6861-5p, hsa-miR-6727-5p, hs a-miR-4513, hsa-miR-6805-3p, hsa-miR-6808- 5p, hsa-miR-4449, hsa-miR-1199-5p, hsa-miR- 1275, hsa-miR-4792, hsa-miR-4443, hsa-miR-6 891-5p, hsa-miR-6826-5p, hsa-miR-6807-5p, h sa-miR-7150, hsa-miR-4534, hsa-miR-4476, hs a-miR-4649-5p, hsa-miR-4525, hsa-miR-1915- 3p, hsa-miR-4516, hsa-miR-4417, hsa-miR-642 b-3p, hsa-miR-3141, hsa-miR-5100, hsa-miR-6 848-5p, hsa-miR-4739, hsa-miR-4459, hsa-miR -1237-5p, hsa-miR-296-3p, hsa-miR-4665-3p, hsa-miR-6786-5p, hsa-miR-4258, hsa-miR-651 0-5p, hsa-miR-1343-5p, hsa-miR-1247-3p, hsa -miR-6805-5p, hsa-miR-4492, hsa-miR-1469, h sa-miR-1268b, hsa-miR-6858-5p, hsa-miR-393 7, hsa-miR-939-5p, hsa-miR-3656, hsa-miR-74 4-5p, hsa-miR-4687-3p, hsa-miR-4763-3p, hsa -miR-3620-5p, hsa-miR-3195, hsa-miR-6842-5 p, hsa-miR-4707-5p, hsa-miR-642a-3p, hsa-mi R-7113-3p, hsa-miR-4728-5p, hsa-miR-5195-3 p, hsa-miR-1185-1-3p, hsa-miR-6774-5p, hsa- miR-8059, hsa-miR-3131, hsa-miR-7847-3p, hs a-miR-4463, hsa-miR-128-2-5p, hsa-miR-4508 , hsa-miR-6806-5p, hsa-miR-7111-5p, hsa-miR -6782-5p, hsa-miR-4734, hsa-miR-3162-5p, hs a-miR-887-3p, hsa-miR-6752-5p, hsa-miR-672 4-5p, hsa-miR-6757-5p, hsa-miR-4448, hsa-mi R-671-5p, hsa-miR-3178, hsa-miR-4725-3p, hs a-miR-940, hsa-miR-6789-5p, hsa-miR-4484, h sa-miR-4634, hsa-miR-4745-5p, hsa-miR-4730 , hsa-miR-6803-5p, hsa-miR-6798-5p, hsa-miR -3648, hsa-miR-4783-3p, hsa-miR-6836-3p, hs a-miR-23b-3p, hsa-miR-23a-3p, hsa-miR-625- 3p, hsa-miR-1228-3p, hsa-miR-614, hsa-miR-1 913, hsa-miR-92a-2-5p, hsa-miR-187-5p, hsa- miR-16-5p, hsa-miR-92b-3p, hsa-miR-150-3p, hsa-miR-564, hsa-miR-125a-3p, hsa-miR-92b- 5p, hsa-miR-92a-3p, hsa-miR-663a, hsa-miR-4 688, hsa-miR-4648, hsa-miR-6085, hsa-miR-61 26, hsa-miR-6880-5p, hsa-miR-328-5p, hsa-mi R-6768-5p, hsa-miR-3180, hsa-miR-6087, hsa- miR-1273g-3p, hsa-miR-1225-5p, hsa-miR-319 6, hsa-miR-4695-5p, hsa-miR-6732-5p, hsa-mi R-638, hsa-miR-6813-5p, hsa-miR-665, hsa-mi R-486-3p, hsa-miR-4466, hsa-miR-30c-1-3p, h sa-miR-3621, hsa-miR-6743-5p, hsa-miR-4298 、hsa-miR-4741, hsa-miR-3619-3p, hsa-miR-68 24-5p, hsa-miR-5698, hsa-miR-371a-5p, hsa-m iR-4488, hsa-miR-1233-5p, hsa-miR-4723-5p, hsa-miR-24-3p, hsa-miR-1238-5p, hsa-miR-44 42, hsa-miR-3928-3p, hsa-miR-6716-5p, hsa-m iR-6089, hsa-miR-6124, hsa-miR-6778-5p, hsa -miR-557 and hsa-miR-6090), its homologs, its transcription products, and those It includes variants or derivatives. Here, the gene, homolog, transcript, variant and derivative are as defined above.

[0331] A preferred target nucleic acid is a human gene containing a base sequence represented by any of SEQ ID NOs: 1 to 765, or its transcript, more preferably the transcript, that is, miRNA, its precursor RNA, pri-miRNA or pre-miRNA.

[0332] The first target gene is the hsa-miR-1343-3p gene, its homologs, its transcripts, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcript can be a marker for liver cancer.

[0333] The second target gene is the hsa-miR-6726-5p gene, its homologs, its transcripts, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcript can be a marker for liver cancer.

[0334] The third target gene is the hsa-miR-6515-3p gene, its homologs, its transcripts, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcript can be a marker for liver cancer.

[0335] The fourth target gene is the hsa-miR-4651 gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcript can be a marker for liver cancer.

[0336] The fifth target gene is the hsa-miR-4257 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report indicating that changes in the expression of this gene or its transcription

[0337] products can serve as a marker for liver cancer. The sixth target gene is the hsa-miR-3188 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no

[0338] report indicating that changes in the expression of this gene or its transcription products can serve as a marker for liver cancer. The seventh target gene is the hsa-miR-6131 gene, its homologs, their

[0339] transcription products, or their variants or derivatives. So far, there has been no report indicating that changes in the expression of this gene or its transcription products can serve as a marker for liver cancer.

[0340] The eighth target gene is the hsa-miR-6766-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report indicating that changes in the expression of this gene or its transcription

[0341] products can serve as a marker for liver cancer. They are transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0342] The 11th target gene is the hsa-miR-3679-3p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0343] The 12th target gene is the hsa-miR-6787-5p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0344] The 13th target gene is the hsa-miR-4454 gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0345] The 14th target gene is the hsa-miR-3135b gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0346] The 15th target gene is the hsa-miR-6765-3p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its There is no report that changes in the expression of the transcription product can be a marker for liver cancer.

[0347] The 16th target gene is the hsa-miR-7975 gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0348] The 17th target gene is the hsa-miR-204-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0349] The 18th target gene is the hsa-miR-7977 gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0350] The 19th target gene is the hsa-miR-7110-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0351] The 20th target gene is the hsa-miR-6717-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0352] The 21st target gene is the hsa-miR-6870-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0353] The 22nd target gene is the hsa-miR-663b gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0354] The 23rd target gene is the hsa-miR-6875-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0355] The 24th target gene is the hsa-miR-8072 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0356] The 25th target gene is the hsa-miR-6816-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0357] The 26th target gene is the hsa-miR-4281 gene, its homologs, their It is a transcription product, or a variant or derivative thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0358] The 27th target gene is the hsa-miR-6729-5p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0359] The 28th target gene is the hsa-miR-8069 gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0360] The 29th target gene is the hsa-miR-4706 gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0361] The 30th target gene is the hsa-miR-7108-5p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0362] The 31st target gene is the hsa-miR-4433b-3p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report on this gene or There is no report that the change in the expression of the transcription product can be a marker for liver cancer. 。

[0363] The 32nd target gene is the hsa-miR-6893-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there is no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0364] The 33rd target gene is the hsa-miR-6857-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there is no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0365] The 34th target gene is the hsa-miR-1227-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there is no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0366] The 35th target gene is the hsa-miR-6741-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there is no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0367] The 36th target gene is the hsa-miR-451a gene, its homologs, their transcription products, or their mutants or derivatives. So far, there is no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0368] The 37th target gene is the hsa-miR-8063 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0369] The 38th target gene is the hsa-miR-3622a-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0370] The 39th target gene is the hsa-miR-615-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0371] The 40th target gene is the hsa-miR-128-1-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0372] The 41st target gene is the hsa-miR-6825-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0373] The 42nd target gene is the hsa-miR-1260b gene, its homologs,​​ Its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0374] The 43rd target gene is the hsa-miR-4433-3p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0375] The 44th target gene is the hsa-miR-4665-5p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0376] The 45th target gene is the hsa-miR-7845-5p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0377] The 46th target gene is the hsa-miR-1908-5p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0378] The 47th target gene is the hsa-miR-6840-3p gene, its homologs, its transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its There is no report that the change in the expression of the transcription product can be a marker for liver cancer.

[0379] The 48th target gene is the hsa-miR-6765-5p gene, its homologs, their transcription products, or their mutants or derivatives. There has been no report so far that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0380] The 49th target gene is the hsa-miR-296-5p gene, its homologs, its transcription products, or their mutants or derivatives. There has been no report so far that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0381] The 50th target gene is the hsa-miR-3675-3p gene, its homologs, their transcription products, or their mutants or derivatives. There has been no report so far that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0382] The 51st target gene is the hsa-miR-6781-5p gene, its homologs, their transcription products, or their mutants or derivatives. There has been no report so far that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0383] The 52nd target gene is the hsa-miR-423-5p gene, its homologs, its transcription products, or their mutants or derivatives. There has been no report so far that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0384] The 53rd target gene is the hsa-miR-3663-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report indicating that changes in the expression of this gene or its

[0385] transcription products can serve as markers for liver cancer. The 54th target gene is the hsa-miR-6784-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no

[0386] report indicating that changes in the expression of this gene or its transcription products can serve as markers for liver cancer. The 55th target gene is the hsa-miR-6749-5p gene, its homologs, their

[0387] transcription products, or their variants or derivatives. So far, there has been no report indicating that changes in the expression of this gene or its transcription products can serve as markers for liver cancer.

[0388] The 56th target gene is the hsa-miR-1231 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report indicating that changes in the expression of this gene or its transcription products can serve as markers for liver cancer.

[0388] The 57th target gene is the hsa-miR-4746-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report indicating that changes in the expression of this gene or its

[0389] transcription products can serve as markers for liver cancer. The 58th target gene is the hsa-miR-6780b-5p gene, its homologs, They are those transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or the change in the expression of its transcription product can be a marker for liver cancer. .

[0390] The 59th target gene is the hsa-miR-4758-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0391] The 60th target gene is the hsa-miR-3679-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0392] The 61st target gene is the hsa-miR-3184-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0393] The 62nd target gene is the hsa-miR-6125 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0394] The 63rd target gene is the hsa-miR-6721-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its There is no report that changes in the expression of the transcription product can be a marker for liver cancer.

[0395] The 64th target gene is the hsa-miR-6791-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0396] The 65th target gene is the hsa-miR-3185 gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0397] The 66th target gene is the hsa-miR-1260a gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that changes in the expression of this gene or its trans cription product can be a marker for liver cancer.

[0398] The 67th target gene is the hsa-miR-3197 gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0399] The 68th target gene is the hsa-miR-6845-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0400] The 69th target gene is the hsa-miR-6887-5p gene, its homologs, their transcripts, or their variants or derivatives. There has been no report indicating that changes in the expression of this gene or its

[0401] transcripts can serve as a marker for liver cancer. The 70th target gene is the hsa-miR-6738-5p gene, its homologs, their transcripts, or their variants or derivatives. There has been no

[0402] report indicating that changes in the expression of this gene or its transcripts can serve as a marker for liver cancer. The 71st target gene is the hsa-miR-6872-3p gene, its homologs,

[0403] their transcripts, or their variants or derivatives. There has been no report indicating that changes in the expression of this gene or its transcripts can serve as a marker for liver cancer.

[0404] The 73rd target gene is the hsa-miR-1229-5p gene, its homologs, their transcripts, or their variants or derivatives. There has been no report indicating that changes in the expression of this gene or its

[0405] transcripts can serve as a marker for liver cancer. They are these transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0406] The 75th target gene is the hsa-miR-6777-5p gene, its homologs, its transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0407] The 76th target gene is the hsa-miR-3917 gene, its homologs, its transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0408] The 77th target gene is the hsa-miR-5787 gene, its homologs, its transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0409] The 78th target gene is the hsa-miR-4286 gene, its homologs, its transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0410] The 79th target gene is the hsa-miR-6877-5p gene, its homologs, its transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its There is no report that changes in the expression of the transcription product can be a marker for liver cancer.

[0411] The 80th target gene is the hsa-miR-1225-3p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0412] The 81st target gene is the hsa-miR-6088 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0413] The 82nd target gene is the hsa-miR-6800-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0414] The 83rd target gene is the hsa-miR-1246 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0415] The 84th target gene is the hsa-miR-4467 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there is no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0416] The 85th target gene is the hsa-miR-4419b gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0417] The 86th target gene is the hsa-miR-1914-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0418] The 87th target gene is the hsa-miR-4632-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0419] The 88th target gene is the hsa-miR-1915-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0420] The 89th target gene is the hsa-miR-3940-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0421] The 90th target gene is the hsa-miR-1185-2-3p gene, its homologs , their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0422] The 91st target gene is the hsa-miR-6746-5p gene, its homologs, its transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0423] The 92nd target gene is the hsa-miR-5001-5p gene, its homologs, its transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0424] The 93rd target gene is the hsa-miR-1228-5p gene, its homologs, its transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0425] The 94th target gene is the hsa-miR-5572 gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0426] The 95th target gene is the hsa-miR-4327 gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript ​There is no report that changes in the expression of the product can be a marker for liver cancer.

[0427] The 96th target gene is the hsa-miR-4638-5p gene, its homologs, their transcription products, or their variants or derivatives. There is no report that changes in the expression of this gene or its transcription products can be a marker for liver cancer.

[0428] The 97th target gene is the hsa-miR-6799-5p gene, its homologs, their transcription products, or their variants or derivatives. There is no report that changes in the expression of this gene or its transcription products can be a marker for liver cancer.

[0429] The 98th target gene is the hsa-miR-6861-5p gene, its homologs, their transcription products, or their variants or derivatives. There is no report that changes in the expression of this gene or its transcription products can be a marker for liver cancer.

[0430] The 99th target gene is the hsa-miR-6727-5p gene, its homologs, their transcription products, or their variants or derivatives. There is no report that changes in the expression of this gene or its transcription products can be a marker for liver cancer.

[0431] The 100th target gene is the hsa-miR-4513 gene, its homologs, their transcription products, or their variants or derivatives. There is no report that changes in the expression of this gene or its transcription products can be a marker for liver cancer.

[0432] The 101st target gene is the hsa-miR-6805-3p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. .

[0433] The 102nd target gene is the hsa-miR-6808-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. .

[0434] The 103rd target gene is the hsa-miR-4449 gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0435] The 104th target gene is the hsa-miR-1199-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. .

[0436] The 105th target gene is the hsa-miR-1275 gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0437] The 106th target gene is the hsa-miR-4792 gene, its homologs, their is a transcription product thereof, or a variant or derivative thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0438] The 107th target gene is the hsa-miR-4443 gene, its homologs, their transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0439] The 108th target gene is the hsa-miR-6891-5p gene, its homologs, their transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer. .

[0440] The 109th target gene is the hsa-miR-6826-5p gene, its homologs, their transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer. .

[0441] The 110th target gene is the hsa-miR-6807-5p gene, its homologs, their transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer. .

[0442] The 111th target gene is the hsa-miR-7150 gene, its homologs, themselves is a transcription product, or a variant or derivative thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0443] The 112th target gene is the hsa-miR-4534 gene, its homologs, their transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0444] The 113th target gene is the hsa-miR-4476 gene, its homologs, their transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0445] The 114th target gene is the hsa-miR-4649-5p gene, its homologs, their transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer. .

[0446] The 115th target gene is the hsa-miR-4525 gene, its homologs, their transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer. So far, there has been no report that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0447] The 116th target gene is the hsa-miR-1915-3p gene, its homologs, their transcription products, or variants or derivatives thereof. So far, there has been no report that changes in the expression of this gene or There is no report indicating that the change in the expression of the transcription product can be a marker for liver cancer. 。

[0448] The 117th target gene is the hsa-miR-4516 gene, its homologs, their transcription products, or their mutants or derivatives. There is no report indicating that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0449] The 118th target gene is the hsa-miR-4417 gene, its homologs, their transcription products, or their mutants or derivatives. There is no report indicating that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0450] The 119th target gene is the hsa-miR-642b-3p gene, its homologs, their transcription products, or their mutants or derivatives. There is no report indicating that the change in the expression of this gene or its transcription product can be a marker for liver cancer. 。

[0451] The 120th target gene is the hsa-miR-3141 gene, its homologs, their transcription products, or their mutants or derivatives. There is no report indicating that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0452] The 121st target gene is the hsa-miR-5100 gene, its homologs, their transcription products, or their mutants or derivatives. There is no report indicating that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0453] The 122nd target gene is the hsa-miR-6848-5p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. .

[0454] The 123rd target gene is the hsa-miR-4739 gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0455] The 124th target gene is the hsa-miR-4459 gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0456] The 125th target gene is the hsa-miR-1237-5p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. .

[0457] The 126th target gene is the hsa-miR-296-3p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0458] The 127th target gene is the hsa-miR-4665-3p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer .

[0459] The 128th target gene is the hsa-miR-6786-5p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer .

[0460] The 129th target gene is the hsa-miR-4258 gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its trans cript can be a marker for liver cancer.

[0461] The 130th target gene is the hsa-miR-6510-5p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer .

[0462] The 131st target gene is the hsa-miR-1343-5p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer .

[0463] The 132nd target gene is the hsa-miR-1247-3p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer .

[0464] The 133rd target gene is the hsa-miR-6805-5p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer .

[0465] The 134th target gene is the hsa-miR-4492 gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its trans cript can be a marker for liver cancer.

[0466] The 135th target gene is the hsa-miR-1469 gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its trans cript can be a marker for liver cancer.

[0467] The 136th target gene is the hsa-miR-1268b gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0468] The 137th target gene is the hsa-miR-6858-5p gene, its homologs, They are those transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer. .

[0469] The 138th target gene is the hsa-miR-3937 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0470] The 139th target gene is the hsa-miR-939-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0471] The 140th target gene is the hsa-miR-3656 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0472] The 141st target gene is the hsa-miR-744-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0473] The 142nd target gene is the hsa-miR-4687-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report about this gene or There is no report indicating that changes in the expression of the transcription product can be a marker for liver cancer 。

[0474] The 143rd target gene is the hsa-miR-4763-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report indicating that changes in the expression of this gene or its transcription product can be a marker for liver cancer 。

[0475] The 144th target gene is the hsa-miR-3620-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report indicating that changes in the expression of this gene or its transcription product can be a marker for liver cancer 。

[0476] The 145th target gene is the hsa-miR-3195 gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report indicating that changes in the expression of this gene or its transcription product can be a marker for liver cancer.

[0477] The 146th target gene is the hsa-miR-6842-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report indicating that changes in the expression of this gene or its transcription product can be a marker for liver cancer 。

[0478] The 147th target gene is the hsa-miR-4707-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report indicating that changes in the expression of this gene or There is no report that the change in the expression of the transcription product can be a marker for liver cancer .

[0479] The 148th target gene is the hsa-miR-642a-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer .

[0480] The 149th target gene is the hsa-miR-7113-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer .

[0481] The 150th target gene is the hsa-miR-4728-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer .

[0482] The 151st target gene is the hsa-miR-5195-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer .

[0483] The 152nd target gene is the hsa-miR-1185-1-3p gene, its homologs bodies, their transcription products, or their variants or derivatives. So far, this gene Reports that changes in the expression of or its transcription products can become markers for liver cancer are not known No

[0484] The 153rd target gene is the hsa-miR-6774-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there are no reports that changes in the expression of this gene or its transcription products can become markers for liver cancer No

[0485] The 154th target gene is the hsa-miR-8059 gene, its homologs, their transcription products, or their variants or derivatives. So far, there are no reports that changes in the expression of this gene or its transcription products can become markers for liver cancer

[0486] The 155th target gene is the hsa-miR-3131 gene, its homologs, their transcription products, or their variants or derivatives. So far, there are no reports that changes in the expression of this gene or its transcription products can become markers for liver cancer

[0487] The 156th target gene is the hsa-miR-7847-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there are no reports that changes in the expression of this gene or its transcription products can become markers for liver cancer No

[0488] The 157th target gene is the hsa-miR-4463 gene, its homologs, their transcription products, or their variants or derivatives. So far, there are no reports that changes in the expression of this gene or its transcription products can become markers for liver cancer

[0489] The 158th target gene is the hsa-miR-128-2-5p gene, its homologs , their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0490] The 159th target gene is the hsa-miR-4508 gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0491] The 160th target gene is the hsa-miR-6806-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0492] The 161st target gene is the hsa-miR-7111-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0493] The 162nd target gene is the hsa-miR-6782-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0494] ​​​​​ The 163rd target gene is the hsa-miR-4734 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0495] The 164th target gene is the hsa-miR-3162-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer. .

[0496] The 165th target gene is the hsa-miR-887-3p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer.

[0497] The 166th target gene is the hsa-miR-6752-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer. .

[0498] The 167th target gene is the hsa-miR-6724-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcription product can be a marker for liver cancer. .

[0499] The 168th target gene is the hsa-miR-23b-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there have been reports indicating that changes in the expression of this gene or its transcription products may serve as markers for liver cancer (Patent Documents 2 and 3).

[0500] The 169th target gene is the hsa-miR-23a-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there have been reports indicating that changes in the expression of this gene or its transcription products may serve as markers for liver cancer (Patent Document 2).

[0501] The 170th target gene is the hsa-miR-625-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there have been reports indicating that changes in the expression of this gene or its transcription products may serve as markers for liver cancer (Patent Document 4).

[0502] The 171st target gene is the hsa-miR-1228-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there have been no reports indicating that changes in the expression of this gene or its transcription products may serve as markers for liver cancer.

[0503] The 172nd target gene is the hsa-miR-614 gene, its homologs, their transcription products, or their variants or derivatives. So far, there have been reports indicating that changes in the expression of this gene or its transcription products may serve as markers for liver cancer (Patent Document 2).

[0504] The 173rd target gene is the hsa-miR-1913 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be markers for liver cancer (Patent Document 4).

[0505] The 174th target gene is the hsa-miR-92a-2-5p gene, its homologs , their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be markers for liver cancer (Patent Document 1).

[0506] The 175th target gene is the hsa-miR-187-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be markers for liver cancer (Patent Document 5).

[0507] The 176th target gene is the hsa-miR-16-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be markers for liver cancer (Patent Documents 4 and 5).

[0508] The 177th target gene is the hsa-miR-92b-3p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be markers for liver cancer (Patent Document 1). ​​​​​

[0509] The 178th target gene is the hsa-miR-150-3p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be markers for liver cancer (Patent Document 2).

[0510] The 179th target gene is the hsa-miR-564 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be markers for liver cancer (Patent Document 2).

[0511] The 180th target gene is the hsa-miR-125a-3p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be markers for liver cancer (Patent Document 3).

[0512] The 181st target gene is the hsa-miR-92b-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be markers for liver cancer (Patent Document 1).

[0513] The 182nd target gene is the hsa-miR-92a-3p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be markers for liver cancer (Patent​ (Patent Documents 1, 4, and 5).

[0514] The target gene of No. 183 is the hsa-miR-663a gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been reports that changes in the expression of this gene or its transcription products can be used as markers for liver cancer (Patent Document 4). (Patent Document 4).

[0515] The target gene of No. 184 is the hsa-miR-4688 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been no reports that changes in the expression of this gene or its transcription products can be used as markers for liver cancer.

[0516] The target gene of No. 185 is the hsa-miR-4648 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been no reports that changes in the expression of this gene or its transcription products can be used as markers for liver cancer.

[0517] The target gene of No. 186 is the hsa-miR-6085 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been no reports that changes in the expression of this gene or its transcription products can be used as markers for liver cancer.

[0518] The target gene of No. 187 is the hsa-miR-6126 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there have been no reports that changes in the expression of this gene or its transcription products can be used as markers for liver cancer.

[0519] ​​​​​The 188th target gene is the hsa-miR-6880-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. .

[0520] The 189th target gene is the hsa-miR-328-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0521] The 190th target gene is the hsa-miR-6768-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. .

[0522] The 191st target gene is the hsa-miR-3180 gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0523] The 192nd target gene is the hsa-miR-6087 gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0524] The 193rd target gene is the hsa-miR-1273g-3p gene, its homologs , their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. None.

[0525] The 194th target gene is the hsa-miR-1225-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. None.

[0526] The 195th target gene is the hsa-miR-3196 gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its trans cript can be a marker for liver cancer.

[0527] The 196th target gene is the hsa-miR-4695-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. None.

[0528] The 197th target gene is the hsa-miR-6732-5p gene, its homologs, their transcripts, or their variants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. None.

[0529] The 198th target gene is the hsa-miR-638 gene, its homologs, their The gene or its transcription product, or a variant or derivative thereof, has been There are no known reports suggesting that changes in expression of these products could be markers for liver cancer.

[0530] The 199th target gene is the hsa-miR-6813-5p gene, its homologs, The present invention relates to a transcription product thereof, or a mutant or derivative thereof. There are no known reports that changes in the expression of this transcript could be a marker for liver cancer. .

[0531] The 200th target gene is the hsa-miR-665 gene, its homologs, The gene or its transcription product, or a variant or derivative thereof, has been There are no known reports suggesting that changes in expression of these products could be markers for liver cancer.

[0532] The 201st target gene is the hsa-miR-486-3p gene, its homologs, and The gene or its variants or derivatives are the transcription products of the gene or its variants or derivatives. It has been reported that changes in the expression of the transcripts of the following genes can be markers for liver cancer (especially in Patent Document 2 and Patent Document 3).

[0533] The 202nd target gene is the hsa-miR-4466 gene, its homologs, and their The gene or its variant or derivative is a transcription product of the There are no known reports suggesting that altered expression of transcripts could be a marker for liver cancer.

[0534] The 203rd target gene is the hsa-miR-30c-1-3p gene and its homologues , their transcription products, or their mutants or derivatives. It is known that changes in the expression of its transcription products can be markers for liver cancer (Patent Documents 3 and 5).

[0535] The 204th target gene is the hsa-miR-3621 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0536] The 205th target gene is the hsa-miR-6743-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer. .

[0537] The 206th target gene is the hsa-miR-4298 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0538] The 207th target gene is the hsa-miR-4741 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products can be markers for liver cancer.

[0539] The 208th target gene is the hsa-miR-3619-3p gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of this gene or There is no report indicating that the change in the expression of the transcription product can be a marker for liver cancer 。

[0540] The 209th target gene is the hsa-miR-6824-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report indicating that the change in the expression of this gene or its transcription product can be a marker for liver cancer 。

[0541] The 210th target gene is the hsa-miR-5698 gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report indicating that the change in the expression of this gene or its transcription product can be a marker for liver cancer

[0542] The 211th target gene is the hsa-miR-371a-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report indicating that the change in the expression of this gene or its transcription product can be a marker for liver cancer 。

[0543] The 212th target gene is the hsa-miR-4488 gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report indicating that the change in the expression of this gene or its transcription product can be a marker for liver cancer

[0544] The 213th target gene is the hsa-miR-1233-5p gene, its homologs, their transcription products, or their variants or derivatives. So far, there is no report indicating that the change in the expression of this gene or its transcription product can be a marker for liver cancer .

[0545] The 214th target gene is the hsa-miR-4723-5p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer .

[0546] The 215th target gene is the hsa-miR-24-3p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been a report that the change in the expression of this gene or its transcript can be a marker for liver cancer (Patent Document 2).

[0547] The 216th target gene is the hsa-miR-1238-5p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer .

[0548] The 217th target gene is the hsa-miR-4442 gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its trans cript can be a marker for liver cancer.

[0549] The 218th target gene is the hsa-miR-3928-3p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer .

[0550] The 219th target gene is the hsa-miR-6716-5p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. .

[0551] The 220th target gene is the hsa-miR-6089 gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0552] The 221st target gene is the hsa-miR-6124 gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer.

[0553] The 222nd target gene is the hsa-miR-6778-5p gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been no report that the change in the expression of this gene or its transcript can be a marker for liver cancer. .

[0554] The 223rd target gene is the hsa-miR-557 gene, its homologs, their transcripts, or their mutants or derivatives. So far, there has been a report that the change in the expression of this gene or its transcript can be a marker for liver cancer (Patent Document 2).

[0555] The 224th target gene is the hsa-miR-6090 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there has been no report that changes in the expression of this gene or its transcription products

[0556] could be markers for liver cancer. The 225th target gene is the hsa-miR-6757-5p gene, its homologs, their transcription products, or their mutants or derivatives. So far, there has been no

[0557] report that changes in the expression of the gene or its transcription products could be markers for liver cancer. The 226th target gene is the hsa-miR-4448 gene, its homologs, their

[0558] transcription products, or their mutants or derivatives. So far, there has been no report that changes in the expression of the gene or its transcription products could be markers for liver cancer.

[0559] The 228th target gene is the hsa-miR-3178 gene, its homologs, their transcription products, or their mutants or derivatives. So far, there has been no report that changes in the expression of the gene or its transcription products

[0560] could be markers for liver cancer. They are those transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of a gene or its transcription product can be a marker for liver cancer.

[0561] The 230th target gene is the hsa-miR-940 gene, its homologs, their transcription products, or their variants or derivatives. So far, there has been no report that changes in the expression of a gene or its transcription product can be a marker for liver cancer.

[0562] The 231st target gene is the hsa-miR-6789-5p gene, its homologs, ...

Claims

1. A kit for detecting liver cancer, comprising a nucleic acid capable of specifically binding to a polynucleotide of miR-6088, which is a liver cancer marker.

2. The kit according to claim 1, wherein the nucleic acid is selected from the group consisting of a polynucleotide or a fragment thereof shown in the following (a) to (e): (a) (1) A polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 81 or a nucleotide sequence in which u is t in the nucleotide sequence, or a fragment thereof containing 15 or more consecutive bases, (2) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of 1 or 2 bases in the polynucleotide or the fragment of (1), (3) A polynucleotide or a fragment thereof showing 90% or more identity with the nucleotide sequence of the polynucleotide or the fragment of (1), (4) A polynucleotide or a fragment thereof according to any one of (1) to (3), containing a modified nucleic acid and / or a modified nucleotide, (b) A polynucleotide containing the nucleotide sequence represented by SEQ ID NO: 81, or a fragment thereof containing 15 or more consecutive bases, (c) (5) A polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 81 or a nucleotide sequence in which u is t in the nucleotide sequence, or a fragment thereof containing 15 or more consecutive bases, (6) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of 1 or 2 bases in the polynucleotide or the fragment of (5), (7) A polynucleotide or a fragment thereof showing 90% or more identity with the nucleotide sequence of the polynucleotide or the fragment of (5), (8) A polynucleotide or a fragment thereof according to any one of (5) to (7), containing a modified nucleic acid and / or a modified nucleotide, (d) A polynucleotide containing a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 81 or a nucleotide sequence in which u is t in the nucleotide sequence, or a fragment thereof containing 15 or more consecutive bases, and (e) A polynucleotide that hybridizes under stringent conditions with a polynucleotide or a fragment thereof according to any one of (a) to (d).

3. The kit includes miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641, miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p, miR-6717-5p, miR-6870-5p, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p, miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR-6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6749-5p, miR-1231, miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185, miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR-6777-5p, miR-3917, miR-4286, miR-6877-5p, miR-1225-3p, miR-6800-5p, miR-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p, miR-1228-5p, which are another liver cancer marker.The group consisting of miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR-1247-3p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR-4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6724-5p, miR-6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR-4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p and miR-6836-3p; and / or miR-23b-3p,The kit according to claim 1 or 2, further comprising a nucleic acid capable of specifically binding to at least one or more polynucleotides selected from the group consisting of miR-23a-3p, miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p, miR-663a, miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR-6087, miR-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619-3p, miR-6824-5p, miR-5698, miR-371a-5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, miR-6124, miR-6778-5p, miR-557 and miR-6090.

4. The kit according to claim 3, wherein the nucleic acid is selected from the group consisting of a polynucleotide or a fragment thereof shown in the following (f) to (j): (f) A polynucleotide consisting of a base sequence represented by any of SEQ ID NOs: 2 to 21, 23 to 53, 55 to 76, 78 to 80, 82 to 167, 714 to 729, and 168 to 224, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases, (10) A polynucleotide or a fragment thereof, which contains a deletion, substitution, addition, or insertion of 1 or 2 bases in the polynucleotide or the fragment of (9). (11) A polynucleotide or a fragment thereof, which shows a % identity of 90% or more with the base sequence of the polynucleotide or the fragment of (9). (12) A polynucleotide or a fragment thereof according to any of (9) to (11), which contains a modified nucleic acid and / or a modified nucleotide. (g) A polynucleotide containing a base sequence represented by any of SEQ ID NOs: 2 to 21, 23 to 53, 55 to 76, 78 to 80, 82 to 167, 714 to 729, and 168 to 224, or a fragment thereof containing 15 or more consecutive bases, (h) (13) A polynucleotide consisting of a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 2 to 21, 23 to 53, 55 to 76, 78 to 80, 82 to 167, 714 to 729, and 168 to 224, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases, (14) A polynucleotide or a fragment thereof, which contains a deletion, substitution, addition, or insertion of 1 or 2 bases in the polynucleotide or the fragment of (13). (15) A polynucleotide or a fragment thereof, which shows a % identity of 90% or more with the base sequence of the polynucleotide or the fragment of (13). (16) A polynucleotide or a fragment thereof according to any of (13) to (15), which contains a modified nucleic acid and / or a modified nucleotide. (i) A polynucleotide containing a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 2 to 21, 23 to 53, 55 to 76, 78 to 80, 82 to 167, 714 to 729, and 168 to 224, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases, and (j) A polynucleotide that hybridizes under stringent conditions with the polynucleotide or a fragment thereof according to any of (f) to (i).

5. A device for detecting liver cancer, which contains a nucleic acid that can specifically bind to the polynucleotide of miR-6088, which is a liver cancer marker.

6. The device according to claim 5, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof shown in the following (a) to (e): (a) A polynucleotide consisting of the nucleotide sequence represented by SEQ ID NO: 81 or a nucleotide sequence in which u is t in the nucleotide sequence, or a fragment thereof containing 15 or more consecutive bases, (26) a polynucleotide or a fragment thereof containing a deletion, substitution, addition or insertion of 1 or 2 bases in the polynucleotide or the fragment of (25), (27) A polynucleotide or a fragment thereof showing 90% or more identity with the nucleotide sequence of the polynucleotide or the fragment of (25), (28) A polynucleotide or a fragment thereof of any one of (25) to (27) containing a modified nucleic acid and / or a modified nucleotide, (b) A polynucleotide containing the nucleotide sequence represented by SEQ ID NO: 81, or a fragment thereof containing 15 or more consecutive bases, (c) (29) A polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 81 or a nucleotide sequence in which u is t in the nucleotide sequence, or a fragment thereof containing 15 or more consecutive bases, (30) A polynucleotide or a fragment thereof containing a deletion, substitution, addition or insertion of 1 or 2 bases in the polynucleotide or the fragment of (29), (31) A polynucleotide or a fragment thereof showing 90% or more identity with the nucleotide sequence of the polynucleotide or the fragment of (29), (32) A polynucleotide or a fragment thereof of any one of (29) to (31) containing a modified nucleic acid and / or a modified nucleotide, (d) A polynucleotide containing a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 81 or a nucleotide sequence in which u is t in the nucleotide sequence, or a fragment thereof containing 15 or more consecutive bases, and (e) A polynucleotide that hybridizes under stringent conditions with a polynucleotide or a fragment thereof of any one of the above (a) to (d).

7. The device is another liver cancer marker, miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641, miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p, miR-6717-5p, miR-6870-5p, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p, miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR-6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6749-5p, miR-1231, miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185, miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR-6777-5p, miR-3917, miR-4286, miR-6877-5p, miR-1225-3p, miR-6800-5p, miR-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p, miR-1228-5p,The group consisting of miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR-1247-3p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR-4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6724-5p, miR-6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR-4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p, and miR-6836-3p; and / or miR-23b-3p,The device according to claim 5 or 6, further comprising a nucleic acid capable of specifically binding to at least one polynucleotide selected from the group consisting of miR-23a-3p, miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p, miR-663a, miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR-6087, miR-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619-3p, miR-6824-5p, miR-5698, miR-371a-5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, miR-6124, miR-6778-5p, miR-557 and miR-6090.

8. The device according to claim 7, wherein the nucleic acid is selected from the group consisting of polynucleotides or fragments thereof shown in the following (f) to (j): (f) A polynucleotide consisting of a base sequence represented by any of SEQ ID NOs: 2 to 21, 23 to 53, 55 to 76, 78 to 80, 82 to 167, 714 to 729, and 168 to 224, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases, (34) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of 1 or 2 bases in the polynucleotide or the fragment of (33). (35) A polynucleotide or a fragment thereof showing 90% or more % identity with the base sequence of the polynucleotide or the fragment of (33). (36) A polynucleotide or a fragment thereof according to any of (33) to (35), containing a modified nucleic acid and / or a modified nucleotide. (g) A polynucleotide containing a base sequence represented by any of SEQ ID NOs: 2 to 21, 23 to 53, 55 to 76, 78 to 80, 82 to 167, 714 to 729, and 168 to 224, or a fragment thereof containing 15 or more consecutive bases. (h) (37) A polynucleotide consisting of a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 2 to 21, 23 to 53, 55 to 76, 78 to 80, 82 to 167, 714 to 729, and 168 to 224, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases. (38) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of 1 or 2 bases in the polynucleotide or the fragment of (37). (39) A polynucleotide or a fragment thereof showing 90% or more % identity with the base sequence of the polynucleotide or the fragment of (37). (40) A polynucleotide or a fragment thereof according to any of (37) to (39), containing a modified nucleic acid and / or a modified nucleotide. (i) A polynucleotide containing a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 2 to 21, 23 to 53, 55 to 76, 78 to 80, 82 to 167, 714 to 729, and 168 to 224, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases, and (j) A polynucleotide that hybridizes with a polynucleotide or a fragment thereof according to any of (f) to (i) under stringent conditions.

9. The device according to any one of claims 5 to 8, wherein the device is a device for measurement by hybridization technology.

10. The device according to claim 9, wherein the hybridization technology is nucleic acid array technology.

11. Using the kit according to any one of claims 1 to 4 or the device according to any one of claims 5 to 10, measuring the expression level of a target nucleic acid in a specimen of a subject, and using the measured expression level and a control expression level of a healthy subject measured in the same manner, evaluating in vitro whether the subject has liver cancer or does not have liver cancer. A method for evaluating the presence or absence of liver cancer, comprising:

12. The method according to claim 11, wherein the subject is a human.

13. The method according to claim 11 or 12, wherein the specimen is blood, serum or plasma.

14. Use of a polynucleotide of miR-6088 as a liver cancer marker for evaluating the presence or absence of liver cancer.

15. The polynucleotide of the aforementioned miR-6088 is miR-6726-5p, miR-6515-3p, miR-4651, miR-4257, miR-3188, miR-6131, miR-6766-3p, miR-7641, miR-1249, miR-3679-3p, miR-6787-5p, miR-4454, miR-3135b, miR-6765-3p, miR-7975, miR-204-3p, miR-7977, miR-7110-5p, miR-6717-5p, miR-6870-5p, miR-6875-5p, miR-8072, miR-6816-5p, miR-4281, miR-6729-5p, miR-8069, miR-4706, miR-7108-5p, miR-4433b-3p, miR-6893-5p, miR-6857-5p, miR-1227-5p, miR-6741-5p, miR-451a, miR-8063, miR-3622a-5p, miR-615-5p, miR-128-1-5p, miR-6825-5p, miR-1260b, miR-4433-3p, miR-4665-5p, miR-7845-5p, miR-1908-5p, miR-6840-3p, miR-6765-5p, miR-296-5p, miR-3675-3p, miR-6781-5p, miR-423-5p, miR-3663-3p, miR-6749-5p, miR-1231, miR-4746-3p, miR-6780b-5p, miR-4758-5p, miR-3679-5p, miR-3184-5p, miR-6125, miR-6721-5p, miR-6791-5p, miR-3185, miR-1260a, miR-3197, miR-6845-5p, miR-6887-5p, miR-6738-5p, miR-6872-3p, miR-4497, miR-1229-5p, miR-6820-5p, miR-6777-5p, miR-3917, miR-4286, miR-6877-5p, miR-1225-3p, miR-6800-5p, miR-1246, miR-4467, miR-4419b, miR-1914-3p, miR-4632-5p, miR-1915-5p, miR-3940-5p, miR-1185-2-3p, miR-6746-5p, miR-5001-5p, miR-1228-5p,The group consisting of miR-5572, miR-4327, miR-4638-5p, miR-6799-5p, miR-6861-5p, miR-6727-5p, miR-4513, miR-6805-3p, miR-6808-5p, miR-4449, miR-1199-5p, miR-1275, miR-4792, miR-4443, miR-6891-5p, miR-6826-5p, miR-6807-5p, miR-7150, miR-4534, miR-4476, miR-4649-5p, miR-4525, miR-1915-3p, miR-4516, miR-4417, miR-642b-3p, miR-3141, miR-5100, miR-6848-5p, miR-4739, miR-4459, miR-1237-5p, miR-296-3p, miR-4665-3p, miR-6786-5p, miR-4258, miR-6510-5p, miR-1343-5p, miR-1247-3p, miR-6805-5p, miR-4492, miR-1469, miR-1268b, miR-6858-5p, miR-3937, miR-939-5p, miR-3656, miR-744-5p, miR-4687-3p, miR-4763-3p, miR-3620-5p, miR-3195, miR-6842-5p, miR-4707-5p, miR-642a-3p, miR-7113-3p, miR-4728-5p, miR-5195-3p, miR-1185-1-3p, miR-6774-5p, miR-8059, miR-3131, miR-7847-3p, miR-4463, miR-128-2-5p, miR-4508, miR-6806-5p, miR-7111-5p, miR-6782-5p, miR-4734, miR-3162-5p, miR-887-3p, miR-6752-5p, miR-6724-5p, miR-6757-5p, miR-4448, miR-671-5p, miR-3178, miR-4725-3p, miR-940, miR-6789-5p, miR-4484, miR-4634, miR-4745-5p, miR-4730, miR-6803-5p, miR-6798-5p, miR-3648, miR-4783-3p, and miR-6836-3p; and / or miR-23b-3p,At least one polynucleotide selected from the group consisting of miR-23a-3p, miR-625-3p, miR-1228-3p, miR-614, miR-1913, miR-92a-2-5p, miR-187-5p, miR-16-5p, miR-92b-3p, miR-150-3p, miR-564, miR-125a-3p, miR-92b-5p, miR-92a-3p, miR-663a, miR-4688, miR-4648, miR-6085, miR-6126, miR-6880-5p, miR-328-5p, miR-6768-5p, miR-3180, miR-6087, miR-1273g-3p, miR-1225-5p, miR-3196, miR-4695-5p, miR-6732-5p, miR-638, miR-6813-5p, miR-665, miR-486-3p, miR-4466, miR-30c-1-3p, miR-3621, miR-6743-5p, miR-4298, miR-4741, miR-3619-3p, miR-6824-5p, miR-5698, miR-371a-5p, miR-4488, miR-1233-5p, miR-4723-5p, miR-24-3p, miR-1238-5p, miR-4442, miR-3928-3p, miR-6716-5p, miR-6089, miR-6124, miR-6778-5p, miR-557 and miR-6090, for use as a liver cancer marker for assessing the presence or absence of liver cancer, the use according to claim 14.,

16. The at least one polynucleotide is as follows (f) and (g): (f) A polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 2 to 21, 23 to 53, 55 to 76, 78 to 80, 82 to 167, 714 to 729, and 168 to 224, (g) A polynucleotide containing a base sequence represented by any one of SEQ ID NOs: 2 to 21, 23 to 53, 55 to 76, 78 to 80, 82 to 167, 714 to 729, and 168 to 224, The use according to claim 15, which is at least one polynucleotide selected from the group consisting of polynucleotides.

Images